Mitch Report
Antony Kaspi & Mark Ziemann
date generated: 2026-05-06
Background
Mitch performs unidimensional and multidimensional gene set enrichment analysis. The concept behind this dates to work by Cox and Mann (https://doi.org/10.1186/1471-2105-13-S16-S12). This implementation is suited to R based workflows of multi-omics datasets. This software was developed by Antony Kaspi and Mark Ziemann. Learn more about Mitch at the website: https://github.com/markziemann/Mitch
Input profiles
Here is the first few lines of the input profile.
| x | |
|---|---|
| 5_8S_rRNA | 0.8269351 |
| A1BG | -1.0230846 |
| A1BG-AS1 | 0.3566407 |
| A1CF | 2.0122246 |
| A2M | 3.0357470 |
| A2M-AS1 | 2.5238096 |
Here are some metrics about the input data profile:
| Profile metrics | |
|---|---|
| num_genesets | 2725 |
| num_genes_in_profile | 21870 |
| duplicated_genes_present | 0 |
| num_profile_genes_in_sets | 8802 |
| num_profile_genes_not_in_sets | 13068 |
Here is a plot of the input profiles. Note the dynamic ranges.
Here is the contour plot of the profile including all detected genes.
Input genesets
Here are some metrics about the gene sets used:
GMT file of genesets:| Gene sets metrics | |
|---|---|
| num_genesets | 2725 |
| num_genesets_excluded | 1189 |
| num_genesets_included | 1536 |
Differential pathway expression
Interactive enrichment scatterplot
Significance is calculated by -log10(p-value). All points shown are
FDR<0.05.
Significance is calculated by -log10(p-value). Top N sets shown
irrespective of FDR.
Results table
Top N= 50 gene sets| set | setSize | pANOVA | s.dist | p.adjustANOVA |
|---|---|---|---|---|
| Phosphorylation of Emi1 | 6 | 1.03e-03 | -0.774 | 4.80e-03 |
| Classical antibody-mediated complement activation | 70 | 2.66e-28 | -0.762 | 3.95e-26 |
| NR1H2 & NR1H3 regulate gene expression linked to triglyceride lipolysis in adipose | 5 | 3.82e-03 | -0.747 | 1.47e-02 |
| Scavenging of heme from plasma | 71 | 4.21e-27 | -0.739 | 5.07e-25 |
| Creation of C4 and C2 activators | 72 | 3.28e-27 | -0.735 | 4.21e-25 |
| NR1H2 & NR1H3 regulate gene expression linked to lipogenesis | 8 | 4.60e-04 | -0.715 | 2.43e-03 |
| Maturation of spike protein 9683686 | 5 | 5.77e-03 | -0.713 | 2.04e-02 |
| Initial triggering of complement | 80 | 8.73e-27 | -0.692 | 9.48e-25 |
| FCGR activation | 77 | 1.59e-25 | -0.687 | 1.62e-23 |
| Synthesis of GDP-mannose | 6 | 3.81e-03 | -0.682 | 1.47e-02 |
| CD22 mediated BCR regulation | 59 | 1.89e-19 | -0.678 | 8.68e-18 |
| Glycosphingolipid transport | 7 | 2.09e-03 | -0.672 | 8.91e-03 |
| Formation of annular gap junctions | 10 | 2.51e-04 | -0.669 | 1.44e-03 |
| Negative regulation of TCF-dependent signaling by DVL-interacting proteins | 5 | 9.93e-03 | -0.666 | 3.20e-02 |
| Role of LAT2/NTAL/LAB on calcium mobilization | 78 | 5.80e-23 | -0.645 | 3.73e-21 |
| Sulfide oxidation to sulfate | 5 | 1.26e-02 | -0.645 | 3.86e-02 |
| Type I hemidesmosome assembly | 8 | 1.60e-03 | -0.644 | 7.14e-03 |
| Diseases of Base Excision Repair | 5 | 1.28e-02 | -0.642 | 3.93e-02 |
| NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis | 7 | 3.44e-03 | -0.638 | 1.35e-02 |
| NR1H2 & NR1H3 regulate gene expression to limit cholesterol uptake | 5 | 1.37e-02 | -0.636 | 4.10e-02 |
| Unwinding of DNA | 12 | 1.96e-04 | -0.621 | 1.17e-03 |
| Glyoxylate metabolism and glycine degradation | 13 | 1.08e-04 | -0.620 | 7.15e-04 |
| Activation of NIMA Kinases NEK9, NEK6, NEK7 | 7 | 4.50e-03 | -0.620 | 1.68e-02 |
| G2/M DNA replication checkpoint | 5 | 1.70e-02 | -0.616 | 4.90e-02 |
| Role of phospholipids in phagocytosis | 89 | 2.16e-23 | -0.610 | 1.48e-21 |
| Binding and Uptake of Ligands by Scavenger Receptors | 93 | 1.56e-23 | -0.599 | 1.11e-21 |
| Regulation of NFE2L2 gene expression | 8 | 3.68e-03 | -0.593 | 1.43e-02 |
| Nef Mediated CD4 Down-regulation | 9 | 2.16e-03 | -0.590 | 9.19e-03 |
| Expression and translocation of olfactory receptors | 52 | 2.40e-13 | 0.587 | 7.59e-12 |
| FCGR3A-mediated IL10 synthesis | 100 | 5.75e-24 | -0.584 | 4.26e-22 |
| Retrograde neurotrophin signalling | 12 | 4.79e-04 | -0.582 | 2.52e-03 |
| Formation of ATP by chemiosmotic coupling | 20 | 7.81e-06 | -0.577 | 7.75e-05 |
| FCERI mediated Ca+2 mobilization | 93 | 1.22e-21 | -0.573 | 6.01e-20 |
| Synthesis of PG | 8 | 5.18e-03 | -0.571 | 1.86e-02 |
| Regulation of Complement cascade | 97 | 4.37e-22 | -0.567 | 2.63e-20 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | 18 | 3.15e-05 | -0.567 | 2.65e-04 |
| Nef Mediated CD8 Down-regulation | 7 | 9.53e-03 | -0.566 | 3.09e-02 |
| PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 | 9 | 3.40e-03 | -0.564 | 1.34e-02 |
| Beta oxidation of hexanoyl-CoA to butanoyl-CoA | 5 | 2.94e-02 | -0.562 | 7.52e-02 |
| VLDLR internalisation and degradation | 15 | 1.71e-04 | -0.560 | 1.05e-03 |
| Pausing and recovery of Tat-mediated HIV elongation | 30 | 1.37e-07 | -0.556 | 1.90e-06 |
| Tat-mediated HIV elongation arrest and recovery | 30 | 1.37e-07 | -0.556 | 1.90e-06 |
| Complement cascade | 101 | 5.17e-22 | -0.555 | 3.02e-20 |
| FCGR3A-mediated phagocytosis | 122 | 2.77e-25 | -0.544 | 2.42e-23 |
| Leishmania phagocytosis | 122 | 2.77e-25 | -0.544 | 2.42e-23 |
| Parasite infection | 122 | 2.77e-25 | -0.544 | 2.42e-23 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | 23 | 6.98e-06 | -0.541 | 7.08e-05 |
| Gap junction degradation | 11 | 1.98e-03 | -0.539 | 8.52e-03 |
| Activation of PUMA and translocation to mitochondria | 9 | 5.24e-03 | -0.537 | 1.88e-02 |
| Prevention of phagosomal-lysosomal fusion | 9 | 5.30e-03 | -0.537 | 1.90e-02 |
Results (complete table)
Click HERE to show results for all gene sets
| set | setSize | pANOVA | s.dist | p.adjustANOVA |
|---|---|---|---|---|
| Phosphorylation of Emi1 | 6 | 1.03e-03 | -0.774000 | 4.80e-03 |
| Classical antibody-mediated complement activation | 70 | 2.66e-28 | -0.762000 | 3.95e-26 |
| NR1H2 & NR1H3 regulate gene expression linked to triglyceride lipolysis in adipose | 5 | 3.82e-03 | -0.747000 | 1.47e-02 |
| Scavenging of heme from plasma | 71 | 4.21e-27 | -0.739000 | 5.07e-25 |
| Creation of C4 and C2 activators | 72 | 3.28e-27 | -0.735000 | 4.21e-25 |
| NR1H2 & NR1H3 regulate gene expression linked to lipogenesis | 8 | 4.60e-04 | -0.715000 | 2.43e-03 |
| Maturation of spike protein 9683686 | 5 | 5.77e-03 | -0.713000 | 2.04e-02 |
| Initial triggering of complement | 80 | 8.73e-27 | -0.692000 | 9.48e-25 |
| FCGR activation | 77 | 1.59e-25 | -0.687000 | 1.62e-23 |
| Synthesis of GDP-mannose | 6 | 3.81e-03 | -0.682000 | 1.47e-02 |
| CD22 mediated BCR regulation | 59 | 1.89e-19 | -0.678000 | 8.68e-18 |
| Glycosphingolipid transport | 7 | 2.09e-03 | -0.672000 | 8.91e-03 |
| Formation of annular gap junctions | 10 | 2.51e-04 | -0.669000 | 1.44e-03 |
| Negative regulation of TCF-dependent signaling by DVL-interacting proteins | 5 | 9.93e-03 | -0.666000 | 3.20e-02 |
| Role of LAT2/NTAL/LAB on calcium mobilization | 78 | 5.80e-23 | -0.645000 | 3.73e-21 |
| Sulfide oxidation to sulfate | 5 | 1.26e-02 | -0.645000 | 3.86e-02 |
| Type I hemidesmosome assembly | 8 | 1.60e-03 | -0.644000 | 7.14e-03 |
| Diseases of Base Excision Repair | 5 | 1.28e-02 | -0.642000 | 3.93e-02 |
| NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis | 7 | 3.44e-03 | -0.638000 | 1.35e-02 |
| NR1H2 & NR1H3 regulate gene expression to limit cholesterol uptake | 5 | 1.37e-02 | -0.636000 | 4.10e-02 |
| Unwinding of DNA | 12 | 1.96e-04 | -0.621000 | 1.17e-03 |
| Glyoxylate metabolism and glycine degradation | 13 | 1.08e-04 | -0.620000 | 7.15e-04 |
| Activation of NIMA Kinases NEK9, NEK6, NEK7 | 7 | 4.50e-03 | -0.620000 | 1.68e-02 |
| G2/M DNA replication checkpoint | 5 | 1.70e-02 | -0.616000 | 4.90e-02 |
| Role of phospholipids in phagocytosis | 89 | 2.16e-23 | -0.610000 | 1.48e-21 |
| Binding and Uptake of Ligands by Scavenger Receptors | 93 | 1.56e-23 | -0.599000 | 1.11e-21 |
| Regulation of NFE2L2 gene expression | 8 | 3.68e-03 | -0.593000 | 1.43e-02 |
| Nef Mediated CD4 Down-regulation | 9 | 2.16e-03 | -0.590000 | 9.19e-03 |
| Expression and translocation of olfactory receptors | 52 | 2.40e-13 | 0.587000 | 7.59e-12 |
| FCGR3A-mediated IL10 synthesis | 100 | 5.75e-24 | -0.584000 | 4.26e-22 |
| Retrograde neurotrophin signalling | 12 | 4.79e-04 | -0.582000 | 2.52e-03 |
| Formation of ATP by chemiosmotic coupling | 20 | 7.81e-06 | -0.577000 | 7.75e-05 |
| FCERI mediated Ca+2 mobilization | 93 | 1.22e-21 | -0.573000 | 6.01e-20 |
| Synthesis of PG | 8 | 5.18e-03 | -0.571000 | 1.86e-02 |
| Regulation of Complement cascade | 97 | 4.37e-22 | -0.567000 | 2.63e-20 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | 18 | 3.15e-05 | -0.567000 | 2.65e-04 |
| Nef Mediated CD8 Down-regulation | 7 | 9.53e-03 | -0.566000 | 3.09e-02 |
| PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 | 9 | 3.40e-03 | -0.564000 | 1.34e-02 |
| Beta oxidation of hexanoyl-CoA to butanoyl-CoA | 5 | 2.94e-02 | -0.562000 | 7.52e-02 |
| VLDLR internalisation and degradation | 15 | 1.71e-04 | -0.560000 | 1.05e-03 |
| Pausing and recovery of Tat-mediated HIV elongation | 30 | 1.37e-07 | -0.556000 | 1.90e-06 |
| Tat-mediated HIV elongation arrest and recovery | 30 | 1.37e-07 | -0.556000 | 1.90e-06 |
| Complement cascade | 101 | 5.17e-22 | -0.555000 | 3.02e-20 |
| FCGR3A-mediated phagocytosis | 122 | 2.77e-25 | -0.544000 | 2.42e-23 |
| Leishmania phagocytosis | 122 | 2.77e-25 | -0.544000 | 2.42e-23 |
| Parasite infection | 122 | 2.77e-25 | -0.544000 | 2.42e-23 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | 23 | 6.98e-06 | -0.541000 | 7.08e-05 |
| Gap junction degradation | 11 | 1.98e-03 | -0.539000 | 8.52e-03 |
| Activation of PUMA and translocation to mitochondria | 9 | 5.24e-03 | -0.537000 | 1.88e-02 |
| Prevention of phagosomal-lysosomal fusion | 9 | 5.30e-03 | -0.537000 | 1.90e-02 |
| Glycine degradation | 7 | 1.41e-02 | -0.536000 | 4.20e-02 |
| FCERI mediated MAPK activation | 94 | 3.58e-19 | -0.534000 | 1.57e-17 |
| Condensation of Prometaphase Chromosomes | 11 | 2.19e-03 | -0.533000 | 9.29e-03 |
| Regulation of actin dynamics for phagocytic cup formation | 124 | 1.36e-24 | -0.532000 | 1.09e-22 |
| XBP1(S) activates chaperone genes | 44 | 1.43e-09 | -0.527000 | 2.81e-08 |
| ChREBP activates metabolic gene expression | 7 | 1.68e-02 | -0.522000 | 4.87e-02 |
| TGFBR3 regulates TGF-beta signaling | 8 | 1.08e-02 | -0.521000 | 3.40e-02 |
| IRE1alpha activates chaperones | 46 | 9.89e-10 | -0.521000 | 1.99e-08 |
| Nucleotide biosynthesis | 12 | 1.89e-03 | -0.518000 | 8.18e-03 |
| Olfactory Signaling Pathway | 57 | 1.51e-11 | 0.516000 | 3.89e-10 |
| Loss of MECP2 binding ability to the NCoR/SMRT complex | 7 | 1.80e-02 | -0.516000 | 5.09e-02 |
| HIV elongation arrest and recovery | 32 | 4.72e-07 | -0.514000 | 5.94e-06 |
| Pausing and recovery of HIV elongation | 32 | 4.72e-07 | -0.514000 | 5.94e-06 |
| Biotin transport and metabolism | 11 | 3.22e-03 | -0.513000 | 1.30e-02 |
| Activation of NOXA and translocation to mitochondria | 5 | 4.98e-02 | -0.507000 | 1.14e-01 |
| Gluconeogenesis | 19 | 1.44e-04 | -0.504000 | 8.95e-04 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | 84 | 2.23e-15 | -0.500000 | 8.11e-14 |
| Negative regulation of activity of TFAP2 (AP-2) family transcription factors | 6 | 3.56e-02 | -0.495000 | 8.83e-02 |
| WNT5A-dependent internalization of FZD4 | 13 | 2.03e-03 | -0.494000 | 8.71e-03 |
| Polo-like kinase mediated events | 16 | 6.72e-04 | -0.491000 | 3.34e-03 |
| Interleukin-2 signaling | 11 | 4.83e-03 | -0.491000 | 1.76e-02 |
| Removal of the Flap Intermediate from the C-strand | 17 | 4.72e-04 | -0.490000 | 2.49e-03 |
| Assembly Of The HIV Virion | 15 | 1.03e-03 | -0.490000 | 4.80e-03 |
| RHOBTB3 ATPase cycle | 10 | 7.63e-03 | -0.487000 | 2.58e-02 |
| WNT mediated activation of DVL | 8 | 1.72e-02 | -0.486000 | 4.91e-02 |
| Hyaluronan metabolism | 15 | 1.13e-03 | -0.486000 | 5.19e-03 |
| Fcgamma receptor (FCGR) dependent phagocytosis | 148 | 2.25e-24 | -0.485000 | 1.73e-22 |
| Hyaluronan uptake and degradation | 12 | 3.65e-03 | -0.485000 | 1.42e-02 |
| NFE2L2 regulates pentose phosphate pathway genes | 8 | 1.81e-02 | -0.482000 | 5.11e-02 |
| Anti-inflammatory response favouring Leishmania parasite infection | 133 | 8.12e-22 | -0.482000 | 4.12e-20 |
| Leishmania parasite growth and survival | 133 | 8.12e-22 | -0.482000 | 4.12e-20 |
| WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | 11 | 5.75e-03 | -0.481000 | 2.04e-02 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | 22 | 9.67e-05 | -0.480000 | 6.55e-04 |
| G1/S-Specific Transcription | 29 | 8.50e-06 | -0.478000 | 8.32e-05 |
| FCERI mediated NF-kB activation | 130 | 6.69e-21 | -0.476000 | 3.14e-19 |
| CYP2E1 reactions | 5 | 6.72e-02 | -0.473000 | 1.43e-01 |
| Disorders of Developmental Biology | 12 | 4.79e-03 | -0.470000 | 1.76e-02 |
| Disorders of Nervous System Development | 12 | 4.79e-03 | -0.470000 | 1.76e-02 |
| Loss of function of MECP2 in Rett syndrome | 12 | 4.79e-03 | -0.470000 | 1.76e-02 |
| Pervasive developmental disorders | 12 | 4.79e-03 | -0.470000 | 1.76e-02 |
| Negative regulation of FLT3 | 15 | 1.70e-03 | -0.468000 | 7.53e-03 |
| Pentose phosphate pathway | 13 | 3.56e-03 | -0.467000 | 1.39e-02 |
| DNA methylation | 18 | 6.52e-04 | -0.464000 | 3.25e-03 |
| Telomere Extension By Telomerase | 23 | 1.32e-04 | -0.460000 | 8.54e-04 |
| Golgi Cisternae Pericentriolar Stack Reorganization | 14 | 2.90e-03 | -0.460000 | 1.18e-02 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | 51 | 1.46e-08 | -0.458000 | 2.39e-07 |
| Membrane binding and targetting of GAG proteins | 13 | 4.25e-03 | -0.458000 | 1.61e-02 |
| Synthesis And Processing Of GAG, GAGPOL Polyproteins | 13 | 4.25e-03 | -0.458000 | 1.61e-02 |
| Activated point mutants of FGFR2 | 7 | 3.67e-02 | 0.456000 | 9.00e-02 |
| G0 and Early G1 | 27 | 4.19e-05 | -0.455000 | 3.28e-04 |
| Passive transport by Aquaporins | 6 | 5.34e-02 | 0.455000 | 1.19e-01 |
| Processive synthesis on the C-strand of the telomere | 19 | 6.38e-04 | -0.452000 | 3.19e-03 |
| Scavenging by Class F Receptors | 5 | 8.09e-02 | -0.451000 | 1.65e-01 |
| FGFR4 ligand binding and activation | 5 | 8.33e-02 | 0.447000 | 1.69e-01 |
| Activation of the TFAP2 (AP-2) family of transcription factors | 7 | 4.12e-02 | -0.446000 | 9.85e-02 |
| Formation of the ureteric bud | 5 | 8.55e-02 | 0.444000 | 1.72e-01 |
| Cytosolic iron-sulfur cluster assembly | 13 | 6.11e-03 | -0.439000 | 2.11e-02 |
| Cell-extracellular matrix interactions | 15 | 3.31e-03 | -0.438000 | 1.32e-02 |
| Interleukin-23 signaling | 7 | 4.52e-02 | -0.437000 | 1.06e-01 |
| Removal of the Flap Intermediate | 14 | 4.62e-03 | -0.437000 | 1.72e-02 |
| Cytoprotection by HMOX1 | 53 | 3.84e-08 | -0.436000 | 5.97e-07 |
| Malate-aspartate shuttle | 8 | 3.28e-02 | -0.436000 | 8.26e-02 |
| Cell surface interactions at the vascular wall | 173 | 4.28e-23 | -0.436000 | 2.85e-21 |
| Josephin domain DUBs | 10 | 1.71e-02 | -0.435000 | 4.90e-02 |
| Maturation of spike protein 9694548 | 36 | 6.87e-06 | -0.433000 | 7.01e-05 |
| Defective HLCS causes multiple carboxylase deficiency | 7 | 4.74e-02 | -0.433000 | 1.09e-01 |
| Interleukin-21 signaling | 9 | 2.47e-02 | -0.432000 | 6.58e-02 |
| Eicosanoids | 8 | 3.47e-02 | 0.431000 | 8.64e-02 |
| Beta oxidation of lauroyl-CoA to decanoyl-CoA-CoA | 5 | 9.49e-02 | -0.431000 | 1.87e-01 |
| Cleavage of the damaged purine | 22 | 5.11e-04 | -0.428000 | 2.63e-03 |
| Depurination | 22 | 5.11e-04 | -0.428000 | 2.63e-03 |
| Recognition and association of DNA glycosylase with site containing an affected purine | 22 | 5.11e-04 | -0.428000 | 2.63e-03 |
| RMTs methylate histone arginines | 35 | 1.23e-05 | -0.427000 | 1.16e-04 |
| Alternative complement activation | 5 | 9.84e-02 | -0.427000 | 1.92e-01 |
| APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway | 7 | 5.06e-02 | -0.427000 | 1.15e-01 |
| Purine ribonucleoside monophosphate biosynthesis | 9 | 2.69e-02 | -0.426000 | 7.05e-02 |
| Nef and signal transduction | 8 | 3.70e-02 | -0.426000 | 9.07e-02 |
| p75NTR negatively regulates cell cycle via SC1 | 5 | 9.92e-02 | -0.426000 | 1.93e-01 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | 28 | 9.67e-05 | -0.426000 | 6.55e-04 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | 14 | 5.92e-03 | -0.425000 | 2.06e-02 |
| SUMOylation of DNA methylation proteins | 16 | 3.27e-03 | -0.425000 | 1.31e-02 |
| Suppression of apoptosis | 7 | 5.25e-02 | -0.423000 | 1.18e-01 |
| Other interleukin signaling | 19 | 1.41e-03 | -0.423000 | 6.36e-03 |
| NFE2L2 regulating MDR associated enzymes | 8 | 3.85e-02 | -0.423000 | 9.37e-02 |
| DNA strand elongation | 32 | 3.55e-05 | -0.422000 | 2.92e-04 |
| Regulation of TP53 Activity through Acetylation | 29 | 8.57e-05 | -0.421000 | 5.96e-04 |
| Processive synthesis on the lagging strand | 15 | 4.77e-03 | -0.421000 | 1.76e-02 |
| Potential therapeutics for SARS | 150 | 6.14e-19 | -0.420000 | 2.63e-17 |
| APOBEC3G mediated resistance to HIV-1 infection | 5 | 1.05e-01 | -0.419000 | 2.01e-01 |
| Erythrocytes take up oxygen and release carbon dioxide | 7 | 5.52e-02 | -0.419000 | 1.22e-01 |
| Inhibition of DNA recombination at telomere | 33 | 3.29e-05 | -0.418000 | 2.75e-04 |
| Phospholipase C-mediated cascade; FGFR3 | 5 | 1.08e-01 | 0.415000 | 2.05e-01 |
| Degradation of cysteine and homocysteine | 12 | 1.32e-02 | -0.413000 | 4.02e-02 |
| Activation of RAC1 downstream of NMDARs | 7 | 5.85e-02 | -0.413000 | 1.28e-01 |
| Pyrimidine salvage | 10 | 2.41e-02 | -0.412000 | 6.44e-02 |
| PTK6 Regulates Cell Cycle | 6 | 8.17e-02 | -0.410000 | 1.67e-01 |
| FOXO-mediated transcription of cell death genes | 16 | 4.60e-03 | -0.409000 | 1.72e-02 |
| Complex III assembly | 23 | 6.86e-04 | -0.409000 | 3.40e-03 |
| Adenylate cyclase activating pathway | 8 | 4.53e-02 | -0.409000 | 1.06e-01 |
| Plasma lipoprotein clearance | 32 | 6.28e-05 | -0.409000 | 4.67e-04 |
| Telomere Maintenance | 78 | 5.29e-10 | -0.407000 | 1.15e-08 |
| Glycogen breakdown (glycogenolysis) | 13 | 1.15e-02 | -0.405000 | 3.57e-02 |
| Maturation of protein 3a 9683673 | 9 | 3.58e-02 | -0.404000 | 8.86e-02 |
| Maturation of protein 3a 9694719 | 9 | 3.58e-02 | -0.404000 | 8.86e-02 |
| Cristae formation | 33 | 5.97e-05 | -0.404000 | 4.50e-04 |
| MECP2 regulates transcription of neuronal ligands | 5 | 1.19e-01 | -0.403000 | 2.21e-01 |
| Response of Mtb to phagocytosis | 22 | 1.15e-03 | -0.400000 | 5.26e-03 |
| FGFR3 ligand binding and activation | 5 | 1.22e-01 | 0.399000 | 2.25e-01 |
| FGFR3c ligand binding and activation | 5 | 1.22e-01 | 0.399000 | 2.25e-01 |
| Acyl chain remodelling of PI | 10 | 2.88e-02 | 0.399000 | 7.40e-02 |
| Synthesis of Dolichyl-phosphate | 6 | 9.23e-02 | -0.397000 | 1.83e-01 |
| Extension of Telomeres | 51 | 9.49e-07 | -0.397000 | 1.13e-05 |
| Nuclear events stimulated by ALK signaling in cancer | 33 | 8.06e-05 | -0.397000 | 5.69e-04 |
| FLT3 signaling through SRC family kinases | 6 | 9.30e-02 | -0.396000 | 1.84e-01 |
| Degradation of DVL | 43 | 7.14e-06 | -0.396000 | 7.20e-05 |
| TBC/RABGAPs | 45 | 4.39e-06 | -0.396000 | 4.73e-05 |
| NF-kB is activated and signals survival | 12 | 1.79e-02 | -0.395000 | 5.08e-02 |
| POLB-Dependent Long Patch Base Excision Repair | 8 | 5.33e-02 | -0.395000 | 1.19e-01 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | 30 | 1.99e-04 | -0.392000 | 1.18e-03 |
| Transcription of E2F targets under negative control by DREAM complex | 19 | 3.10e-03 | -0.392000 | 1.26e-02 |
| Transcriptional regulation of granulopoiesis | 44 | 6.85e-06 | -0.392000 | 7.01e-05 |
| Zinc influx into cells by the SLC39 gene family | 9 | 4.24e-02 | -0.391000 | 1.01e-01 |
| Packaging Of Telomere Ends | 18 | 4.25e-03 | -0.389000 | 1.61e-02 |
| mRNA Splicing - Minor Pathway | 50 | 1.97e-06 | -0.389000 | 2.25e-05 |
| Ubiquitin Mediated Degradation of Phosphorylated Cdc25A | 39 | 2.72e-05 | -0.388000 | 2.35e-04 |
| p53-Independent DNA Damage Response | 39 | 2.72e-05 | -0.388000 | 2.35e-04 |
| p53-Independent G1/S DNA damage checkpoint | 39 | 2.72e-05 | -0.388000 | 2.35e-04 |
| Synthesis of pyrophosphates in the cytosol | 8 | 5.90e-02 | -0.386000 | 1.28e-01 |
| Tandem pore domain potassium channels | 5 | 1.36e-01 | -0.385000 | 2.43e-01 |
| Peptide chain elongation | 87 | 5.21e-10 | -0.385000 | 1.14e-08 |
| Coenzyme A biosynthesis | 7 | 7.76e-02 | -0.385000 | 1.60e-01 |
| FASTK family proteins regulate processing and stability of mitochondrial RNAs | 19 | 3.77e-03 | -0.384000 | 1.46e-02 |
| Signaling by FGFR2 IIIa TM | 18 | 4.82e-03 | -0.384000 | 1.76e-02 |
| Basigin interactions | 21 | 2.35e-03 | -0.383000 | 9.88e-03 |
| Suppression of phagosomal maturation | 12 | 2.15e-02 | -0.383000 | 5.87e-02 |
| Formation of the Early Elongation Complex | 33 | 1.40e-04 | -0.383000 | 8.80e-04 |
| Formation of the HIV-1 Early Elongation Complex | 33 | 1.40e-04 | -0.383000 | 8.80e-04 |
| Biosynthesis of Lipoxins (LX) | 6 | 1.05e-01 | -0.382000 | 2.02e-01 |
| NR1H2 and NR1H3-mediated signaling | 38 | 4.63e-05 | -0.382000 | 3.60e-04 |
| Condensation of Prophase Chromosomes | 27 | 5.95e-04 | -0.382000 | 3.01e-03 |
| FLT3 signaling by CBL mutants | 7 | 8.06e-02 | -0.381000 | 1.65e-01 |
| Leishmania infection | 213 | 8.05e-22 | -0.381000 | 4.12e-20 |
| Parasitic Infection Pathways | 213 | 8.05e-22 | -0.381000 | 4.12e-20 |
| Arachidonate production from DAG | 5 | 1.40e-01 | -0.381000 | 2.48e-01 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | 42 | 2.13e-05 | -0.379000 | 1.89e-04 |
| HIV Transcription Elongation | 42 | 2.13e-05 | -0.379000 | 1.89e-04 |
| Tat-mediated elongation of the HIV-1 transcript | 42 | 2.13e-05 | -0.379000 | 1.89e-04 |
| Hh mutants are degraded by ERAD | 42 | 2.15e-05 | -0.379000 | 1.90e-04 |
| SARS-CoV-2 modulates autophagy | 11 | 2.96e-02 | -0.379000 | 7.54e-02 |
| Phospholipase C-mediated cascade; FGFR2 | 8 | 6.39e-02 | 0.378000 | 1.37e-01 |
| FGFR2c ligand binding and activation | 5 | 1.44e-01 | 0.378000 | 2.51e-01 |
| Eukaryotic Translation Elongation | 92 | 4.01e-10 | -0.377000 | 9.20e-09 |
| Mitochondrial translation elongation | 90 | 6.36e-10 | -0.377000 | 1.33e-08 |
| Pre-NOTCH Processing in Golgi | 18 | 5.72e-03 | -0.376000 | 2.03e-02 |
| RND2 GTPase cycle | 36 | 9.37e-05 | -0.376000 | 6.40e-04 |
| Heme degradation | 10 | 3.94e-02 | -0.376000 | 9.49e-02 |
| HDMs demethylate histones | 22 | 2.26e-03 | -0.376000 | 9.54e-03 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | 7 | 8.55e-02 | -0.375000 | 1.72e-01 |
| NADE modulates death signalling | 5 | 1.46e-01 | -0.375000 | 2.55e-01 |
| ERKs are inactivated | 13 | 1.92e-02 | -0.375000 | 5.37e-02 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | 188 | 7.34e-19 | -0.375000 | 3.07e-17 |
| Advanced glycosylation endproduct receptor signaling | 12 | 2.50e-02 | -0.374000 | 6.65e-02 |
| DNA Damage Recognition in GG-NER | 38 | 6.90e-05 | -0.373000 | 5.05e-04 |
| Regulation of TP53 Activity through Association with Co-factors | 13 | 1.99e-02 | -0.373000 | 5.52e-02 |
| Vif-mediated degradation of APOBEC3G | 41 | 3.70e-05 | -0.372000 | 3.01e-04 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | 16 | 9.99e-03 | -0.372000 | 3.21e-02 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | 42 | 3.10e-05 | -0.371000 | 2.63e-04 |
| tRNA processing in the mitochondrion | 24 | 1.63e-03 | -0.371000 | 7.26e-03 |
| SCF-beta-TrCP mediated degradation of Emi1 | 42 | 3.14e-05 | -0.371000 | 2.65e-04 |
| Viral mRNA Translation | 87 | 2.23e-09 | -0.371000 | 4.22e-08 |
| Defective CFTR causes cystic fibrosis | 47 | 1.09e-05 | -0.371000 | 1.04e-04 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | 27 | 8.90e-04 | -0.369000 | 4.21e-03 |
| Hh mutants abrogate ligand secretion | 43 | 2.79e-05 | -0.369000 | 2.40e-04 |
| SRP-dependent cotranslational protein targeting to membrane | 110 | 2.32e-11 | -0.369000 | 5.89e-10 |
| rRNA processing in the mitochondrion | 24 | 1.77e-03 | -0.369000 | 7.77e-03 |
| Repression of WNT target genes | 14 | 1.70e-02 | -0.368000 | 4.90e-02 |
| Mucopolysaccharidoses | 11 | 3.46e-02 | -0.368000 | 8.64e-02 |
| Fc epsilon receptor (FCERI) signaling | 180 | 1.65e-17 | -0.368000 | 6.34e-16 |
| The role of Nef in HIV-1 replication and disease pathogenesis | 28 | 7.64e-04 | -0.367000 | 3.72e-03 |
| Autodegradation of the E3 ubiquitin ligase COP1 | 38 | 8.89e-05 | -0.367000 | 6.14e-04 |
| Nectin/Necl trans heterodimerization | 5 | 1.55e-01 | -0.367000 | 2.66e-01 |
| GDP-fucose biosynthesis | 6 | 1.20e-01 | -0.367000 | 2.22e-01 |
| Base Excision Repair | 57 | 1.74e-06 | -0.366000 | 2.01e-05 |
| Eukaryotic Translation Termination | 91 | 1.60e-09 | -0.366000 | 3.11e-08 |
| N-glycan antennae elongation in the medial/trans-Golgi | 21 | 3.72e-03 | -0.366000 | 1.44e-02 |
| Infection with Mycobacterium tuberculosis | 26 | 1.25e-03 | -0.366000 | 5.68e-03 |
| Signaling by the B Cell Receptor (BCR) | 151 | 9.58e-15 | -0.365000 | 3.36e-13 |
| Selenocysteine synthesis | 91 | 1.78e-09 | -0.365000 | 3.40e-08 |
| Formation of a pool of free 40S subunits | 99 | 4.07e-10 | -0.363000 | 9.22e-09 |
| Cross-presentation of soluble exogenous antigens (endosomes) | 35 | 2.00e-04 | -0.363000 | 1.19e-03 |
| EPH-ephrin mediated repulsion of cells | 43 | 3.76e-05 | -0.363000 | 3.03e-04 |
| Vpu mediated degradation of CD4 | 39 | 8.66e-05 | -0.363000 | 6.00e-04 |
| Nucleotide salvage | 21 | 3.98e-03 | -0.363000 | 1.53e-02 |
| Heme biosynthesis | 13 | 2.39e-02 | -0.362000 | 6.41e-02 |
| CRMPs in Sema3A signaling | 14 | 1.92e-02 | -0.361000 | 5.37e-02 |
| Reactions specific to the complex N-glycan synthesis pathway | 7 | 9.82e-02 | -0.361000 | 1.92e-01 |
| Defective LFNG causes SCDO3 | 5 | 1.63e-01 | -0.360000 | 2.74e-01 |
| Cardiogenesis | 14 | 1.96e-02 | -0.360000 | 5.46e-02 |
| Beta oxidation of octanoyl-CoA to hexanoyl-CoA | 5 | 1.63e-01 | -0.360000 | 2.75e-01 |
| Phenylalanine metabolism | 5 | 1.64e-01 | -0.360000 | 2.75e-01 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | 41 | 6.79e-05 | -0.359000 | 5.00e-04 |
| Protein hydroxylation | 17 | 1.04e-02 | -0.359000 | 3.32e-02 |
| RNA Polymerase I Promoter Opening | 17 | 1.05e-02 | -0.359000 | 3.33e-02 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | 93 | 2.28e-09 | -0.358000 | 4.26e-08 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | 23 | 2.97e-03 | -0.358000 | 1.20e-02 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | 13 | 2.58e-02 | -0.357000 | 6.79e-02 |
| Formation of HIV elongation complex in the absence of HIV Tat | 44 | 4.17e-05 | -0.357000 | 3.28e-04 |
| UCH proteinases | 73 | 1.33e-07 | -0.357000 | 1.87e-06 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | 59 | 2.21e-06 | -0.356000 | 2.51e-05 |
| SARS-CoV-1 modulates host translation machinery | 36 | 2.21e-04 | -0.356000 | 1.28e-03 |
| Pexophagy | 10 | 5.16e-02 | -0.355000 | 1.17e-01 |
| HDACs deacetylate histones | 45 | 3.72e-05 | -0.355000 | 3.01e-04 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | 37 | 1.90e-04 | -0.355000 | 1.14e-03 |
| Mitochondrial translation initiation | 90 | 6.09e-09 | -0.354000 | 1.09e-07 |
| G2 Phase | 5 | 1.70e-01 | -0.354000 | 2.83e-01 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | 69 | 3.91e-07 | -0.353000 | 5.05e-06 |
| Phenylalanine and tyrosine metabolism | 9 | 6.67e-02 | -0.353000 | 1.42e-01 |
| Metabolism of porphyrins | 22 | 4.18e-03 | -0.353000 | 1.59e-02 |
| Beta oxidation of decanoyl-CoA to octanoyl-CoA-CoA | 6 | 1.35e-01 | -0.353000 | 2.42e-01 |
| RNA Pol II CTD phosphorylation and interaction with CE | 27 | 1.52e-03 | -0.353000 | 6.80e-03 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | 27 | 1.52e-03 | -0.353000 | 6.80e-03 |
| RUNX2 regulates genes involved in cell migration | 6 | 1.35e-01 | -0.353000 | 2.42e-01 |
| Formation of the beta-catenin:TCF transactivating complex | 44 | 5.23e-05 | -0.352000 | 4.00e-04 |
| Mitochondrial translation termination | 90 | 7.54e-09 | -0.352000 | 1.31e-07 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | 21 | 5.21e-03 | -0.352000 | 1.87e-02 |
| Telomere C-strand (Lagging Strand) Synthesis | 34 | 3.81e-04 | -0.352000 | 2.09e-03 |
| Translation of Structural Proteins 9683701 | 29 | 1.04e-03 | -0.352000 | 4.83e-03 |
| Defects in biotin (Btn) metabolism | 8 | 8.49e-02 | -0.352000 | 1.72e-01 |
| Resolution of Abasic Sites (AP sites) | 38 | 1.79e-04 | -0.351000 | 1.09e-03 |
| Regulation of ornithine decarboxylase (ODC) | 38 | 1.83e-04 | -0.351000 | 1.11e-03 |
| Signaling by FGFR3 in disease | 14 | 2.34e-02 | 0.350000 | 6.33e-02 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | 25 | 2.47e-03 | -0.350000 | 1.03e-02 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | 32 | 6.20e-04 | -0.350000 | 3.12e-03 |
| PKA activation in glucagon signalling | 14 | 2.37e-02 | -0.349000 | 6.38e-02 |
| CDH11 homotypic and heterotypic interactions | 5 | 1.77e-01 | -0.349000 | 2.91e-01 |
| MAPK3 (ERK1) activation | 10 | 5.66e-02 | -0.348000 | 1.24e-01 |
| Negative regulation of NOTCH4 signaling | 44 | 6.57e-05 | -0.348000 | 4.85e-04 |
| Regulation of HMOX1 expression and activity | 5 | 1.78e-01 | -0.348000 | 2.93e-01 |
| Influenza Viral RNA Transcription and Replication | 134 | 3.92e-12 | -0.347000 | 1.08e-10 |
| Ubiquitin-dependent degradation of Cyclin D | 39 | 1.78e-04 | -0.347000 | 1.09e-03 |
| Fibronectin matrix formation | 6 | 1.41e-01 | -0.347000 | 2.49e-01 |
| Phospholipase C-mediated cascade; FGFR4 | 6 | 1.43e-01 | 0.345000 | 2.51e-01 |
| Citric acid cycle (TCA cycle) | 34 | 5.02e-04 | -0.345000 | 2.61e-03 |
| Asymmetric localization of PCP proteins | 49 | 2.99e-05 | -0.345000 | 2.56e-04 |
| Epithelial-Mesenchymal Transition (EMT) during gastrulation | 6 | 1.44e-01 | -0.344000 | 2.52e-01 |
| STAT3 nuclear events downstream of ALK signaling | 11 | 4.82e-02 | -0.344000 | 1.11e-01 |
| Fructose metabolism | 7 | 1.16e-01 | -0.343000 | 2.16e-01 |
| PCP/CE pathway | 75 | 2.81e-07 | -0.343000 | 3.71e-06 |
| Activation of the pre-replicative complex | 32 | 7.88e-04 | -0.343000 | 3.80e-03 |
| Degradation of beta-catenin by the destruction complex | 72 | 4.93e-07 | -0.343000 | 6.17e-06 |
| PCNA-Dependent Long Patch Base Excision Repair | 21 | 6.69e-03 | -0.342000 | 2.29e-02 |
| Translation of Structural Proteins 9694635 | 56 | 9.66e-06 | -0.342000 | 9.30e-05 |
| Regulation of RUNX3 expression and activity | 45 | 7.31e-05 | -0.342000 | 5.27e-04 |
| NFE2L2 regulating ER-stress associated genes | 5 | 1.86e-01 | -0.341000 | 3.03e-01 |
| Interleukin-9 signaling | 8 | 9.46e-02 | -0.341000 | 1.86e-01 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | 14 | 2.71e-02 | -0.341000 | 7.07e-02 |
| L13a-mediated translational silencing of Ceruloplasmin expression | 109 | 7.74e-10 | -0.341000 | 1.60e-08 |
| Respiratory electron transport | 149 | 6.95e-13 | -0.341000 | 2.09e-11 |
| Somitogenesis | 41 | 1.61e-04 | -0.340000 | 9.97e-04 |
| Activation of gene expression by SREBF (SREBP) | 42 | 1.39e-04 | -0.340000 | 8.80e-04 |
| Eicosanoid ligand-binding receptors | 13 | 3.50e-02 | -0.338000 | 8.71e-02 |
| Regulation of expression of SLITs and ROBOs | 148 | 1.30e-12 | -0.338000 | 3.73e-11 |
| Defective Intrinsic Pathway for Apoptosis | 24 | 4.30e-03 | -0.337000 | 1.62e-02 |
| PTK6 promotes HIF1A stabilization | 6 | 1.53e-01 | 0.337000 | 2.64e-01 |
| Late SARS-CoV-2 Infection Events | 64 | 3.26e-06 | -0.336000 | 3.57e-05 |
| Prostanoid ligand receptors | 8 | 9.96e-02 | -0.336000 | 1.93e-01 |
| PKA activation | 15 | 2.42e-02 | -0.336000 | 6.46e-02 |
| GLI3 is processed to GLI3R by the proteasome | 46 | 8.22e-05 | -0.336000 | 5.76e-04 |
| Base-Excision Repair, AP Site Formation | 29 | 1.76e-03 | -0.336000 | 7.75e-03 |
| PRC2 methylates histones and DNA | 27 | 2.55e-03 | -0.335000 | 1.06e-02 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | 25 | 3.72e-03 | -0.335000 | 1.44e-02 |
| Synthesis of PI | 5 | 1.95e-01 | -0.335000 | 3.14e-01 |
| Degradation of GLI2 by the proteasome | 45 | 1.06e-04 | -0.334000 | 7.05e-04 |
| Defective EXT1 causes exostoses 1, TRPS2 and CHDS | 11 | 5.52e-02 | -0.334000 | 1.22e-01 |
| Defective EXT2 causes exostoses 2 | 11 | 5.52e-02 | -0.334000 | 1.22e-01 |
| Lysosphingolipid and LPA receptors | 11 | 5.53e-02 | -0.334000 | 1.22e-01 |
| PI-3K cascade:FGFR3 | 10 | 6.78e-02 | 0.334000 | 1.44e-01 |
| Aerobic respiration and respiratory electron transport | 245 | 2.29e-19 | -0.334000 | 1.02e-17 |
| Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane | 11 | 5.57e-02 | -0.333000 | 1.23e-01 |
| Acyl chain remodeling of CL | 5 | 1.97e-01 | -0.333000 | 3.17e-01 |
| p75NTR recruits signalling complexes | 12 | 4.58e-02 | -0.333000 | 1.07e-01 |
| Formation of paraxial mesoderm | 52 | 3.29e-05 | -0.333000 | 2.75e-04 |
| Cap-dependent Translation Initiation | 117 | 5.67e-10 | -0.332000 | 1.20e-08 |
| Eukaryotic Translation Initiation | 117 | 5.67e-10 | -0.332000 | 1.20e-08 |
| Mitochondrial translation | 96 | 1.94e-08 | -0.332000 | 3.09e-07 |
| Degradation of AXIN | 42 | 2.03e-04 | -0.331000 | 1.20e-03 |
| Orc1 removal from chromatin | 58 | 1.34e-05 | -0.330000 | 1.25e-04 |
| Mitochondrial tRNA aminoacylation | 21 | 8.77e-03 | -0.330000 | 2.88e-02 |
| Hedgehog ligand biogenesis | 47 | 9.03e-05 | -0.330000 | 6.21e-04 |
| PI-3K cascade:FGFR2 | 13 | 3.94e-02 | 0.330000 | 9.49e-02 |
| Metabolism of polyamines | 46 | 1.08e-04 | -0.330000 | 7.18e-04 |
| Carnitine shuttle | 12 | 4.81e-02 | -0.330000 | 1.11e-01 |
| Nuclear events mediated by NFE2L2 | 82 | 2.50e-07 | -0.329000 | 3.39e-06 |
| N-Glycan antennae elongation | 13 | 4.00e-02 | -0.329000 | 9.61e-02 |
| Ethanol oxidation | 7 | 1.32e-01 | -0.329000 | 2.39e-01 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | 35 | 7.74e-04 | -0.328000 | 3.76e-03 |
| Signaling by CSF1 (M-CSF) in myeloid cells | 30 | 1.87e-03 | -0.328000 | 8.11e-03 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | 10 | 7.33e-02 | -0.327000 | 1.54e-01 |
| MASTL Facilitates Mitotic Progression | 10 | 7.36e-02 | -0.327000 | 1.54e-01 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | 16 | 2.38e-02 | -0.326000 | 6.39e-02 |
| Platelet sensitization by LDL | 16 | 2.38e-02 | -0.326000 | 6.40e-02 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | 42 | 2.52e-04 | -0.326000 | 1.44e-03 |
| Diseases associated with glycosylation precursor biosynthesis | 15 | 2.87e-02 | -0.326000 | 7.39e-02 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | 17 | 2.00e-02 | -0.326000 | 5.53e-02 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | 17 | 2.00e-02 | -0.326000 | 5.53e-02 |
| Influenza Infection | 153 | 3.54e-12 | -0.326000 | 9.89e-11 |
| DNA Double Strand Break Response | 47 | 1.12e-04 | -0.326000 | 7.42e-04 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | 110 | 3.72e-09 | -0.325000 | 6.70e-08 |
| Late endosomal microautophagy | 30 | 2.05e-03 | -0.325000 | 8.79e-03 |
| Cellular response to chemical stress | 179 | 6.05e-14 | -0.325000 | 1.97e-12 |
| Regulation of PTEN gene transcription | 59 | 1.56e-05 | -0.325000 | 1.44e-04 |
| Beta-catenin phosphorylation cascade | 17 | 2.04e-02 | -0.325000 | 5.62e-02 |
| Degradation of GLI1 by the proteasome | 46 | 1.38e-04 | -0.325000 | 8.80e-04 |
| Signaling by ALK | 24 | 5.93e-03 | -0.324000 | 2.06e-02 |
| Azathioprine ADME | 20 | 1.20e-02 | -0.324000 | 3.71e-02 |
| Translation | 292 | 1.42e-21 | -0.324000 | 6.83e-20 |
| Chromosome Maintenance | 103 | 1.30e-08 | -0.324000 | 2.16e-07 |
| Synthesis of IP3 and IP4 in the cytosol | 22 | 8.54e-03 | -0.324000 | 2.82e-02 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | 113 | 2.81e-09 | -0.323000 | 5.10e-08 |
| Nonsense-Mediated Decay (NMD) | 113 | 2.81e-09 | -0.323000 | 5.10e-08 |
| Biosynthesis of E-series 18(S)-resolvins | 5 | 2.11e-01 | -0.323000 | 3.34e-01 |
| CS/DS degradation | 9 | 9.35e-02 | -0.323000 | 1.85e-01 |
| Folding of actin by CCT/TriC | 10 | 7.73e-02 | -0.323000 | 1.59e-01 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | 99 | 2.95e-08 | -0.322000 | 4.62e-07 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | 46 | 1.56e-04 | -0.322000 | 9.65e-04 |
| MECP2 regulates transcription factors | 5 | 2.13e-01 | 0.321000 | 3.36e-01 |
| Telomere C-strand synthesis initiation | 13 | 4.48e-02 | -0.321000 | 1.06e-01 |
| G1/S Transition | 120 | 1.25e-09 | -0.321000 | 2.49e-08 |
| Mitochondrial protein degradation | 96 | 5.63e-08 | -0.321000 | 8.34e-07 |
| Complex I biogenesis | 66 | 6.78e-06 | -0.320000 | 6.98e-05 |
| STAT5 activation downstream of FLT3 ITD mutants | 9 | 9.67e-02 | -0.320000 | 1.90e-01 |
| Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE) | 5 | 2.16e-01 | 0.320000 | 3.39e-01 |
| Polymerase switching on the C-strand of the telomere | 26 | 4.82e-03 | -0.319000 | 1.76e-02 |
| Response to metal ions | 6 | 1.76e-01 | -0.319000 | 2.90e-01 |
| Signal transduction by L1 | 20 | 1.35e-02 | -0.319000 | 4.07e-02 |
| Netrin mediated repulsion signals | 5 | 2.17e-01 | -0.319000 | 3.41e-01 |
| Glucagon-type ligand receptors | 20 | 1.37e-02 | -0.318000 | 4.10e-02 |
| Regulation of Apoptosis | 40 | 4.99e-04 | -0.318000 | 2.60e-03 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | 44 | 2.64e-04 | -0.318000 | 1.50e-03 |
| DNA Damage/Telomere Stress Induced Senescence | 42 | 3.67e-04 | -0.318000 | 2.02e-03 |
| Dectin-1 mediated noncanonical NF-kB signaling | 48 | 1.41e-04 | -0.318000 | 8.84e-04 |
| MicroRNA (miRNA) biogenesis | 24 | 7.08e-03 | -0.318000 | 2.40e-02 |
| Respiratory syncytial virus (RSV) attachment and entry | 19 | 1.67e-02 | -0.317000 | 4.85e-02 |
| LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production | 5 | 2.20e-01 | -0.317000 | 3.45e-01 |
| Signaling by Retinoic Acid | 29 | 3.21e-03 | -0.316000 | 1.29e-02 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | 36 | 1.04e-03 | -0.316000 | 4.83e-03 |
| Reduction of cytosolic Ca++ levels | 9 | 1.02e-01 | -0.315000 | 1.97e-01 |
| Regulation of TP53 Activity through Methylation | 19 | 1.77e-02 | -0.314000 | 5.02e-02 |
| Selenoamino acid metabolism | 114 | 6.61e-09 | -0.314000 | 1.17e-07 |
| Activation of the phototransduction cascade | 9 | 1.03e-01 | 0.314000 | 1.98e-01 |
| N-glycan trimming and elongation in the cis-Golgi | 5 | 2.24e-01 | -0.314000 | 3.50e-01 |
| Cellular response to hypoxia | 59 | 3.06e-05 | -0.314000 | 2.61e-04 |
| Diseases of programmed cell death | 58 | 3.57e-05 | -0.314000 | 2.93e-04 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer’s disease models | 21 | 1.29e-02 | -0.313000 | 3.93e-02 |
| Neurodegenerative Diseases | 21 | 1.29e-02 | -0.313000 | 3.93e-02 |
| PD-1 signaling | 28 | 4.10e-03 | -0.313000 | 1.56e-02 |
| Interconversion of nucleotide di- and triphosphates | 27 | 4.87e-03 | -0.313000 | 1.77e-02 |
| LDL clearance | 17 | 2.56e-02 | -0.313000 | 6.76e-02 |
| Formyl peptide receptors bind formyl peptides and many other ligands | 7 | 1.53e-01 | -0.312000 | 2.63e-01 |
| Formation of xylulose-5-phosphate | 5 | 2.27e-01 | -0.312000 | 3.52e-01 |
| TGFBR3 PTM regulation | 10 | 8.85e-02 | -0.311000 | 1.77e-01 |
| Lysosome Vesicle Biogenesis | 32 | 2.34e-03 | -0.311000 | 9.85e-03 |
| Translocation of ZAP-70 to Immunological synapse | 24 | 8.38e-03 | -0.311000 | 2.78e-02 |
| Calnexin/calreticulin cycle | 26 | 6.11e-03 | -0.311000 | 2.11e-02 |
| Mitotic G1 phase and G1/S transition | 138 | 2.99e-10 | -0.310000 | 6.94e-09 |
| Amyloid fiber formation | 51 | 1.28e-04 | -0.310000 | 8.29e-04 |
| RUNX1 regulates transcription of genes involved in BCR signaling | 6 | 1.89e-01 | 0.310000 | 3.06e-01 |
| Serotonin Neurotransmitter Release Cycle | 13 | 5.31e-02 | -0.310000 | 1.19e-01 |
| Metabolism of folate and pterines | 16 | 3.21e-02 | -0.309000 | 8.13e-02 |
| ATF6 (ATF6-alpha) activates chaperone genes | 10 | 9.02e-02 | -0.309000 | 1.79e-01 |
| HDL assembly | 6 | 1.90e-01 | -0.309000 | 3.08e-01 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | 55 | 7.39e-05 | -0.309000 | 5.31e-04 |
| Negative feedback regulation of MAPK pathway | 6 | 1.90e-01 | -0.309000 | 3.08e-01 |
| Host Interactions of HIV factors | 118 | 7.06e-09 | -0.308000 | 1.24e-07 |
| Complex IV assembly | 45 | 3.47e-04 | -0.308000 | 1.93e-03 |
| Calcineurin activates NFAT | 9 | 1.10e-01 | -0.308000 | 2.08e-01 |
| Transcriptional regulation of brown and beige adipocyte differentiation | 23 | 1.08e-02 | -0.307000 | 3.40e-02 |
| Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | 23 | 1.08e-02 | -0.307000 | 3.40e-02 |
| Synaptic adhesion-like molecules | 17 | 2.85e-02 | -0.307000 | 7.34e-02 |
| Cleavage of the damaged pyrimidine | 27 | 5.84e-03 | -0.306000 | 2.05e-02 |
| Depyrimidination | 27 | 5.84e-03 | -0.306000 | 2.05e-02 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | 27 | 5.84e-03 | -0.306000 | 2.05e-02 |
| STAT5 Activation | 7 | 1.60e-01 | -0.306000 | 2.71e-01 |
| Glycogen metabolism | 22 | 1.29e-02 | -0.306000 | 3.93e-02 |
| Synthesis of PIPs at the late endosome membrane | 11 | 7.90e-02 | 0.306000 | 1.62e-01 |
| G1/S DNA Damage Checkpoints | 54 | 1.02e-04 | -0.306000 | 6.86e-04 |
| SCF(Skp2)-mediated degradation of p27/p21 | 50 | 1.85e-04 | -0.306000 | 1.12e-03 |
| Regulation of APC/C activators between G1/S and early anaphase | 68 | 1.32e-05 | -0.306000 | 1.23e-04 |
| Transcriptional regulation by small RNAs | 61 | 3.70e-05 | -0.305000 | 3.01e-04 |
| Neutrophil degranulation | 456 | 4.71e-29 | -0.305000 | 7.57e-27 |
| FGFR2 alternative splicing | 25 | 8.35e-03 | -0.305000 | 2.78e-02 |
| Organic anion transporters | 7 | 1.63e-01 | -0.305000 | 2.74e-01 |
| HuR (ELAVL1) binds and stabilizes mRNA | 10 | 9.55e-02 | -0.304000 | 1.88e-01 |
| ATF6 (ATF6-alpha) activates chaperones | 12 | 6.81e-02 | -0.304000 | 1.44e-01 |
| Chondroitin sulfate/dermatan sulfate metabolism | 39 | 1.04e-03 | -0.303000 | 4.83e-03 |
| Viral Messenger RNA Synthesis | 44 | 4.96e-04 | -0.303000 | 2.59e-03 |
| TNFR1-mediated ceramide production | 6 | 1.98e-01 | -0.303000 | 3.18e-01 |
| TP53 Regulates Transcription of Cell Cycle Genes | 48 | 2.78e-04 | -0.303000 | 1.57e-03 |
| PI-3K cascade:FGFR4 | 11 | 8.19e-02 | 0.303000 | 1.67e-01 |
| Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion | 7 | 1.65e-01 | -0.303000 | 2.77e-01 |
| Lagging Strand Synthesis | 20 | 1.91e-02 | -0.303000 | 5.36e-02 |
| Protein repair | 6 | 1.99e-01 | -0.303000 | 3.19e-01 |
| Ubiquinol biosynthesis | 13 | 5.89e-02 | -0.303000 | 1.28e-01 |
| p75NTR signals via NF-kB | 15 | 4.28e-02 | -0.302000 | 1.01e-01 |
| MET activates PI3K/AKT signaling | 5 | 2.42e-01 | 0.302000 | 3.70e-01 |
| NIK–>noncanonical NF-kB signaling | 46 | 3.94e-04 | -0.302000 | 2.14e-03 |
| Proteasome assembly | 51 | 1.91e-04 | -0.302000 | 1.14e-03 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | 14 | 5.07e-02 | -0.302000 | 1.15e-01 |
| HS-GAG biosynthesis | 21 | 1.67e-02 | -0.302000 | 4.85e-02 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | 62 | 4.09e-05 | -0.301000 | 3.26e-04 |
| Fatty acids | 8 | 1.40e-01 | 0.301000 | 2.48e-01 |
| TCF dependent signaling in response to WNT | 152 | 1.53e-10 | -0.301000 | 3.63e-09 |
| Cyclin A/B1/B2 associated events during G2/M transition | 25 | 9.33e-03 | -0.300000 | 3.04e-02 |
| Regulation of cytoskeletal remodeling and cell spreading by IPP complex components | 8 | 1.42e-01 | -0.300000 | 2.50e-01 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | 64 | 3.36e-05 | -0.300000 | 2.79e-04 |
| Ketone body metabolism | 8 | 1.42e-01 | -0.299000 | 2.50e-01 |
| Sulfur amino acid metabolism | 22 | 1.52e-02 | -0.299000 | 4.48e-02 |
| Metabolism of carbohydrates | 241 | 1.26e-15 | -0.299000 | 4.67e-14 |
| Formation of the ternary complex, and subsequently, the 43S complex | 51 | 2.22e-04 | -0.299000 | 1.29e-03 |
| Cyclin A:Cdk2-associated events at S phase entry | 75 | 7.85e-06 | -0.298000 | 7.75e-05 |
| Beta-oxidation of pristanoyl-CoA | 9 | 1.21e-01 | -0.298000 | 2.24e-01 |
| PIWI-interacting RNA (piRNA) biogenesis | 23 | 1.34e-02 | -0.298000 | 4.05e-02 |
| KEAP1-NFE2L2 pathway | 107 | 1.02e-07 | -0.298000 | 1.50e-06 |
| Glucagon signaling in metabolic regulation | 26 | 8.61e-03 | -0.298000 | 2.84e-02 |
| Stabilization of p53 | 43 | 7.37e-04 | -0.297000 | 3.61e-03 |
| SARS-CoV-2 modulates host translation machinery | 49 | 3.15e-04 | -0.297000 | 1.76e-03 |
| p38MAPK events | 13 | 6.38e-02 | -0.297000 | 1.37e-01 |
| Defective RIPK1-mediated regulated necrosis | 7 | 1.74e-01 | -0.297000 | 2.88e-01 |
| Defective pyroptosis | 27 | 7.61e-03 | -0.297000 | 2.57e-02 |
| Constitutive Signaling by NOTCH1 HD Domain Mutants | 14 | 5.47e-02 | -0.297000 | 1.22e-01 |
| Signaling by NOTCH1 HD Domain Mutants in Cancer | 14 | 5.47e-02 | -0.297000 | 1.22e-01 |
| p53-Dependent G1 DNA Damage Response | 52 | 2.16e-04 | -0.296000 | 1.26e-03 |
| p53-Dependent G1/S DNA damage checkpoint | 52 | 2.16e-04 | -0.296000 | 1.26e-03 |
| Pregnenolone biosynthesis | 10 | 1.05e-01 | -0.296000 | 2.01e-01 |
| Induction of Cell-Cell Fusion | 8 | 1.47e-01 | -0.296000 | 2.55e-01 |
| Synthesis of DNA | 108 | 1.03e-07 | -0.296000 | 1.50e-06 |
| Replacement of protamines by nucleosomes in the male pronucleus | 13 | 6.44e-02 | -0.296000 | 1.38e-01 |
| Paracetamol ADME | 19 | 2.56e-02 | -0.296000 | 6.76e-02 |
| Unfolded Protein Response (UPR) | 85 | 2.42e-06 | -0.296000 | 2.69e-05 |
| CTNNB1 S33 mutants aren’t phosphorylated | 15 | 4.74e-02 | -0.296000 | 1.09e-01 |
| CTNNB1 S37 mutants aren’t phosphorylated | 15 | 4.74e-02 | -0.296000 | 1.09e-01 |
| CTNNB1 S45 mutants aren’t phosphorylated | 15 | 4.74e-02 | -0.296000 | 1.09e-01 |
| CTNNB1 T41 mutants aren’t phosphorylated | 15 | 4.74e-02 | -0.296000 | 1.09e-01 |
| Signaling by CTNNB1 phospho-site mutants | 15 | 4.74e-02 | -0.296000 | 1.09e-01 |
| Signaling by GSK3beta mutants | 15 | 4.74e-02 | -0.296000 | 1.09e-01 |
| mRNA Capping | 29 | 5.87e-03 | -0.296000 | 2.06e-02 |
| Translation initiation complex formation | 58 | 9.86e-05 | -0.296000 | 6.62e-04 |
| Synthesis of Ketone Bodies | 6 | 2.10e-01 | -0.295000 | 3.33e-01 |
| CDK-mediated phosphorylation and removal of Cdc6 | 60 | 7.55e-05 | -0.295000 | 5.39e-04 |
| Prefoldin mediated transfer of substrate to CCT/TriC | 25 | 1.06e-02 | -0.295000 | 3.36e-02 |
| Metabolism of amine-derived hormones | 10 | 1.07e-01 | 0.295000 | 2.03e-01 |
| Diseases of carbohydrate metabolism | 29 | 6.11e-03 | -0.294000 | 2.11e-02 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | 59 | 9.69e-05 | -0.293000 | 6.55e-04 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | 20 | 2.32e-02 | -0.293000 | 6.28e-02 |
| DNA Replication Pre-Initiation | 103 | 2.73e-07 | -0.293000 | 3.66e-06 |
| Spry regulation of FGF signaling | 16 | 4.28e-02 | -0.292000 | 1.01e-01 |
| Cellular response to starvation | 147 | 9.20e-10 | -0.292000 | 1.87e-08 |
| Homology Directed Repair | 110 | 1.16e-07 | -0.292000 | 1.66e-06 |
| Heparan sulfate/heparin (HS-GAG) metabolism | 41 | 1.25e-03 | -0.291000 | 5.67e-03 |
| Inhibition of replication initiation of damaged DNA by RB1/E2F1 | 13 | 6.91e-02 | -0.291000 | 1.46e-01 |
| Signaling by ROBO receptors | 188 | 5.82e-12 | -0.291000 | 1.54e-10 |
| Regulation of gene expression by Hypoxia-inducible Factor | 8 | 1.54e-01 | -0.291000 | 2.65e-01 |
| Notch-HLH transcription pathway | 28 | 7.77e-03 | -0.291000 | 2.61e-02 |
| Glycosaminoglycan metabolism | 98 | 6.60e-07 | -0.291000 | 8.10e-06 |
| HDR through MMEJ (alt-NHEJ) | 12 | 8.18e-02 | -0.290000 | 1.67e-01 |
| Cyclin E associated events during G1/S transition | 73 | 1.80e-05 | -0.290000 | 1.64e-04 |
| G2/M Checkpoints | 126 | 1.93e-08 | -0.290000 | 3.09e-07 |
| SUMOylation of DNA replication proteins | 46 | 6.77e-04 | -0.290000 | 3.36e-03 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | 63 | 7.15e-05 | -0.289000 | 5.20e-04 |
| Mitochondrial protein import | 63 | 7.19e-05 | -0.289000 | 5.21e-04 |
| Purine salvage | 12 | 8.30e-02 | -0.289000 | 1.69e-01 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | 59 | 1.23e-04 | -0.289000 | 8.04e-04 |
| Interleukin receptor SHC signaling | 23 | 1.64e-02 | -0.289000 | 4.79e-02 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | 13 | 7.21e-02 | -0.288000 | 1.51e-01 |
| Modulation by Mtb of host immune system | 7 | 1.88e-01 | -0.287000 | 3.05e-01 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | 28 | 8.49e-03 | -0.287000 | 2.81e-02 |
| Glutamate and glutamine metabolism | 12 | 8.50e-02 | -0.287000 | 1.72e-01 |
| Cholesterol biosynthesis | 26 | 1.13e-02 | -0.287000 | 3.52e-02 |
| Viral Infection Pathways | 775 | 3.16e-42 | -0.287000 | 8.69e-40 |
| Noncanonical activation of NOTCH3 | 8 | 1.60e-01 | -0.287000 | 2.71e-01 |
| Regulation of RAS by GAPs | 55 | 2.37e-04 | -0.286000 | 1.37e-03 |
| A tetrasaccharide linker sequence is required for GAG synthesis | 18 | 3.54e-02 | -0.286000 | 8.79e-02 |
| Myoclonic epilepsy of Lafora | 8 | 1.61e-01 | -0.286000 | 2.72e-01 |
| Plasma lipoprotein assembly, remodeling, and clearance | 55 | 2.40e-04 | -0.286000 | 1.38e-03 |
| SARS-CoV Infections | 434 | 1.34e-24 | -0.286000 | 1.09e-22 |
| DNA Replication | 128 | 2.21e-08 | -0.286000 | 3.50e-07 |
| Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation | 52 | 3.63e-04 | -0.286000 | 2.00e-03 |
| InlA-mediated entry of Listeria monocytogenes into host cells | 9 | 1.38e-01 | -0.286000 | 2.46e-01 |
| Gap junction trafficking | 28 | 8.95e-03 | -0.285000 | 2.93e-02 |
| Adenylate cyclase inhibitory pathway | 11 | 1.02e-01 | -0.285000 | 1.96e-01 |
| Chromatin modifications during the maternal to zygotic transition (MZT) | 23 | 1.80e-02 | -0.285000 | 5.09e-02 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | 60 | 1.38e-04 | -0.285000 | 8.80e-04 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | 52 | 3.86e-04 | -0.284000 | 2.11e-03 |
| Zygotic genome activation (ZGA) | 5 | 2.71e-01 | -0.284000 | 3.99e-01 |
| Ribosomal scanning and start codon recognition | 58 | 1.81e-04 | -0.284000 | 1.10e-03 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | 76 | 1.87e-05 | -0.284000 | 1.69e-04 |
| Regulation of signaling by CBL | 22 | 2.12e-02 | -0.284000 | 5.81e-02 |
| Neurofascin interactions | 5 | 2.73e-01 | 0.283000 | 4.01e-01 |
| RHO GTPases activate IQGAPs | 25 | 1.43e-02 | -0.283000 | 4.26e-02 |
| Metabolism of nucleotides | 85 | 6.57e-06 | -0.283000 | 6.84e-05 |
| PECAM1 interactions | 12 | 8.99e-02 | -0.283000 | 1.79e-01 |
| HSF1 activation | 26 | 1.26e-02 | -0.283000 | 3.87e-02 |
| SUMO is conjugated to E1 (UBA2:SAE1) | 5 | 2.74e-01 | -0.282000 | 4.02e-01 |
| Activated NOTCH1 Transmits Signal to the Nucleus | 27 | 1.11e-02 | -0.282000 | 3.48e-02 |
| Displacement of DNA glycosylase by APEX1 | 9 | 1.43e-01 | -0.282000 | 2.50e-01 |
| DNA Double-Strand Break Repair | 137 | 1.18e-08 | -0.282000 | 2.00e-07 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | 14 | 6.81e-02 | -0.282000 | 1.44e-01 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | 61 | 1.42e-04 | -0.282000 | 8.90e-04 |
| Nucleotide Excision Repair | 108 | 4.49e-07 | -0.281000 | 5.73e-06 |
| CD28 dependent PI3K/Akt signaling | 22 | 2.25e-02 | -0.281000 | 6.13e-02 |
| Assembly of the pre-replicative complex | 87 | 5.90e-06 | -0.281000 | 6.18e-05 |
| Attachment and Entry 9694614 | 15 | 5.97e-02 | -0.281000 | 1.30e-01 |
| Hedgehog ‘on’ state | 66 | 8.00e-05 | -0.281000 | 5.67e-04 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | 61 | 1.50e-04 | -0.281000 | 9.32e-04 |
| Hydrolysis of LPC | 8 | 1.70e-01 | 0.280000 | 2.83e-01 |
| Glutathione synthesis and recycling | 10 | 1.25e-01 | -0.280000 | 2.29e-01 |
| Translesion Synthesis by POLH | 18 | 3.99e-02 | -0.280000 | 9.59e-02 |
| Attachment of GPI anchor to uPAR | 7 | 2.00e-01 | -0.279000 | 3.20e-01 |
| Glucose metabolism | 76 | 2.59e-05 | -0.279000 | 2.27e-04 |
| Inhibition of Signaling by Overexpressed EGFR | 5 | 2.80e-01 | -0.279000 | 4.07e-01 |
| Signaling by Overexpressed Wild-Type EGFR in Cancer | 5 | 2.80e-01 | -0.279000 | 4.07e-01 |
| Evasion by RSV of host interferon responses | 20 | 3.12e-02 | -0.278000 | 7.93e-02 |
| Common Pathway of Fibrin Clot Formation | 13 | 8.26e-02 | -0.278000 | 1.68e-01 |
| mTORC1-mediated signalling | 24 | 1.84e-02 | -0.278000 | 5.17e-02 |
| tRNA Aminoacylation | 42 | 1.84e-03 | -0.278000 | 8.03e-03 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | 29 | 9.84e-03 | -0.277000 | 3.17e-02 |
| Formation of TC-NER Pre-Incision Complex | 51 | 6.34e-04 | -0.277000 | 3.18e-03 |
| Recycling pathway of L1 | 40 | 2.48e-03 | -0.276000 | 1.03e-02 |
| Maturation of TCA enzymes and regulation of TCA cycle | 20 | 3.24e-02 | -0.276000 | 8.19e-02 |
| Autodegradation of Cdh1 by Cdh1:APC/C | 54 | 4.43e-04 | -0.276000 | 2.35e-03 |
| MTOR signalling | 39 | 2.83e-03 | -0.276000 | 1.17e-02 |
| DNA replication initiation | 8 | 1.76e-01 | -0.276000 | 2.90e-01 |
| APC/C:Cdc20 mediated degradation of Securin | 55 | 3.97e-04 | -0.276000 | 2.15e-03 |
| NOTCH1 Intracellular Domain Regulates Transcription | 44 | 1.53e-03 | -0.276000 | 6.85e-03 |
| SUMO is transferred from E1 to E2 (UBE2I, UBC9) | 7 | 2.06e-01 | -0.276000 | 3.28e-01 |
| Infectious disease | 958 | 1.37e-47 | -0.276000 | 6.62e-45 |
| Switching of origins to a post-replicative state | 79 | 2.27e-05 | -0.276000 | 2.00e-04 |
| COPI-mediated anterograde transport | 92 | 4.88e-06 | -0.276000 | 5.19e-05 |
| Molybdenum cofactor biosynthesis | 6 | 2.43e-01 | -0.275000 | 3.71e-01 |
| RHOC GTPase cycle | 71 | 6.16e-05 | -0.275000 | 4.60e-04 |
| Signaling by NOTCH3 | 42 | 2.11e-03 | -0.274000 | 8.99e-03 |
| Thrombin signalling through proteinase activated receptors (PARs) | 27 | 1.37e-02 | -0.274000 | 4.10e-02 |
| APC truncation mutants have impaired AXIN binding | 14 | 7.61e-02 | -0.274000 | 1.58e-01 |
| AXIN missense mutants destabilize the destruction complex | 14 | 7.61e-02 | -0.274000 | 1.58e-01 |
| Signaling by AMER1 mutants | 14 | 7.61e-02 | -0.274000 | 1.58e-01 |
| Signaling by APC mutants | 14 | 7.61e-02 | -0.274000 | 1.58e-01 |
| Signaling by AXIN mutants | 14 | 7.61e-02 | -0.274000 | 1.58e-01 |
| Truncations of AMER1 destabilize the destruction complex | 14 | 7.61e-02 | -0.274000 | 1.58e-01 |
| APC/C-mediated degradation of cell cycle proteins | 75 | 4.15e-05 | -0.274000 | 3.28e-04 |
| Regulation of mitotic cell cycle | 75 | 4.15e-05 | -0.274000 | 3.28e-04 |
| SHC-mediated cascade:FGFR2 | 13 | 8.76e-02 | 0.274000 | 1.75e-01 |
| Chromatin modifying enzymes | 214 | 5.19e-12 | -0.274000 | 1.39e-10 |
| Chromatin organization | 214 | 5.19e-12 | -0.274000 | 1.39e-10 |
| The NLRP3 inflammasome | 16 | 5.82e-02 | -0.273000 | 1.27e-01 |
| Formation of RNA Pol II elongation complex | 56 | 4.06e-04 | -0.273000 | 2.19e-03 |
| RNA Polymerase II Transcription Elongation | 56 | 4.06e-04 | -0.273000 | 2.19e-03 |
| Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA | 6 | 2.47e-01 | -0.273000 | 3.75e-01 |
| Deactivation of the beta-catenin transactivating complex | 36 | 4.61e-03 | -0.273000 | 1.72e-02 |
| FLT3 Signaling | 38 | 3.65e-03 | -0.272000 | 1.42e-02 |
| HSF1-dependent transactivation | 30 | 9.82e-03 | -0.272000 | 3.17e-02 |
| Protein folding | 83 | 1.78e-05 | -0.272000 | 1.63e-04 |
| Transport to the Golgi and subsequent modification | 171 | 8.71e-10 | -0.272000 | 1.78e-08 |
| COPI-dependent Golgi-to-ER retrograde traffic | 90 | 9.11e-06 | -0.271000 | 8.87e-05 |
| Activation of RAS in B cells | 5 | 2.96e-01 | 0.270000 | 4.24e-01 |
| RHOB GTPase cycle | 64 | 1.89e-04 | -0.270000 | 1.14e-03 |
| G beta:gamma signalling through PLC beta | 17 | 5.41e-02 | -0.270000 | 1.21e-01 |
| Presynaptic function of Kainate receptors | 17 | 5.41e-02 | -0.270000 | 1.21e-01 |
| DEx/H-box helicases activate type I IFN and inflammatory cytokines production | 7 | 2.18e-01 | -0.269000 | 3.42e-01 |
| H139Hfs13* PPM1K causes a mild variant of MSUD | 5 | 2.98e-01 | 0.269000 | 4.25e-01 |
| Maple Syrup Urine Disease | 5 | 2.98e-01 | 0.269000 | 4.25e-01 |
| HIV Infection | 213 | 1.46e-11 | -0.268000 | 3.80e-10 |
| Proton-coupled monocarboxylate transport | 6 | 2.56e-01 | -0.268000 | 3.84e-01 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | 104 | 2.34e-06 | -0.268000 | 2.62e-05 |
| Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580 K2555) Translocation Mutant | 6 | 2.56e-01 | -0.268000 | 3.84e-01 |
| Signaling by NOTCH1 t(7;9)(NOTCH1:M1580 K2555) Translocation Mutant | 6 | 2.56e-01 | -0.268000 | 3.84e-01 |
| Thyroxine biosynthesis | 5 | 3.00e-01 | 0.267000 | 4.28e-01 |
| Phosphorylation of CD3 and TCR zeta chains | 27 | 1.62e-02 | -0.267000 | 4.75e-02 |
| Glycolysis | 68 | 1.37e-04 | -0.267000 | 8.80e-04 |
| TP53 Regulates Transcription of Caspase Activators and Caspases | 12 | 1.09e-01 | -0.267000 | 2.06e-01 |
| Translesion synthesis by REV1 | 16 | 6.45e-02 | -0.267000 | 1.38e-01 |
| Vitamin B5 (pantothenate) metabolism | 20 | 3.88e-02 | -0.267000 | 9.41e-02 |
| PKA-mediated phosphorylation of CREB | 17 | 5.69e-02 | -0.267000 | 1.25e-01 |
| Budding and maturation of HIV virion | 26 | 1.86e-02 | -0.267000 | 5.23e-02 |
| Mismatch Repair | 15 | 7.41e-02 | -0.266000 | 1.55e-01 |
| MAPK1 (ERK2) activation | 9 | 1.67e-01 | -0.266000 | 2.78e-01 |
| PTEN Regulation | 127 | 2.28e-07 | -0.266000 | 3.11e-06 |
| Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET) | 5 | 3.04e-01 | 0.266000 | 4.31e-01 |
| Signaling by NOTCH | 173 | 1.65e-09 | -0.266000 | 3.17e-08 |
| Role of ABL in ROBO-SLIT signaling | 6 | 2.60e-01 | -0.265000 | 3.88e-01 |
| FRS-mediated FGFR2 signaling | 15 | 7.53e-02 | 0.265000 | 1.57e-01 |
| RHOV GTPase cycle | 36 | 5.90e-03 | -0.265000 | 2.06e-02 |
| Hemostasis | 558 | 8.86e-27 | -0.265000 | 9.48e-25 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | 30 | 1.20e-02 | -0.265000 | 3.71e-02 |
| rRNA processing | 213 | 2.67e-11 | -0.265000 | 6.59e-10 |
| Post-chaperonin tubulin folding pathway | 18 | 5.21e-02 | -0.264000 | 1.17e-01 |
| Dual incision in TC-NER | 63 | 2.86e-04 | -0.264000 | 1.62e-03 |
| MHC class II antigen presentation | 113 | 1.23e-06 | -0.264000 | 1.45e-05 |
| Chaperonin-mediated protein folding | 77 | 6.16e-05 | -0.264000 | 4.60e-04 |
| Association of TriC/CCT with target proteins during biosynthesis | 35 | 6.90e-03 | -0.264000 | 2.35e-02 |
| CTLA4 inhibitory signaling | 21 | 3.64e-02 | -0.264000 | 8.96e-02 |
| DNA Repair | 289 | 1.24e-14 | -0.263000 | 4.26e-13 |
| Inositol phosphate metabolism | 42 | 3.13e-03 | -0.263000 | 1.26e-02 |
| RA biosynthesis pathway | 13 | 1.01e-01 | -0.263000 | 1.94e-01 |
| ABC transporter disorders | 60 | 4.24e-04 | -0.263000 | 2.26e-03 |
| Cellular responses to stress | 697 | 2.45e-32 | -0.263000 | 5.25e-30 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | 38 | 5.07e-03 | -0.263000 | 1.83e-02 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | 76 | 7.55e-05 | -0.263000 | 5.39e-04 |
| Protein localization | 157 | 1.42e-08 | -0.262000 | 2.34e-07 |
| HCMV Late Events | 67 | 2.10e-04 | -0.262000 | 1.24e-03 |
| Uptake and function of anthrax toxins | 11 | 1.34e-01 | -0.261000 | 2.41e-01 |
| Signaling by WNT in cancer | 30 | 1.34e-02 | -0.261000 | 4.05e-02 |
| Linoleic acid (LA) metabolism | 7 | 2.33e-01 | -0.261000 | 3.59e-01 |
| Gap junction trafficking and regulation | 30 | 1.35e-02 | -0.260000 | 4.07e-02 |
| Cytosolic sulfonation of small molecules | 18 | 5.58e-02 | -0.260000 | 1.23e-01 |
| SHC-mediated cascade:FGFR3 | 10 | 1.54e-01 | 0.260000 | 2.64e-01 |
| RHOU GTPase cycle | 40 | 4.43e-03 | -0.260000 | 1.66e-02 |
| EGFR interacts with phospholipase C-gamma | 6 | 2.70e-01 | -0.260000 | 3.99e-01 |
| Signaling by NOTCH4 | 68 | 2.11e-04 | -0.260000 | 1.24e-03 |
| Activation of ATR in response to replication stress | 37 | 6.28e-03 | -0.260000 | 2.16e-02 |
| Vesicle-mediated transport | 665 | 3.05e-30 | -0.259000 | 5.34e-28 |
| S Phase | 150 | 4.21e-08 | -0.259000 | 6.49e-07 |
| Innate Immune System | 970 | 1.07e-42 | -0.259000 | 3.42e-40 |
| VEGFR2 mediated vascular permeability | 25 | 2.49e-02 | -0.259000 | 6.61e-02 |
| Glycogen synthesis | 11 | 1.37e-01 | -0.259000 | 2.44e-01 |
| RUNX1 regulates transcription of genes involved in differentiation of myeloid cells | 6 | 2.73e-01 | -0.258000 | 4.01e-01 |
| Cellular responses to stimuli | 778 | 1.14e-34 | -0.258000 | 2.75e-32 |
| G beta:gamma signalling through PI3Kgamma | 22 | 3.59e-02 | -0.258000 | 8.86e-02 |
| Inactivation of CSF3 (G-CSF) signaling | 24 | 2.85e-02 | -0.258000 | 7.34e-02 |
| Transport of vitamins, nucleosides, and related molecules | 31 | 1.29e-02 | -0.258000 | 3.93e-02 |
| Constitutive Signaling by AKT1 E17K in Cancer | 26 | 2.30e-02 | -0.258000 | 6.24e-02 |
| Signaling by activated point mutants of FGFR1 | 5 | 3.19e-01 | 0.258000 | 4.47e-01 |
| Initiation of Nuclear Envelope (NE) Reformation | 19 | 5.19e-02 | -0.258000 | 1.17e-01 |
| Positive epigenetic regulation of rRNA expression | 60 | 5.61e-04 | -0.257000 | 2.85e-03 |
| TP53 Regulates Transcription of DNA Repair Genes | 61 | 5.12e-04 | -0.257000 | 2.63e-03 |
| Role of second messengers in netrin-1 signaling | 6 | 2.76e-01 | -0.257000 | 4.03e-01 |
| SUMOylation of immune response proteins | 12 | 1.24e-01 | -0.257000 | 2.27e-01 |
| Signaling by NOTCH1 | 66 | 3.12e-04 | -0.257000 | 1.75e-03 |
| Interleukin-2 family signaling | 38 | 6.24e-03 | -0.256000 | 2.15e-02 |
| ER to Golgi Anterograde Transport | 145 | 1.04e-07 | -0.256000 | 1.50e-06 |
| The canonical retinoid cycle in rods (twilight vision) | 9 | 1.84e-01 | -0.256000 | 3.01e-01 |
| NFE2L2 regulating tumorigenic genes | 11 | 1.42e-01 | -0.255000 | 2.50e-01 |
| Caspase-mediated cleavage of cytoskeletal proteins | 12 | 1.28e-01 | -0.254000 | 2.32e-01 |
| Synthesis of 5-eicosatetraenoic acids | 7 | 2.45e-01 | -0.254000 | 3.73e-01 |
| Sema4D mediated inhibition of cell attachment and migration | 7 | 2.47e-01 | -0.253000 | 3.75e-01 |
| FRS-mediated FGFR3 signaling | 12 | 1.30e-01 | 0.252000 | 2.36e-01 |
| Transcriptional regulation by RUNX2 | 89 | 3.98e-05 | -0.252000 | 3.18e-04 |
| Recognition of DNA damage by PCNA-containing replication complex | 30 | 1.71e-02 | -0.252000 | 4.90e-02 |
| TLR3-mediated TICAM1-dependent programmed cell death | 6 | 2.87e-01 | -0.251000 | 4.14e-01 |
| rRNA processing in the nucleus and cytosol | 189 | 2.67e-09 | -0.251000 | 4.94e-08 |
| p75 NTR receptor-mediated signalling | 89 | 4.52e-05 | -0.250000 | 3.53e-04 |
| Synthesis of wybutosine at G37 of tRNA(Phe) | 6 | 2.89e-01 | 0.250000 | 4.17e-01 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | 14 | 1.05e-01 | -0.250000 | 2.02e-01 |
| HS-GAG degradation | 20 | 5.30e-02 | -0.250000 | 1.19e-01 |
| Ephrin signaling | 18 | 6.64e-02 | -0.250000 | 1.41e-01 |
| Cell death signalling via NRAGE, NRIF and NADE | 69 | 3.31e-04 | -0.250000 | 1.84e-03 |
| NRAGE signals death through JNK | 52 | 1.83e-03 | -0.250000 | 8.00e-03 |
| Regulation of CDH11 gene transcription | 5 | 3.34e-01 | -0.250000 | 4.64e-01 |
| Activation of BH3-only proteins | 30 | 1.80e-02 | -0.249000 | 5.09e-02 |
| HCMV Infection | 106 | 9.25e-06 | -0.249000 | 8.96e-05 |
| RORA activates gene expression | 18 | 6.73e-02 | -0.249000 | 1.43e-01 |
| RSK activation | 7 | 2.54e-01 | -0.249000 | 3.83e-01 |
| Miscellaneous substrates | 8 | 2.23e-01 | 0.249000 | 3.49e-01 |
| Senescence-Associated Secretory Phenotype (SASP) | 65 | 5.32e-04 | -0.248000 | 2.72e-03 |
| Asparagine N-linked glycosylation | 286 | 5.33e-13 | -0.248000 | 1.63e-11 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | 11 | 1.56e-01 | -0.247000 | 2.67e-01 |
| Mitochondrial biogenesis | 91 | 4.73e-05 | -0.247000 | 3.65e-04 |
| Acyl chain remodelling of PG | 11 | 1.57e-01 | 0.247000 | 2.68e-01 |
| Interleukin-12 signaling | 44 | 4.69e-03 | -0.246000 | 1.74e-02 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | 32 | 1.59e-02 | -0.246000 | 4.67e-02 |
| Costimulation by the CD28 family | 74 | 2.50e-04 | -0.246000 | 1.44e-03 |
| Global Genome Nucleotide Excision Repair (GG-NER) | 84 | 9.72e-05 | -0.246000 | 6.55e-04 |
| AKT phosphorylates targets in the cytosol | 14 | 1.12e-01 | -0.245000 | 2.10e-01 |
| Glycogen storage diseases | 13 | 1.26e-01 | -0.245000 | 2.30e-01 |
| Major pathway of rRNA processing in the nucleolus and cytosol | 179 | 1.50e-08 | -0.245000 | 2.43e-07 |
| Regulation of PTEN stability and activity | 55 | 1.66e-03 | -0.245000 | 7.36e-03 |
| rRNA modification in the mitochondrion | 8 | 2.31e-01 | -0.245000 | 3.57e-01 |
| Frs2-mediated activation | 11 | 1.60e-01 | -0.245000 | 2.71e-01 |
| Pre-NOTCH Expression and Processing | 63 | 7.89e-04 | -0.244000 | 3.80e-03 |
| RHOA GTPase cycle | 138 | 7.10e-07 | -0.244000 | 8.63e-06 |
| NFE2L2 regulating inflammation associated genes | 5 | 3.44e-01 | -0.244000 | 4.75e-01 |
| PI-3K cascade:FGFR1 | 13 | 1.28e-01 | 0.244000 | 2.32e-01 |
| Cellular responses to mechanical stimuli | 82 | 1.40e-04 | -0.243000 | 8.80e-04 |
| Response of endothelial cells to shear stress | 82 | 1.40e-04 | -0.243000 | 8.80e-04 |
| GPVI-mediated activation cascade | 32 | 1.74e-02 | -0.243000 | 4.95e-02 |
| Mitotic Prophase | 96 | 3.95e-05 | -0.243000 | 3.17e-04 |
| Regulation of MITF-M-dependent genes involved in pigmentation | 38 | 9.65e-03 | -0.243000 | 3.13e-02 |
| Golgi-to-ER retrograde transport | 123 | 3.36e-06 | -0.243000 | 3.66e-05 |
| GPER1 signaling | 38 | 9.78e-03 | -0.242000 | 3.16e-02 |
| NFE2L2 regulating anti-oxidant/detoxification enzymes | 16 | 9.36e-02 | -0.242000 | 1.85e-01 |
| EPH-Ephrin signaling | 81 | 1.67e-04 | -0.242000 | 1.03e-03 |
| Regulation of IFNA/IFNB signaling | 12 | 1.47e-01 | -0.242000 | 2.55e-01 |
| Signaling by FGFR4 in disease | 11 | 1.66e-01 | 0.241000 | 2.78e-01 |
| Synthesis of 12-eicosatetraenoic acid derivatives | 6 | 3.06e-01 | -0.241000 | 4.34e-01 |
| Diseases associated with glycosaminoglycan metabolism | 26 | 3.33e-02 | -0.241000 | 8.38e-02 |
| RHO GTPases Activate WASPs and WAVEs | 35 | 1.37e-02 | -0.241000 | 4.10e-02 |
| RUNX2 regulates bone development | 24 | 4.12e-02 | -0.241000 | 9.85e-02 |
| RNA Polymerase I Promoter Clearance | 64 | 8.70e-04 | -0.241000 | 4.13e-03 |
| RNA Polymerase I Transcription | 64 | 8.70e-04 | -0.241000 | 4.13e-03 |
| Regulation of innate immune responses to cytosolic DNA | 14 | 1.19e-01 | -0.241000 | 2.21e-01 |
| SARS-CoV-1-host interactions | 94 | 5.54e-05 | -0.241000 | 4.19e-04 |
| Generation of second messenger molecules | 38 | 1.04e-02 | -0.240000 | 3.32e-02 |
| SUMOylation of chromatin organization proteins | 57 | 1.72e-03 | -0.240000 | 7.58e-03 |
| Signaling by CSF3 (G-CSF) | 29 | 2.55e-02 | -0.240000 | 6.74e-02 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | 50 | 3.38e-03 | -0.240000 | 1.34e-02 |
| Transcriptional Regulation by TP53 | 346 | 1.95e-14 | -0.239000 | 6.58e-13 |
| Activation of HOX genes during differentiation | 70 | 5.46e-04 | -0.239000 | 2.77e-03 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | 70 | 5.46e-04 | -0.239000 | 2.77e-03 |
| Synthesis of 15-eicosatetraenoic acid derivatives | 6 | 3.11e-01 | 0.239000 | 4.39e-01 |
| Phospholipase C-mediated cascade: FGFR1 | 8 | 2.43e-01 | 0.238000 | 3.71e-01 |
| Androgen biosynthesis | 5 | 3.57e-01 | 0.238000 | 4.89e-01 |
| G2/M Transition | 177 | 4.90e-08 | -0.238000 | 7.33e-07 |
| Signaling by WNT | 240 | 2.32e-10 | -0.237000 | 5.46e-09 |
| Fanconi Anemia Pathway | 36 | 1.38e-02 | -0.237000 | 4.10e-02 |
| Mitotic G2-G2/M phases | 179 | 4.48e-08 | -0.237000 | 6.80e-07 |
| SHC-mediated cascade:FGFR4 | 11 | 1.75e-01 | 0.236000 | 2.88e-01 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | 53 | 2.91e-03 | -0.236000 | 1.18e-02 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | 53 | 2.91e-03 | -0.236000 | 1.18e-02 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | 53 | 2.91e-03 | -0.236000 | 1.18e-02 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | 53 | 2.91e-03 | -0.236000 | 1.18e-02 |
| Signaling by NOTCH1 in Cancer | 53 | 2.91e-03 | -0.236000 | 1.18e-02 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | 27 | 3.35e-02 | -0.236000 | 8.41e-02 |
| Transport and synthesis of PAPS | 6 | 3.16e-01 | -0.236000 | 4.45e-01 |
| Transcription of the HIV genome | 67 | 8.32e-04 | -0.236000 | 3.98e-03 |
| Cellular Senescence | 143 | 1.11e-06 | -0.236000 | 1.31e-05 |
| HATs acetylate histones | 92 | 9.26e-05 | -0.236000 | 6.35e-04 |
| RAS processing | 23 | 5.06e-02 | -0.235000 | 1.15e-01 |
| Clathrin-mediated endocytosis | 126 | 5.09e-06 | -0.235000 | 5.38e-05 |
| ER-Phagosome pathway | 75 | 4.31e-04 | -0.235000 | 2.29e-03 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | 36 | 1.47e-02 | -0.235000 | 4.33e-02 |
| Cytosolic tRNA aminoacylation | 24 | 4.64e-02 | -0.235000 | 1.08e-01 |
| Formation of tubulin folding intermediates by CCT/TriC | 21 | 6.24e-02 | -0.235000 | 1.35e-01 |
| Adipogenesis | 95 | 7.60e-05 | -0.235000 | 5.40e-04 |
| RUNX2 regulates osteoblast differentiation | 19 | 7.71e-02 | -0.234000 | 1.59e-01 |
| Cell Cycle, Mitotic | 488 | 8.21e-19 | -0.234000 | 3.37e-17 |
| FGFRL1 modulation of FGFR1 signaling | 7 | 2.84e-01 | 0.234000 | 4.12e-01 |
| Transcriptional regulation by RUNX1 | 170 | 1.49e-07 | -0.233000 | 2.05e-06 |
| Late Phase of HIV Life Cycle | 131 | 4.04e-06 | -0.233000 | 4.37e-05 |
| Energy dependent regulation of mTOR by LKB1-AMPK | 27 | 3.63e-02 | -0.233000 | 8.95e-02 |
| FRS-mediated FGFR4 signaling | 13 | 1.47e-01 | 0.233000 | 2.55e-01 |
| Metabolism of fat-soluble vitamins | 28 | 3.34e-02 | -0.232000 | 8.40e-02 |
| Drug ADME | 57 | 2.43e-03 | -0.232000 | 1.02e-02 |
| Transcriptional Regulation by E2F6 | 34 | 1.92e-02 | -0.232000 | 5.37e-02 |
| Intrinsic Pathway for Apoptosis | 54 | 3.24e-03 | -0.232000 | 1.30e-02 |
| Attenuation phase | 23 | 5.47e-02 | -0.231000 | 1.22e-01 |
| BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members | 9 | 2.30e-01 | -0.231000 | 3.56e-01 |
| Meiotic synapsis | 43 | 8.72e-03 | -0.231000 | 2.87e-02 |
| RNA Polymerase III Chain Elongation | 18 | 8.96e-02 | -0.231000 | 1.79e-01 |
| alpha-linolenic (omega3) and linoleic (omega6) acid metabolism | 12 | 1.66e-01 | -0.231000 | 2.78e-01 |
| alpha-linolenic acid (ALA) metabolism | 12 | 1.66e-01 | -0.231000 | 2.78e-01 |
| G-protein beta:gamma signalling | 29 | 3.16e-02 | -0.231000 | 8.01e-02 |
| Regulation of RUNX2 expression and activity | 54 | 3.39e-03 | -0.230000 | 1.34e-02 |
| DNA Damage Reversal | 8 | 2.59e-01 | -0.230000 | 3.87e-01 |
| Beta-catenin independent WNT signaling | 126 | 7.90e-06 | -0.230000 | 7.76e-05 |
| Autophagy | 142 | 2.12e-06 | -0.230000 | 2.42e-05 |
| Mitochondrial iron-sulfur cluster biogenesis | 13 | 1.51e-01 | -0.230000 | 2.60e-01 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | 28 | 3.53e-02 | -0.230000 | 8.77e-02 |
| Regulation of TP53 Activity | 153 | 9.30e-07 | -0.230000 | 1.11e-05 |
| Nuclear Pore Complex (NPC) Disassembly | 36 | 1.71e-02 | -0.230000 | 4.90e-02 |
| Effects of PIP2 hydrolysis | 24 | 5.20e-02 | -0.229000 | 1.17e-01 |
| Mitochondrial RNA degradation | 25 | 4.74e-02 | -0.229000 | 1.09e-01 |
| EGFR Transactivation by Gastrin | 7 | 2.94e-01 | 0.229000 | 4.23e-01 |
| SARS-CoV-2 targets host intracellular signalling and regulatory pathways | 11 | 1.88e-01 | -0.229000 | 3.06e-01 |
| Termination of translesion DNA synthesis | 32 | 2.51e-02 | -0.229000 | 6.66e-02 |
| Antimicrobial peptides | 34 | 2.10e-02 | -0.229000 | 5.77e-02 |
| Vasopressin regulates renal water homeostasis via Aquaporins | 34 | 2.12e-02 | -0.228000 | 5.81e-02 |
| Amino acids regulate mTORC1 | 48 | 6.23e-03 | -0.228000 | 2.15e-02 |
| Cell Cycle | 611 | 6.04e-22 | -0.228000 | 3.42e-20 |
| Processing of DNA double-strand break ends | 69 | 1.06e-03 | -0.228000 | 4.92e-03 |
| Disease | 1623 | 5.13e-53 | -0.228000 | 9.88e-50 |
| COPII-mediated vesicle transport | 67 | 1.27e-03 | -0.228000 | 5.75e-03 |
| Interleukin-15 signaling | 14 | 1.41e-01 | -0.227000 | 2.49e-01 |
| TP53 Regulates Metabolic Genes | 78 | 5.20e-04 | -0.227000 | 2.67e-03 |
| Translesion synthesis by POLI | 17 | 1.06e-01 | -0.227000 | 2.02e-01 |
| SUMO E3 ligases SUMOylate target proteins | 161 | 7.12e-07 | -0.226000 | 8.63e-06 |
| G alpha (s) signalling events | 96 | 1.28e-04 | -0.226000 | 8.29e-04 |
| Ion transport by P-type ATPases | 44 | 9.46e-03 | -0.226000 | 3.07e-02 |
| SUMOylation of transcription factors | 16 | 1.17e-01 | -0.226000 | 2.19e-01 |
| Erythropoietin activates STAT5 | 6 | 3.38e-01 | -0.226000 | 4.69e-01 |
| SARS-CoV-1 Infection | 137 | 5.50e-06 | -0.225000 | 5.80e-05 |
| HIV Life Cycle | 144 | 3.24e-06 | -0.225000 | 3.57e-05 |
| Macroautophagy | 128 | 1.16e-05 | -0.224000 | 1.09e-04 |
| Prostacyclin signalling through prostacyclin receptor | 16 | 1.20e-01 | -0.224000 | 2.23e-01 |
| Organic cation transport | 8 | 2.72e-01 | 0.224000 | 4.01e-01 |
| Organic cation/anion/zwitterion transport | 8 | 2.72e-01 | 0.224000 | 4.01e-01 |
| Semaphorin interactions | 57 | 3.44e-03 | -0.224000 | 1.35e-02 |
| Pre-NOTCH Processing in the Endoplasmic Reticulum | 6 | 3.43e-01 | -0.224000 | 4.74e-01 |
| Activation of NF-kappaB in B cells | 54 | 4.46e-03 | -0.224000 | 1.67e-02 |
| Regulation of TP53 Expression and Degradation | 36 | 2.03e-02 | -0.224000 | 5.59e-02 |
| DCC mediated attractive signaling | 13 | 1.63e-01 | -0.224000 | 2.74e-01 |
| RUNX3 regulates NOTCH signaling | 14 | 1.49e-01 | -0.223000 | 2.57e-01 |
| RNA Polymerase I Transcription Initiation | 47 | 8.29e-03 | -0.223000 | 2.76e-02 |
| OAS antiviral response | 8 | 2.76e-01 | 0.223000 | 4.03e-01 |
| RAF-independent MAPK1/3 activation | 22 | 7.08e-02 | -0.223000 | 1.49e-01 |
| Metabolism of amino acids and derivatives | 305 | 2.41e-11 | -0.222000 | 6.04e-10 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | 191 | 1.19e-07 | -0.222000 | 1.70e-06 |
| CD28 co-stimulation | 33 | 2.75e-02 | -0.222000 | 7.12e-02 |
| Oncogene Induced Senescence | 33 | 2.78e-02 | -0.221000 | 7.18e-02 |
| Regulation of TP53 Degradation | 35 | 2.35e-02 | -0.221000 | 6.33e-02 |
| SARS-CoV-2 Infection | 267 | 4.91e-10 | -0.221000 | 1.09e-08 |
| Defective B3GALT6 causes EDSP2 and SEMDJL1 | 12 | 1.85e-01 | -0.221000 | 3.02e-01 |
| Interleukin-12 family signaling | 53 | 5.47e-03 | -0.221000 | 1.95e-02 |
| Dual Incision in GG-NER | 41 | 1.45e-02 | -0.221000 | 4.31e-02 |
| ERK/MAPK targets | 22 | 7.45e-02 | -0.220000 | 1.56e-01 |
| Oxidative Stress Induced Senescence | 77 | 8.68e-04 | -0.219000 | 4.13e-03 |
| Hedgehog ‘off’ state | 92 | 2.74e-04 | -0.219000 | 1.56e-03 |
| MAP2K and MAPK activation | 36 | 2.27e-02 | -0.219000 | 6.17e-02 |
| Cargo concentration in the ER | 31 | 3.46e-02 | -0.219000 | 8.64e-02 |
| Signaling by Nuclear Receptors | 210 | 4.33e-08 | -0.219000 | 6.62e-07 |
| Regulation of pyruvate metabolism | 32 | 3.19e-02 | -0.219000 | 8.08e-02 |
| Acetylcholine binding and downstream events | 5 | 3.97e-01 | -0.219000 | 5.31e-01 |
| Postsynaptic nicotinic acetylcholine receptors | 5 | 3.97e-01 | -0.219000 | 5.31e-01 |
| Pyruvate metabolism | 44 | 1.21e-02 | -0.219000 | 3.71e-02 |
| Zinc transporters | 12 | 1.91e-01 | -0.218000 | 3.08e-01 |
| Sema3A PAK dependent Axon repulsion | 16 | 1.31e-01 | -0.218000 | 2.37e-01 |
| Defective B4GALT7 causes EDS, progeroid type | 12 | 1.92e-01 | -0.218000 | 3.10e-01 |
| ABC-family proteins mediated transport | 81 | 7.11e-04 | -0.218000 | 3.50e-03 |
| RHO GTPases activate PKNs | 46 | 1.10e-02 | -0.217000 | 3.45e-02 |
| Signaling by ALK fusions and activated point mutants | 89 | 4.18e-04 | -0.216000 | 2.24e-03 |
| Signaling by ALK in cancer | 89 | 4.18e-04 | -0.216000 | 2.24e-03 |
| Trafficking of GluR2-containing AMPA receptors | 11 | 2.14e-01 | -0.216000 | 3.37e-01 |
| Collagen biosynthesis and modifying enzymes | 46 | 1.12e-02 | -0.216000 | 3.50e-02 |
| AURKA Activation by TPX2 | 72 | 1.55e-03 | -0.216000 | 6.90e-03 |
| VEGF binds to VEGFR leading to receptor dimerization | 5 | 4.04e-01 | -0.216000 | 5.38e-01 |
| VEGF ligand-receptor interactions | 5 | 4.04e-01 | -0.216000 | 5.38e-01 |
| SUMOylation | 167 | 1.52e-06 | -0.216000 | 1.77e-05 |
| SUMOylation of transcription cofactors | 44 | 1.34e-02 | -0.215000 | 4.05e-02 |
| Acetylcholine regulates insulin secretion | 9 | 2.64e-01 | -0.215000 | 3.92e-01 |
| ER Quality Control Compartment (ERQC) | 21 | 8.79e-02 | -0.215000 | 1.76e-01 |
| Metabolism | 1827 | 1.05e-52 | -0.215000 | 1.01e-49 |
| Acyl chain remodelling of PS | 14 | 1.64e-01 | 0.215000 | 2.75e-01 |
| Mitotic Telophase/Cytokinesis | 13 | 1.80e-01 | -0.215000 | 2.95e-01 |
| Erythropoietin activates RAS | 13 | 1.80e-01 | -0.215000 | 2.95e-01 |
| DNA Damage Bypass | 47 | 1.09e-02 | -0.215000 | 3.45e-02 |
| Aspartate and asparagine metabolism | 9 | 2.66e-01 | 0.214000 | 3.94e-01 |
| Rab regulation of trafficking | 121 | 4.75e-05 | -0.214000 | 3.65e-04 |
| Metabolism of proteins | 1775 | 8.52e-51 | -0.214000 | 5.48e-48 |
| Retinoid metabolism and transport | 25 | 6.48e-02 | -0.213000 | 1.38e-01 |
| HCMV Early Events | 84 | 7.32e-04 | -0.213000 | 3.60e-03 |
| Downstream signaling of activated FGFR2 | 20 | 9.98e-02 | 0.213000 | 1.94e-01 |
| Cell Cycle Checkpoints | 246 | 9.30e-09 | -0.213000 | 1.60e-07 |
| Pre-NOTCH Transcription and Translation | 47 | 1.18e-02 | -0.212000 | 3.64e-02 |
| Signalling to RAS | 19 | 1.10e-01 | -0.212000 | 2.07e-01 |
| Ribavirin ADME | 11 | 2.24e-01 | -0.212000 | 3.50e-01 |
| Fructose catabolism | 5 | 4.13e-01 | -0.211000 | 5.46e-01 |
| Activation of SMO | 14 | 1.72e-01 | -0.211000 | 2.85e-01 |
| Platelet calcium homeostasis | 22 | 8.69e-02 | -0.211000 | 1.74e-01 |
| Synthesis of substrates in N-glycan biosythesis | 59 | 5.18e-03 | -0.210000 | 1.86e-02 |
| Activation of kainate receptors upon glutamate binding | 26 | 6.34e-02 | -0.210000 | 1.37e-01 |
| Signaling by Hedgehog | 121 | 6.48e-05 | -0.210000 | 4.80e-04 |
| NRIF signals cell death from the nucleus | 15 | 1.59e-01 | -0.210000 | 2.70e-01 |
| Estrogen-dependent gene expression | 96 | 3.92e-04 | -0.209000 | 2.14e-03 |
| Resolution of D-Loop Structures | 35 | 3.25e-02 | -0.209000 | 8.21e-02 |
| TNFR2 non-canonical NF-kB pathway | 84 | 9.42e-04 | -0.209000 | 4.44e-03 |
| Interleukin-20 family signaling | 17 | 1.38e-01 | -0.208000 | 2.45e-01 |
| Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | 12 | 2.12e-01 | -0.208000 | 3.35e-01 |
| Transport of connexons to the plasma membrane | 12 | 2.12e-01 | -0.208000 | 3.35e-01 |
| Recycling of eIF2:GDP | 8 | 3.09e-01 | -0.208000 | 4.37e-01 |
| Signaling by high-kinase activity BRAF mutants | 33 | 3.90e-02 | -0.208000 | 9.42e-02 |
| Release of apoptotic factors from the mitochondria | 6 | 3.80e-01 | -0.207000 | 5.15e-01 |
| Adaptive Immune System | 771 | 1.22e-22 | -0.207000 | 7.58e-21 |
| The activation of arylsulfatases | 10 | 2.57e-01 | -0.207000 | 3.85e-01 |
| Mitophagy | 38 | 2.73e-02 | -0.207000 | 7.07e-02 |
| M Phase | 346 | 3.72e-11 | -0.207000 | 9.07e-10 |
| Meiotic recombination | 37 | 2.94e-02 | -0.207000 | 7.52e-02 |
| RHO GTPases Activate Formins | 128 | 5.41e-05 | -0.207000 | 4.10e-04 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | 24 | 8.00e-02 | -0.206000 | 1.64e-01 |
| SARS-CoV-1 activates/modulates innate immune responses | 40 | 2.39e-02 | -0.206000 | 6.41e-02 |
| Factors involved in megakaryocyte development and platelet production | 129 | 5.29e-05 | -0.206000 | 4.03e-04 |
| PKMTs methylate histone lysines | 43 | 1.94e-02 | -0.206000 | 5.41e-02 |
| InlB-mediated entry of Listeria monocytogenes into host cell | 12 | 2.17e-01 | -0.206000 | 3.41e-01 |
| Synthesis of PIPs at the Golgi membrane | 16 | 1.54e-01 | -0.206000 | 2.65e-01 |
| NoRC negatively regulates rRNA expression | 60 | 5.88e-03 | -0.206000 | 2.06e-02 |
| Kinesins | 51 | 1.11e-02 | -0.206000 | 3.48e-02 |
| Regulation of endogenous retroelements | 93 | 6.17e-04 | -0.205000 | 3.11e-03 |
| Downstream TCR signaling | 89 | 8.11e-04 | -0.205000 | 3.90e-03 |
| RHO GTPase Effectors | 259 | 1.30e-08 | -0.205000 | 2.16e-07 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | 19 | 1.22e-01 | -0.205000 | 2.25e-01 |
| Smooth Muscle Contraction | 34 | 3.91e-02 | -0.204000 | 9.43e-02 |
| Negative regulation of MAPK pathway | 42 | 2.20e-02 | -0.204000 | 6.02e-02 |
| Thromboxane signalling through TP receptor | 20 | 1.15e-01 | -0.203000 | 2.16e-01 |
| Inflammasomes | 21 | 1.07e-01 | -0.203000 | 2.04e-01 |
| Signaling by Leptin | 10 | 2.67e-01 | -0.203000 | 3.95e-01 |
| Norepinephrine Neurotransmitter Release Cycle | 12 | 2.24e-01 | -0.203000 | 3.50e-01 |
| ADP signalling through P2Y purinoceptor 1 | 21 | 1.08e-01 | -0.202000 | 2.05e-01 |
| Synthesis of PIPs at the early endosome membrane | 16 | 1.61e-01 | 0.202000 | 2.73e-01 |
| Aggrephagy | 34 | 4.15e-02 | -0.202000 | 9.90e-02 |
| Reversal of alkylation damage by DNA dioxygenases | 7 | 3.55e-01 | -0.202000 | 4.87e-01 |
| Sema4D in semaphorin signaling | 22 | 1.01e-01 | -0.202000 | 1.96e-01 |
| CaM pathway | 28 | 6.45e-02 | -0.202000 | 1.38e-01 |
| Calmodulin induced events | 28 | 6.45e-02 | -0.202000 | 1.38e-01 |
| Translesion synthesis by POLK | 17 | 1.50e-01 | -0.202000 | 2.59e-01 |
| Mitotic Metaphase and Anaphase | 212 | 4.12e-07 | -0.202000 | 5.30e-06 |
| G alpha (12/13) signalling events | 68 | 4.02e-03 | -0.202000 | 1.54e-02 |
| CLEC7A (Dectin-1) signaling | 86 | 1.23e-03 | -0.202000 | 5.59e-03 |
| Transcriptional regulation of white adipocyte differentiation | 77 | 2.23e-03 | -0.202000 | 9.45e-03 |
| Presynaptic depolarization and calcium channel opening | 8 | 3.24e-01 | 0.201000 | 4.53e-01 |
| ADORA2B mediated anti-inflammatory cytokines production | 36 | 3.65e-02 | -0.201000 | 8.98e-02 |
| Alpha-oxidation of phytanate | 6 | 3.94e-01 | -0.201000 | 5.29e-01 |
| Membrane Trafficking | 574 | 1.93e-16 | -0.201000 | 7.30e-15 |
| Gene Silencing by RNA | 87 | 1.22e-03 | -0.201000 | 5.55e-03 |
| Mitotic Anaphase | 211 | 5.09e-07 | -0.201000 | 6.33e-06 |
| Regulation of MECP2 expression and activity | 29 | 6.20e-02 | -0.200000 | 1.34e-01 |
| Signaling by Erythropoietin | 24 | 8.97e-02 | -0.200000 | 1.79e-01 |
| Platelet homeostasis | 69 | 4.06e-03 | -0.200000 | 1.55e-02 |
| Separation of Sister Chromatids | 168 | 7.83e-06 | -0.200000 | 7.75e-05 |
| Selective autophagy | 77 | 2.46e-03 | -0.200000 | 1.03e-02 |
| Transcriptional regulation by RUNX3 | 80 | 2.03e-03 | -0.200000 | 8.71e-03 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | 23 | 9.77e-02 | -0.199000 | 1.91e-01 |
| Immune System | 1841 | 9.99e-46 | -0.199000 | 3.85e-43 |
| Apoptotic cleavage of cell adhesion proteins | 8 | 3.30e-01 | 0.199000 | 4.59e-01 |
| Keratan sulfate/keratin metabolism | 28 | 6.86e-02 | -0.199000 | 1.45e-01 |
| RUNX3 regulates p14-ARF | 10 | 2.76e-01 | -0.199000 | 4.03e-01 |
| Rev-mediated nuclear export of HIV RNA | 35 | 4.19e-02 | -0.199000 | 9.98e-02 |
| Downstream signaling events of B Cell Receptor (BCR) | 68 | 4.61e-03 | -0.199000 | 1.72e-02 |
| Plasma lipoprotein assembly | 10 | 2.77e-01 | -0.199000 | 4.03e-01 |
| Keratan sulfate biosynthesis | 20 | 1.24e-01 | -0.198000 | 2.28e-01 |
| EPHB-mediated forward signaling | 40 | 3.00e-02 | -0.198000 | 7.64e-02 |
| RHOD GTPase cycle | 49 | 1.63e-02 | -0.198000 | 4.77e-02 |
| Molecules associated with elastic fibres | 26 | 8.10e-02 | -0.198000 | 1.65e-01 |
| RNA Polymerase II Pre-transcription Events | 77 | 2.71e-03 | -0.198000 | 1.12e-02 |
| Regulation of localization of FOXO transcription factors | 12 | 2.36e-01 | -0.197000 | 3.63e-01 |
| Downregulation of ERBB2 signaling | 24 | 9.43e-02 | -0.197000 | 1.86e-01 |
| Receptor Mediated Mitophagy | 11 | 2.57e-01 | -0.197000 | 3.85e-01 |
| VEGFA-VEGFR2 Pathway | 92 | 1.09e-03 | -0.197000 | 5.03e-03 |
| Interactions of Vpr with host cellular proteins | 37 | 3.83e-02 | -0.197000 | 9.33e-02 |
| Negative epigenetic regulation of rRNA expression | 63 | 7.07e-03 | -0.196000 | 2.40e-02 |
| TP53 Regulates Transcription of Cell Death Genes | 43 | 2.60e-02 | -0.196000 | 6.84e-02 |
| EGFR downregulation | 26 | 8.39e-02 | -0.196000 | 1.70e-01 |
| Detoxification of Reactive Oxygen Species | 30 | 6.38e-02 | -0.196000 | 1.37e-01 |
| Axon guidance | 459 | 7.09e-13 | -0.195000 | 2.10e-11 |
| PI5P Regulates TP53 Acetylation | 8 | 3.39e-01 | -0.195000 | 4.69e-01 |
| Interleukin-7 signaling | 21 | 1.21e-01 | -0.195000 | 2.24e-01 |
| HDR through Homologous Recombination (HRR) | 68 | 5.49e-03 | -0.195000 | 1.95e-02 |
| Mitochondrial calcium ion transport | 22 | 1.14e-01 | -0.194000 | 2.14e-01 |
| Respiratory Syncytial Virus Infection Pathway | 99 | 8.25e-04 | -0.194000 | 3.96e-03 |
| Downstream signaling of activated FGFR3 | 17 | 1.66e-01 | 0.194000 | 2.78e-01 |
| Phase 3 - rapid repolarisation | 6 | 4.11e-01 | 0.194000 | 5.45e-01 |
| Regulation of KIT signaling | 15 | 1.94e-01 | -0.194000 | 3.13e-01 |
| Signaling by VEGF | 99 | 8.77e-04 | -0.193000 | 4.15e-03 |
| E3 ubiquitin ligases ubiquitinate target proteins | 51 | 1.68e-02 | -0.193000 | 4.87e-02 |
| EPHA-mediated growth cone collapse | 21 | 1.25e-01 | -0.193000 | 2.29e-01 |
| Cargo recognition for clathrin-mediated endocytosis | 87 | 1.87e-03 | -0.193000 | 8.11e-03 |
| mRNA Splicing - Major Pathway | 203 | 2.25e-06 | -0.193000 | 2.53e-05 |
| PLC beta mediated events | 40 | 3.57e-02 | -0.192000 | 8.83e-02 |
| Class C/3 (Metabotropic glutamate/pheromone receptors) | 11 | 2.70e-01 | 0.192000 | 3.99e-01 |
| Elastic fibre formation | 33 | 5.64e-02 | -0.192000 | 1.24e-01 |
| Loss of Nlp from mitotic centrosomes | 69 | 5.85e-03 | -0.192000 | 2.05e-02 |
| Loss of proteins required for interphase microtubule organization from the centrosome | 69 | 5.85e-03 | -0.192000 | 2.05e-02 |
| RHO GTPases activate CIT | 18 | 1.59e-01 | -0.192000 | 2.70e-01 |
| RUNX1 regulates transcription of genes involved in WNT signaling | 5 | 4.58e-01 | -0.192000 | 5.89e-01 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | 16 | 1.85e-01 | -0.191000 | 3.02e-01 |
| Signal regulatory protein family interactions | 13 | 2.32e-01 | -0.191000 | 3.59e-01 |
| Maternal to zygotic transition (MZT) | 72 | 5.09e-03 | -0.191000 | 1.84e-02 |
| Acetylcholine Neurotransmitter Release Cycle | 10 | 2.96e-01 | -0.191000 | 4.24e-01 |
| FRS-mediated FGFR1 signaling | 15 | 2.01e-01 | 0.191000 | 3.21e-01 |
| MAPK1/MAPK3 signaling | 231 | 6.05e-07 | -0.191000 | 7.47e-06 |
| Antigen processing-Cross presentation | 89 | 1.90e-03 | -0.190000 | 8.20e-03 |
| Glycosphingolipid catabolism | 31 | 6.67e-02 | -0.190000 | 1.42e-01 |
| HIV Transcription Initiation | 45 | 2.72e-02 | -0.190000 | 7.07e-02 |
| RNA Polymerase II HIV Promoter Escape | 45 | 2.72e-02 | -0.190000 | 7.07e-02 |
| RNA Polymerase II Promoter Escape | 45 | 2.72e-02 | -0.190000 | 7.07e-02 |
| RNA Polymerase II Transcription Initiation | 45 | 2.72e-02 | -0.190000 | 7.07e-02 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | 45 | 2.72e-02 | -0.190000 | 7.07e-02 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | 45 | 2.72e-02 | -0.190000 | 7.07e-02 |
| TP53 Regulates Transcription of Death Receptors and Ligands | 12 | 2.54e-01 | -0.190000 | 3.83e-01 |
| Nervous system development | 478 | 1.05e-12 | -0.190000 | 3.06e-11 |
| SARS-CoV-2-host interactions | 182 | 9.92e-06 | -0.190000 | 9.49e-05 |
| RNA Polymerase II Transcription Termination | 66 | 7.64e-03 | -0.190000 | 2.58e-02 |
| Processing of Capped Intronless Pre-mRNA | 29 | 7.70e-02 | -0.190000 | 1.59e-01 |
| Diseases associated with N-glycosylation of proteins | 20 | 1.42e-01 | -0.190000 | 2.50e-01 |
| Prolonged ERK activation events | 13 | 2.37e-01 | -0.190000 | 3.63e-01 |
| Diseases of signal transduction by growth factor receptors and second messengers | 401 | 7.28e-11 | -0.189000 | 1.75e-09 |
| Nuclear Envelope (NE) Reassembly | 68 | 6.89e-03 | -0.189000 | 2.35e-02 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | 34 | 5.63e-02 | -0.189000 | 1.24e-01 |
| B-WICH complex positively regulates rRNA expression | 45 | 2.84e-02 | -0.189000 | 7.34e-02 |
| Regulation of lipid metabolism by PPARalpha | 107 | 7.56e-04 | -0.188000 | 3.70e-03 |
| Metabolism of RNA | 717 | 7.92e-18 | -0.188000 | 3.12e-16 |
| Centrosome maturation | 81 | 3.37e-03 | -0.188000 | 1.34e-02 |
| Recruitment of mitotic centrosome proteins and complexes | 81 | 3.37e-03 | -0.188000 | 1.34e-02 |
| Downstream signaling of activated FGFR1 | 22 | 1.26e-01 | 0.188000 | 2.30e-01 |
| Caspase activation via Dependence Receptors in the absence of ligand | 9 | 3.29e-01 | -0.188000 | 4.58e-01 |
| APC/C:Cdc20 mediated degradation of Cyclin B | 24 | 1.11e-01 | -0.188000 | 2.09e-01 |
| Bacterial Infection Pathways | 65 | 8.75e-03 | -0.188000 | 2.87e-02 |
| SUMOylation of RNA binding proteins | 47 | 2.58e-02 | -0.188000 | 6.79e-02 |
| Binding of TCF/LEF:CTNNB1 to target gene promoters | 8 | 3.57e-01 | -0.188000 | 4.90e-01 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | 35 | 5.45e-02 | -0.188000 | 1.22e-01 |
| FGFR2 mutant receptor activation | 23 | 1.19e-01 | -0.188000 | 2.21e-01 |
| Apoptosis | 158 | 4.68e-05 | -0.188000 | 3.62e-04 |
| Mitochondrial Fatty Acid Beta-Oxidation | 36 | 5.15e-02 | -0.188000 | 1.17e-01 |
| Intracellular signaling by second messengers | 267 | 1.33e-07 | -0.187000 | 1.87e-06 |
| RND3 GTPase cycle | 35 | 5.50e-02 | -0.187000 | 1.22e-01 |
| SHC-mediated cascade:FGFR1 | 13 | 2.42e-01 | 0.187000 | 3.70e-01 |
| Carboxyterminal post-translational modifications of tubulin | 34 | 5.89e-02 | -0.187000 | 1.28e-01 |
| Meiosis | 67 | 8.06e-03 | -0.187000 | 2.70e-02 |
| TCR signaling | 110 | 6.96e-04 | -0.187000 | 3.44e-03 |
| Recruitment of NuMA to mitotic centrosomes | 88 | 2.44e-03 | -0.187000 | 1.02e-02 |
| G2/M DNA damage checkpoint | 66 | 8.66e-03 | -0.187000 | 2.85e-02 |
| Leading Strand Synthesis | 14 | 2.26e-01 | -0.187000 | 3.52e-01 |
| Polymerase switching | 14 | 2.26e-01 | -0.187000 | 3.52e-01 |
| Listeria monocytogenes entry into host cells | 17 | 1.82e-01 | -0.187000 | 2.98e-01 |
| Deposition of new CENPA-containing nucleosomes at the centromere | 38 | 4.64e-02 | -0.187000 | 1.08e-01 |
| Nucleosome assembly | 38 | 4.64e-02 | -0.187000 | 1.08e-01 |
| Interactions of Rev with host cellular proteins | 37 | 4.94e-02 | -0.187000 | 1.14e-01 |
| Nicotinamide salvaging | 16 | 1.96e-01 | 0.187000 | 3.16e-01 |
| PIP3 activates AKT signaling | 234 | 8.89e-07 | -0.186000 | 1.07e-05 |
| tRNA processing in the nucleus | 59 | 1.34e-02 | -0.186000 | 4.05e-02 |
| Metabolism of cofactors | 25 | 1.08e-01 | -0.186000 | 2.04e-01 |
| Other semaphorin interactions | 16 | 1.99e-01 | -0.186000 | 3.19e-01 |
| Interleukin-18 signaling | 6 | 4.32e-01 | -0.185000 | 5.64e-01 |
| CD163 mediating an anti-inflammatory response | 9 | 3.36e-01 | -0.185000 | 4.67e-01 |
| Nuclear import of Rev protein | 34 | 6.16e-02 | -0.185000 | 1.34e-01 |
| RAF/MAP kinase cascade | 225 | 1.72e-06 | -0.185000 | 1.99e-05 |
| Death Receptor Signaling | 145 | 1.21e-04 | -0.185000 | 7.94e-04 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | 10 | 3.13e-01 | -0.184000 | 4.41e-01 |
| Neddylation | 216 | 3.01e-06 | -0.184000 | 3.33e-05 |
| Signaling by TGFBR3 | 39 | 4.65e-02 | -0.184000 | 1.08e-01 |
| RHO GTPases Activate NADPH Oxidases | 22 | 1.36e-01 | -0.184000 | 2.43e-01 |
| RSV-host interactions | 78 | 5.03e-03 | -0.184000 | 1.83e-02 |
| Nuclear Envelope Breakdown | 53 | 2.07e-02 | -0.184000 | 5.71e-02 |
| Collagen formation | 64 | 1.11e-02 | -0.184000 | 3.47e-02 |
| Biosynthesis of DHA-derived SPMs | 14 | 2.34e-01 | -0.184000 | 3.61e-01 |
| Regulation of gene expression in beta cells | 8 | 3.69e-01 | 0.183000 | 5.04e-01 |
| RHOF GTPase cycle | 38 | 5.07e-02 | -0.183000 | 1.15e-01 |
| Downstream signaling of activated FGFR4 | 18 | 1.79e-01 | 0.183000 | 2.93e-01 |
| ARMS-mediated activation | 6 | 4.39e-01 | 0.182000 | 5.71e-01 |
| Downregulation of ERBB2:ERBB3 signaling | 12 | 2.74e-01 | -0.182000 | 4.02e-01 |
| Post-translational protein modification | 1245 | 2.62e-27 | -0.182000 | 3.61e-25 |
| Regulation of PLK1 Activity at G2/M Transition | 87 | 3.32e-03 | -0.182000 | 1.32e-02 |
| Regulation of CDH11 function | 9 | 3.45e-01 | -0.182000 | 4.76e-01 |
| Bicarbonate transporters | 9 | 3.45e-01 | -0.182000 | 4.76e-01 |
| Interleukin-27 signaling | 11 | 2.97e-01 | -0.182000 | 4.25e-01 |
| Biosynthesis of specialized proresolving mediators (SPMs) | 16 | 2.09e-01 | -0.181000 | 3.32e-01 |
| DARPP-32 events | 22 | 1.41e-01 | -0.181000 | 2.49e-01 |
| Ca-dependent events | 30 | 8.60e-02 | -0.181000 | 1.73e-01 |
| PPARA activates gene expression | 105 | 1.36e-03 | -0.181000 | 6.12e-03 |
| TNFs bind their physiological receptors | 25 | 1.19e-01 | -0.180000 | 2.21e-01 |
| FasL/ CD95L signaling | 5 | 4.86e-01 | -0.180000 | 6.11e-01 |
| mRNA Splicing | 211 | 6.74e-06 | -0.180000 | 6.98e-05 |
| mitochondrial fatty acid beta-oxidation of saturated fatty acids | 11 | 3.02e-01 | -0.180000 | 4.30e-01 |
| SIRT1 negatively regulates rRNA expression | 22 | 1.45e-01 | -0.180000 | 2.53e-01 |
| Diseases of glycosylation | 110 | 1.15e-03 | -0.179000 | 5.26e-03 |
| RHOT2 GTPase cycle | 7 | 4.12e-01 | -0.179000 | 5.46e-01 |
| Axonal growth inhibition (RHOA activation) | 7 | 4.12e-01 | -0.179000 | 5.46e-01 |
| p75NTR regulates axonogenesis | 7 | 4.12e-01 | -0.179000 | 5.46e-01 |
| Defective B3GAT3 causes JDSSDHD | 12 | 2.84e-01 | -0.179000 | 4.12e-01 |
| Cytosolic sensors of pathogen-associated DNA | 63 | 1.42e-02 | -0.179000 | 4.22e-02 |
| Protein ubiquitination | 71 | 9.34e-03 | -0.178000 | 3.04e-02 |
| Receptor-type tyrosine-protein phosphatases | 11 | 3.06e-01 | 0.178000 | 4.34e-01 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | 23 | 1.39e-01 | -0.178000 | 2.47e-01 |
| Formation of the Editosome | 6 | 4.51e-01 | 0.178000 | 5.82e-01 |
| mRNA Editing: C to U Conversion | 6 | 4.51e-01 | 0.178000 | 5.82e-01 |
| Maturation of hRSV A proteins | 13 | 2.67e-01 | -0.178000 | 3.95e-01 |
| Disorders of transmembrane transporters | 136 | 3.48e-04 | -0.178000 | 1.93e-03 |
| RHOG GTPase cycle | 70 | 1.02e-02 | -0.177000 | 3.28e-02 |
| Mitotic Prometaphase | 193 | 2.13e-05 | -0.177000 | 1.89e-04 |
| Deubiquitination | 225 | 4.51e-06 | -0.177000 | 4.82e-05 |
| Signaling by Rho GTPases, Miro GTPases and RHOBTB3 | 623 | 4.11e-14 | -0.177000 | 1.37e-12 |
| Processing of Capped Intron-Containing Pre-mRNA | 279 | 3.54e-07 | -0.177000 | 4.64e-06 |
| Mitochondrial Uncoupling | 6 | 4.53e-01 | -0.177000 | 5.84e-01 |
| Resolution of Sister Chromatid Cohesion | 116 | 9.89e-04 | -0.177000 | 4.65e-03 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | 43 | 4.47e-02 | -0.177000 | 1.06e-01 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | 41 | 5.02e-02 | -0.177000 | 1.15e-01 |
| Signaling by RAS mutants | 41 | 5.02e-02 | -0.177000 | 1.15e-01 |
| Signaling by moderate kinase activity BRAF mutants | 41 | 5.02e-02 | -0.177000 | 1.15e-01 |
| Signaling downstream of RAS mutants | 41 | 5.02e-02 | -0.177000 | 1.15e-01 |
| Metabolism of vitamins and cofactors | 167 | 8.31e-05 | -0.176000 | 5.80e-04 |
| COPI-independent Golgi-to-ER retrograde traffic | 45 | 4.08e-02 | -0.176000 | 9.78e-02 |
| G-protein mediated events | 44 | 4.32e-02 | -0.176000 | 1.02e-01 |
| PDH complex synthesizes acetyl-CoA from PYR | 5 | 4.96e-01 | -0.176000 | 6.23e-01 |
| Regulation of NF-kappa B signaling | 18 | 1.97e-01 | -0.176000 | 3.16e-01 |
| Programmed Cell Death | 187 | 3.43e-05 | -0.176000 | 2.84e-04 |
| Metabolism of steroids | 123 | 7.79e-04 | -0.175000 | 3.77e-03 |
| STING mediated induction of host immune responses | 15 | 2.40e-01 | -0.175000 | 3.68e-01 |
| Cyclin D associated events in G1 | 47 | 3.77e-02 | -0.175000 | 9.19e-02 |
| G1 Phase | 47 | 3.77e-02 | -0.175000 | 9.19e-02 |
| Erythrocytes take up carbon dioxide and release oxygen | 11 | 3.14e-01 | -0.175000 | 4.43e-01 |
| O2/CO2 exchange in erythrocytes | 11 | 3.14e-01 | -0.175000 | 4.43e-01 |
| NOTCH3 Intracellular Domain Regulates Transcription | 20 | 1.75e-01 | -0.175000 | 2.89e-01 |
| RHO GTPases activate KTN1 | 11 | 3.15e-01 | -0.175000 | 4.43e-01 |
| Cellular response to heat stress | 94 | 3.39e-03 | -0.175000 | 1.34e-02 |
| Platelet activation, signaling and aggregation | 221 | 7.46e-06 | -0.175000 | 7.48e-05 |
| E2F mediated regulation of DNA replication | 22 | 1.56e-01 | -0.175000 | 2.67e-01 |
| PI3K events in ERBB4 signaling | 6 | 4.59e-01 | 0.175000 | 5.89e-01 |
| AKT phosphorylates targets in the nucleus | 10 | 3.40e-01 | -0.174000 | 4.71e-01 |
| Chaperone Mediated Autophagy | 20 | 1.78e-01 | -0.174000 | 2.93e-01 |
| Formation of WDR5-containing histone-modifying complexes | 42 | 5.11e-02 | -0.174000 | 1.16e-01 |
| SUMOylation of DNA damage response and repair proteins | 77 | 8.31e-03 | -0.174000 | 2.77e-02 |
| G beta:gamma signalling through BTK | 15 | 2.45e-01 | -0.173000 | 3.73e-01 |
| Digestion and absorption | 7 | 4.27e-01 | -0.173000 | 5.61e-01 |
| RNA Polymerase I Promoter Escape | 45 | 4.43e-02 | -0.173000 | 1.05e-01 |
| Signaling by Rho GTPases | 607 | 3.05e-13 | -0.173000 | 9.49e-12 |
| Interleukin-1 processing | 8 | 3.96e-01 | -0.173000 | 5.31e-01 |
| Protein methylation | 15 | 2.47e-01 | -0.173000 | 3.75e-01 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | 29 | 1.07e-01 | -0.173000 | 2.04e-01 |
| Glutathione conjugation | 27 | 1.21e-01 | -0.172000 | 2.24e-01 |
| Peroxisomal protein import | 58 | 2.34e-02 | -0.172000 | 6.32e-02 |
| SUMOylation of SUMOylation proteins | 35 | 7.86e-02 | -0.172000 | 1.62e-01 |
| Transport of Mature Transcript to Cytoplasm | 81 | 7.60e-03 | -0.172000 | 2.57e-02 |
| Formation of definitive endoderm | 9 | 3.73e-01 | 0.171000 | 5.07e-01 |
| Crosslinking of collagen fibrils | 13 | 2.85e-01 | 0.171000 | 4.12e-01 |
| RHOQ GTPase cycle | 54 | 2.94e-02 | -0.171000 | 7.52e-02 |
| SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs | 11 | 3.25e-01 | -0.171000 | 4.55e-01 |
| CDC42 GTPase cycle | 140 | 4.90e-04 | -0.171000 | 2.57e-03 |
| Interleukin-1 signaling | 99 | 3.35e-03 | -0.171000 | 1.33e-02 |
| Cell junction organization | 78 | 9.33e-03 | -0.170000 | 3.04e-02 |
| IRF3-mediated induction of type I IFN | 12 | 3.07e-01 | -0.170000 | 4.35e-01 |
| Peroxisomal lipid metabolism | 27 | 1.26e-01 | -0.170000 | 2.30e-01 |
| mRNA 3’-end processing | 57 | 2.64e-02 | -0.170000 | 6.94e-02 |
| Depolymerization of the Nuclear Lamina | 15 | 2.55e-01 | -0.170000 | 3.84e-01 |
| Interleukin-35 Signalling | 12 | 3.09e-01 | -0.170000 | 4.37e-01 |
| PI3K/AKT activation | 8 | 4.06e-01 | -0.169000 | 5.41e-01 |
| Developmental Biology | 924 | 2.38e-18 | -0.169000 | 9.54e-17 |
| Nef mediated downregulation of MHC class I complex cell surface expression | 10 | 3.54e-01 | -0.169000 | 4.85e-01 |
| Signalling to ERKs | 32 | 9.84e-02 | -0.169000 | 1.92e-01 |
| EML4 and NUDC in mitotic spindle formation | 107 | 2.60e-03 | -0.168000 | 1.08e-02 |
| Signaling by Non-Receptor Tyrosine Kinases | 47 | 4.58e-02 | -0.168000 | 1.07e-01 |
| Signaling by PTK6 | 47 | 4.58e-02 | -0.168000 | 1.07e-01 |
| Interleukin-1 family signaling | 127 | 1.06e-03 | -0.168000 | 4.92e-03 |
| Erythropoietin activates Phospholipase C gamma (PLCG) | 6 | 4.76e-01 | -0.168000 | 6.02e-01 |
| Biosynthesis of maresins | 6 | 4.77e-01 | -0.168000 | 6.03e-01 |
| Transcriptional activation of mitochondrial biogenesis | 52 | 3.67e-02 | -0.167000 | 9.00e-02 |
| Intra-Golgi traffic | 43 | 5.81e-02 | -0.167000 | 1.27e-01 |
| Downstream signal transduction | 27 | 1.34e-01 | -0.167000 | 2.41e-01 |
| Regulated proteolysis of p75NTR | 11 | 3.39e-01 | -0.167000 | 4.69e-01 |
| DAG and IP3 signaling | 34 | 9.33e-02 | -0.166000 | 1.85e-01 |
| Drug-mediated inhibition of CDK4/CDK6 activity | 5 | 5.20e-01 | -0.166000 | 6.45e-01 |
| MAPK6/MAPK4 signaling | 69 | 1.71e-02 | -0.166000 | 4.90e-02 |
| mRNA decay by 3’ to 5’ exoribonuclease | 13 | 3.01e-01 | -0.166000 | 4.28e-01 |
| Cellular response to mitochondrial stress | 9 | 3.90e-01 | -0.166000 | 5.24e-01 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | 36 | 8.67e-02 | -0.165000 | 1.74e-01 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | 91 | 6.63e-03 | -0.165000 | 2.27e-02 |
| Amplification of signal from the kinetochores | 91 | 6.63e-03 | -0.165000 | 2.27e-02 |
| Circadian Clock | 67 | 2.00e-02 | -0.164000 | 5.53e-02 |
| Gastrulation | 76 | 1.33e-02 | -0.164000 | 4.03e-02 |
| Signal attenuation | 9 | 3.95e-01 | -0.164000 | 5.29e-01 |
| Sphingolipid de novo biosynthesis | 35 | 9.36e-02 | -0.164000 | 1.85e-01 |
| Phosphate bond hydrolysis by NUDT proteins | 7 | 4.53e-01 | -0.164000 | 5.85e-01 |
| Butyrophilin (BTN) family interactions | 10 | 3.70e-01 | 0.164000 | 5.05e-01 |
| Platelet degranulation | 105 | 3.93e-03 | -0.163000 | 1.51e-02 |
| TGF-beta receptor signaling activates SMADs | 45 | 5.96e-02 | -0.162000 | 1.29e-01 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | 72 | 1.73e-02 | -0.162000 | 4.95e-02 |
| G beta:gamma signalling through CDC42 | 17 | 2.49e-01 | -0.161000 | 3.77e-01 |
| Class I peroxisomal membrane protein import | 20 | 2.11e-01 | -0.161000 | 3.35e-01 |
| ESR-mediated signaling | 157 | 4.82e-04 | -0.161000 | 2.53e-03 |
| Downregulation of ERBB4 signaling | 8 | 4.30e-01 | -0.161000 | 5.63e-01 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | 15 | 2.80e-01 | -0.161000 | 4.07e-01 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | 117 | 2.63e-03 | -0.161000 | 1.09e-02 |
| IRAK2 mediated activation of TAK1 complex | 10 | 3.78e-01 | -0.161000 | 5.14e-01 |
| Transport of Mature mRNA Derived from an Intronless Transcript | 42 | 7.13e-02 | -0.161000 | 1.50e-01 |
| Signaling by RAF1 mutants | 37 | 9.14e-02 | -0.160000 | 1.82e-01 |
| Interleukin-37 signaling | 19 | 2.26e-01 | -0.160000 | 3.52e-01 |
| Export of Viral Ribonucleoproteins from Nucleus | 33 | 1.11e-01 | -0.160000 | 2.09e-01 |
| Gamma-carboxylation, transport, and amino-terminal cleavage of proteins | 7 | 4.64e-01 | -0.160000 | 5.92e-01 |
| Diseases of metabolism | 204 | 8.21e-05 | -0.160000 | 5.76e-04 |
| RNA Polymerase III Transcription Initiation | 36 | 9.75e-02 | -0.160000 | 1.91e-01 |
| Nonhomologous End-Joining (NHEJ) | 40 | 8.08e-02 | -0.160000 | 1.65e-01 |
| Activation of BAD and translocation to mitochondria | 15 | 2.85e-01 | -0.159000 | 4.13e-01 |
| tRNA processing | 128 | 1.85e-03 | -0.159000 | 8.06e-03 |
| Opioid Signalling | 75 | 1.72e-02 | -0.159000 | 4.91e-02 |
| Signal amplification | 28 | 1.46e-01 | -0.159000 | 2.54e-01 |
| LGI-ADAM interactions | 9 | 4.10e-01 | -0.158000 | 5.45e-01 |
| TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling | 13 | 3.23e-01 | -0.158000 | 4.53e-01 |
| Metal ion SLC transporters | 19 | 2.33e-01 | -0.158000 | 3.60e-01 |
| Epigenetic regulation of gene expression | 264 | 9.95e-06 | -0.158000 | 9.49e-05 |
| RAB GEFs exchange GTP for GDP on RABs | 88 | 1.05e-02 | -0.158000 | 3.33e-02 |
| Removal of aminoterminal propeptides from gamma-carboxylated proteins | 6 | 5.03e-01 | -0.158000 | 6.29e-01 |
| Ub-specific processing proteases | 153 | 7.58e-04 | -0.158000 | 3.70e-03 |
| Early Phase of HIV Life Cycle | 14 | 3.07e-01 | -0.158000 | 4.35e-01 |
| Signaling by FGFR | 73 | 1.99e-02 | -0.158000 | 5.52e-02 |
| Killing mechanisms | 10 | 3.89e-01 | -0.157000 | 5.23e-01 |
| WNT5:FZD7-mediated leishmania damping | 10 | 3.89e-01 | -0.157000 | 5.23e-01 |
| TRAF3-dependent IRF activation pathway | 13 | 3.27e-01 | -0.157000 | 4.56e-01 |
| Transport of the SLBP Dependant Mature mRNA | 36 | 1.03e-01 | -0.157000 | 1.98e-01 |
| Defects in vitamin and cofactor metabolism | 21 | 2.13e-01 | -0.157000 | 3.36e-01 |
| CLEC7A (Dectin-1) induces NFAT activation | 11 | 3.67e-01 | -0.157000 | 5.03e-01 |
| Activation of C3 and C5 | 7 | 4.72e-01 | -0.157000 | 5.98e-01 |
| Glycosphingolipid metabolism | 46 | 6.58e-02 | -0.157000 | 1.40e-01 |
| RNA Polymerase III Transcription Termination | 22 | 2.03e-01 | -0.157000 | 3.24e-01 |
| Synthesis of bile acids and bile salts via 27-hydroxycholesterol | 9 | 4.16e-01 | -0.157000 | 5.48e-01 |
| Formation of the active cofactor, UDP-glucuronate | 5 | 5.44e-01 | -0.157000 | 6.65e-01 |
| RHOJ GTPase cycle | 49 | 5.81e-02 | -0.156000 | 1.27e-01 |
| Signal Transduction | 2051 | 1.78e-31 | -0.156000 | 3.43e-29 |
| Vpr-mediated nuclear import of PICs | 34 | 1.16e-01 | -0.156000 | 2.17e-01 |
| MAPK family signaling cascades | 263 | 1.40e-05 | -0.156000 | 1.30e-04 |
| Chondroitin sulfate biosynthesis | 12 | 3.51e-01 | -0.156000 | 4.83e-01 |
| Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation | 11 | 3.72e-01 | -0.155000 | 5.06e-01 |
| Response to elevated platelet cytosolic Ca2+ | 109 | 5.05e-03 | -0.155000 | 1.83e-02 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | 74 | 2.09e-02 | -0.155000 | 5.74e-02 |
| Respiratory syncytial virus (RSV) genome replication, transcription and translation | 16 | 2.82e-01 | -0.155000 | 4.10e-01 |
| G alpha (z) signalling events | 36 | 1.07e-01 | -0.155000 | 2.04e-01 |
| ADP signalling through P2Y purinoceptor 12 | 18 | 2.55e-01 | -0.155000 | 3.84e-01 |
| Signaling by NTRK1 (TRKA) | 102 | 6.90e-03 | -0.155000 | 2.35e-02 |
| Aryl hydrocarbon receptor signalling | 6 | 5.12e-01 | -0.155000 | 6.37e-01 |
| rRNA modification in the nucleus and cytosol | 60 | 3.86e-02 | -0.154000 | 9.37e-02 |
| Transport of small molecules | 556 | 4.77e-10 | -0.154000 | 1.07e-08 |
| MET receptor recycling | 9 | 4.23e-01 | -0.154000 | 5.56e-01 |
| RIP-mediated NFkB activation via ZBP1 | 17 | 2.71e-01 | -0.154000 | 3.99e-01 |
| Regulation of FZD by ubiquitination | 16 | 2.86e-01 | -0.154000 | 4.13e-01 |
| Defective C1GALT1C1 causes TNPS | 10 | 4.00e-01 | 0.154000 | 5.34e-01 |
| Ion homeostasis | 42 | 8.55e-02 | -0.153000 | 1.72e-01 |
| Signaling by Hippo | 18 | 2.61e-01 | 0.153000 | 3.89e-01 |
| Metabolism of water-soluble vitamins and cofactors | 116 | 4.43e-03 | -0.153000 | 1.66e-02 |
| Signaling by FGFR2 | 61 | 3.89e-02 | -0.153000 | 9.41e-02 |
| NEP/NS2 Interacts with the Cellular Export Machinery | 32 | 1.35e-01 | -0.153000 | 2.42e-01 |
| Ovarian tumor domain proteases | 37 | 1.08e-01 | -0.153000 | 2.05e-01 |
| Negative regulation of MET activity | 18 | 2.64e-01 | -0.152000 | 3.93e-01 |
| FGFR2 ligand binding and activation | 9 | 4.30e-01 | 0.152000 | 5.63e-01 |
| CREB1 phosphorylation through the activation of Adenylate Cyclase | 9 | 4.30e-01 | -0.152000 | 5.63e-01 |
| SUMOylation of intracellular receptors | 26 | 1.80e-01 | -0.152000 | 2.95e-01 |
| Signaling by Interleukins | 390 | 2.63e-07 | -0.152000 | 3.55e-06 |
| Termination of O-glycan biosynthesis | 16 | 2.93e-01 | -0.152000 | 4.22e-01 |
| RHO GTPases Activate Rhotekin and Rhophilins | 8 | 4.58e-01 | -0.152000 | 5.89e-01 |
| Interleukin-6 signaling | 11 | 3.86e-01 | -0.151000 | 5.21e-01 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | 85 | 1.63e-02 | -0.151000 | 4.76e-02 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | 85 | 1.63e-02 | -0.151000 | 4.76e-02 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | 85 | 1.63e-02 | -0.151000 | 4.76e-02 |
| CDC6 association with the ORC:origin complex | 8 | 4.61e-01 | 0.151000 | 5.91e-01 |
| PINK1-PRKN Mediated Mitophagy | 31 | 1.48e-01 | -0.150000 | 2.57e-01 |
| Processing of SMDT1 | 15 | 3.15e-01 | -0.150000 | 4.43e-01 |
| CREB3 factors activate genes | 6 | 5.25e-01 | -0.150000 | 6.49e-01 |
| Dissolution of Fibrin Clot | 12 | 3.70e-01 | 0.149000 | 5.05e-01 |
| RHO GTPases activate PAKs | 20 | 2.47e-01 | -0.149000 | 3.75e-01 |
| Retrograde transport at the Trans-Golgi-Network | 49 | 7.08e-02 | -0.149000 | 1.49e-01 |
| TYSND1 cleaves peroxisomal proteins | 7 | 4.94e-01 | -0.149000 | 6.21e-01 |
| Gain-of-function MRAS complexes activate RAF signaling | 8 | 4.65e-01 | 0.149000 | 5.93e-01 |
| SHOC2 M1731 mutant abolishes MRAS complex function | 8 | 4.65e-01 | 0.149000 | 5.93e-01 |
| Signaling by MRAS-complex mutants | 8 | 4.65e-01 | 0.149000 | 5.93e-01 |
| SUMOylation of ubiquitinylation proteins | 39 | 1.08e-01 | -0.149000 | 2.05e-01 |
| Sema4D induced cell migration and growth-cone collapse | 19 | 2.62e-01 | -0.149000 | 3.91e-01 |
| Pyroptosis | 25 | 1.99e-01 | -0.148000 | 3.19e-01 |
| APC-Cdc20 mediated degradation of Nek2A | 26 | 1.91e-01 | -0.148000 | 3.08e-01 |
| Sodium/Proton exchangers | 7 | 4.97e-01 | -0.148000 | 6.23e-01 |
| Cell recruitment (pro-inflammatory response) | 25 | 2.01e-01 | -0.148000 | 3.21e-01 |
| Purinergic signaling in leishmaniasis infection | 25 | 2.01e-01 | -0.148000 | 3.21e-01 |
| Signaling by ERBB2 | 44 | 9.00e-02 | -0.148000 | 1.79e-01 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | 48 | 7.69e-02 | -0.148000 | 1.59e-01 |
| Synthesis, secretion, and deacylation of Ghrelin | 11 | 3.97e-01 | -0.147000 | 5.31e-01 |
| The phototransduction cascade | 27 | 1.88e-01 | 0.146000 | 3.05e-01 |
| RHO GTPase cycle | 411 | 3.67e-07 | -0.146000 | 4.77e-06 |
| Post-translational protein phosphorylation | 67 | 3.87e-02 | -0.146000 | 9.38e-02 |
| Cell-Cell communication | 110 | 8.21e-03 | -0.146000 | 2.74e-02 |
| Defensins | 8 | 4.75e-01 | -0.146000 | 6.02e-01 |
| KSRP (KHSRP) binds and destabilizes mRNA | 17 | 2.98e-01 | -0.146000 | 4.26e-01 |
| G-protein activation | 19 | 2.72e-01 | -0.146000 | 4.01e-01 |
| GAB1 signalosome | 14 | 3.48e-01 | -0.145000 | 4.79e-01 |
| Integrin signaling | 22 | 2.39e-01 | -0.145000 | 3.67e-01 |
| Bile acid and bile salt metabolism | 30 | 1.70e-01 | -0.145000 | 2.83e-01 |
| 2-LTR circle formation | 7 | 5.08e-01 | -0.145000 | 6.34e-01 |
| Early SARS-CoV-2 Infection Events | 32 | 1.57e-01 | -0.145000 | 2.68e-01 |
| Signaling by TGF-beta Receptor Complex | 90 | 1.78e-02 | -0.145000 | 5.05e-02 |
| Formation of the cornified envelope | 37 | 1.28e-01 | -0.144000 | 2.32e-01 |
| Wax and plasmalogen biosynthesis | 5 | 5.76e-01 | 0.144000 | 6.91e-01 |
| PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases | 13 | 3.67e-01 | -0.144000 | 5.03e-01 |
| Diseases of mitotic cell cycle | 38 | 1.25e-01 | -0.144000 | 2.29e-01 |
| Phosphorylation of the APC/C | 20 | 2.66e-01 | -0.144000 | 3.95e-01 |
| Transcriptional Regulation by VENTX | 39 | 1.21e-01 | -0.143000 | 2.24e-01 |
| Dopamine Neurotransmitter Release Cycle | 18 | 2.92e-01 | -0.143000 | 4.22e-01 |
| Aquaporin-mediated transport | 38 | 1.28e-01 | -0.143000 | 2.32e-01 |
| Class B/2 (Secretin family receptors) | 57 | 6.25e-02 | -0.143000 | 1.35e-01 |
| Signaling by NTRKs | 116 | 8.01e-03 | -0.143000 | 2.69e-02 |
| Signaling by Receptor Tyrosine Kinases | 443 | 2.75e-07 | -0.142000 | 3.66e-06 |
| MITF-M-dependent gene expression | 84 | 2.42e-02 | -0.142000 | 6.46e-02 |
| IL-6-type cytokine receptor ligand interactions | 13 | 3.75e-01 | 0.142000 | 5.09e-01 |
| LTC4-CYSLTR mediated IL4 production | 5 | 5.82e-01 | -0.142000 | 6.96e-01 |
| Formation of Incision Complex in GG-NER | 43 | 1.07e-01 | -0.142000 | 2.04e-01 |
| Mitotic Spindle Checkpoint | 108 | 1.07e-02 | -0.142000 | 3.40e-02 |
| Germ layer formation at gastrulation | 9 | 4.61e-01 | 0.142000 | 5.91e-01 |
| Extracellular matrix organization | 219 | 3.04e-04 | -0.142000 | 1.71e-03 |
| trans-Golgi Network Vesicle Budding | 69 | 4.22e-02 | -0.141000 | 1.01e-01 |
| TGFBR3 expression | 20 | 2.74e-01 | -0.141000 | 4.02e-01 |
| RUNX1 regulates expression of components of tight junctions | 5 | 5.84e-01 | 0.141000 | 6.98e-01 |
| RAC2 GTPase cycle | 85 | 2.47e-02 | -0.141000 | 6.58e-02 |
| TICAM1-dependent activation of IRF3/IRF7 | 13 | 3.82e-01 | -0.140000 | 5.17e-01 |
| Regulation of TNFR1 signaling | 47 | 9.67e-02 | -0.140000 | 1.90e-01 |
| Negative regulation of TCF-dependent signaling by WNT ligand antagonists | 6 | 5.53e-01 | -0.140000 | 6.74e-01 |
| Postmitotic nuclear pore complex (NPC) reformation | 27 | 2.10e-01 | -0.139000 | 3.33e-01 |
| RNA polymerase II transcribes snRNA genes | 71 | 4.25e-02 | -0.139000 | 1.01e-01 |
| Transport of Ribonucleoproteins into the Host Nucleus | 32 | 1.73e-01 | -0.139000 | 2.87e-01 |
| activated TAK1 mediates p38 MAPK activation | 23 | 2.48e-01 | -0.139000 | 3.76e-01 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | 12 | 4.04e-01 | -0.139000 | 5.38e-01 |
| Elevation of cytosolic Ca2+ levels | 13 | 3.86e-01 | -0.139000 | 5.21e-01 |
| Organelle biogenesis and maintenance | 278 | 7.13e-05 | -0.138000 | 5.20e-04 |
| Sphingolipid metabolism | 92 | 2.25e-02 | -0.138000 | 6.13e-02 |
| Transport of inorganic cations/anions and amino acids/oligopeptides | 79 | 3.46e-02 | -0.137000 | 8.64e-02 |
| Nephron development | 5 | 5.95e-01 | -0.137000 | 7.07e-01 |
| Transport of the SLBP independent Mature mRNA | 35 | 1.60e-01 | -0.137000 | 2.71e-01 |
| Propionyl-CoA catabolism | 5 | 5.96e-01 | -0.137000 | 7.07e-01 |
| FLT3 signaling in disease | 27 | 2.19e-01 | -0.137000 | 3.43e-01 |
| Metabolism of non-coding RNA | 53 | 8.50e-02 | -0.137000 | 1.72e-01 |
| snRNP Assembly | 53 | 8.50e-02 | -0.137000 | 1.72e-01 |
| Reproduction | 86 | 2.90e-02 | -0.136000 | 7.45e-02 |
| RUNX1 regulates transcription of genes involved in differentiation of keratinocytes | 7 | 5.33e-01 | 0.136000 | 6.56e-01 |
| RUNX3 Regulates Immune Response and Cell Migration | 5 | 5.99e-01 | -0.136000 | 7.08e-01 |
| Reelin signalling pathway | 5 | 5.99e-01 | 0.136000 | 7.08e-01 |
| Signaling by RNF43 mutants | 7 | 5.34e-01 | -0.136000 | 6.56e-01 |
| Methionine salvage pathway | 6 | 5.65e-01 | -0.136000 | 6.83e-01 |
| Regulation of HSF1-mediated heat shock response | 79 | 3.74e-02 | -0.135000 | 9.15e-02 |
| Signaling by NOTCH2 | 33 | 1.79e-01 | -0.135000 | 2.93e-01 |
| Class I MHC mediated antigen processing & presentation | 345 | 1.61e-05 | -0.135000 | 1.48e-04 |
| Antigen processing: Ubiquitination & Proteasome degradation | 276 | 1.14e-04 | -0.135000 | 7.53e-04 |
| Abacavir ADME | 5 | 6.02e-01 | -0.135000 | 7.10e-01 |
| Synthesis of bile acids and bile salts | 26 | 2.35e-01 | -0.135000 | 3.61e-01 |
| Beta-oxidation of very long chain fatty acids | 11 | 4.40e-01 | -0.135000 | 5.72e-01 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | 108 | 1.57e-02 | -0.135000 | 4.62e-02 |
| Regulation of CDH11 Expression and Function | 22 | 2.75e-01 | -0.134000 | 4.03e-01 |
| TRAF6 mediated NF-kB activation | 23 | 2.65e-01 | -0.134000 | 3.94e-01 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | 30 | 2.06e-01 | -0.133000 | 3.28e-01 |
| Processing of Intronless Pre-mRNAs | 20 | 3.02e-01 | -0.133000 | 4.29e-01 |
| Activation of the AP-1 family of transcription factors | 10 | 4.65e-01 | 0.133000 | 5.93e-01 |
| Regulation of BACH1 activity | 11 | 4.44e-01 | -0.133000 | 5.76e-01 |
| RUNX3 regulates WNT signaling | 8 | 5.15e-01 | -0.133000 | 6.39e-01 |
| Vitamin B2 (riboflavin) metabolism | 6 | 5.73e-01 | -0.133000 | 6.90e-01 |
| Nuclear Receptor transcription pathway | 38 | 1.57e-01 | -0.133000 | 2.68e-01 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | 61 | 7.34e-02 | -0.133000 | 1.54e-01 |
| Signaling by SCF-KIT | 40 | 1.47e-01 | -0.132000 | 2.55e-01 |
| Keratinization | 38 | 1.60e-01 | -0.132000 | 2.71e-01 |
| Signaling by LTK | 10 | 4.72e-01 | -0.131000 | 5.98e-01 |
| mRNA Editing | 8 | 5.20e-01 | 0.131000 | 6.45e-01 |
| Apoptotic factor-mediated response | 19 | 3.22e-01 | -0.131000 | 4.52e-01 |
| CLEC7A/inflammasome pathway | 6 | 5.78e-01 | -0.131000 | 6.93e-01 |
| Apoptotic cleavage of cellular proteins | 35 | 1.79e-01 | -0.131000 | 2.94e-01 |
| VxPx cargo-targeting to cilium | 19 | 3.24e-01 | -0.131000 | 4.53e-01 |
| Regulation of TP53 Activity through Phosphorylation | 88 | 3.43e-02 | -0.131000 | 8.60e-02 |
| C-type lectin receptors (CLRs) | 118 | 1.46e-02 | -0.130000 | 4.33e-02 |
| Ion channel transport | 141 | 7.71e-03 | -0.130000 | 2.59e-02 |
| Cytokine Signaling in Immune system | 668 | 1.09e-08 | -0.130000 | 1.86e-07 |
| Diseases of hemostasis | 14 | 4.02e-01 | -0.129000 | 5.37e-01 |
| Plasma lipoprotein remodeling | 18 | 3.48e-01 | -0.128000 | 4.79e-01 |
| mitochondrial fatty acid beta-oxidation of unsaturated fatty acids | 6 | 5.88e-01 | -0.128000 | 7.01e-01 |
| Metalloprotease DUBs | 20 | 3.24e-01 | -0.127000 | 4.53e-01 |
| Signaling by EGFR | 47 | 1.31e-01 | -0.127000 | 2.37e-01 |
| GP1b-IX-V activation signalling | 11 | 4.66e-01 | -0.127000 | 5.93e-01 |
| Inactivation of CDC42 and RAC1 | 7 | 5.62e-01 | 0.127000 | 6.81e-01 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | 76 | 5.66e-02 | -0.126000 | 1.24e-01 |
| Generic Transcription Pathway | 1079 | 2.30e-12 | -0.126000 | 6.52e-11 |
| Reversible hydration of carbon dioxide | 8 | 5.36e-01 | -0.126000 | 6.57e-01 |
| NrCAM interactions | 6 | 5.92e-01 | -0.126000 | 7.04e-01 |
| Iron uptake and transport | 52 | 1.15e-01 | -0.126000 | 2.16e-01 |
| Metabolism of lipids | 641 | 4.82e-08 | -0.126000 | 7.26e-07 |
| RNA Polymerase II Transcription | 1197 | 1.96e-13 | -0.126000 | 6.30e-12 |
| Trafficking and processing of endosomal TLR | 13 | 4.32e-01 | -0.126000 | 5.64e-01 |
| Gene expression (Transcription) | 1404 | 2.62e-15 | -0.126000 | 9.37e-14 |
| RNA Polymerase III Abortive And Retractive Initiation | 40 | 1.68e-01 | -0.126000 | 2.81e-01 |
| RNA Polymerase III Transcription | 40 | 1.68e-01 | -0.126000 | 2.81e-01 |
| CHL1 interactions | 8 | 5.38e-01 | 0.126000 | 6.59e-01 |
| Synthesis of PIPs at the ER membrane | 5 | 6.26e-01 | -0.126000 | 7.30e-01 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | 49 | 1.28e-01 | -0.126000 | 2.32e-01 |
| Chemokine receptors bind chemokines | 41 | 1.64e-01 | 0.126000 | 2.75e-01 |
| Signaling by TGFB family members | 137 | 1.11e-02 | -0.126000 | 3.48e-02 |
| MET activates PTK2 signaling | 23 | 2.98e-01 | 0.125000 | 4.25e-01 |
| Synthesis of diphthamide-EEF2 | 8 | 5.42e-01 | -0.124000 | 6.64e-01 |
| Assembly of the ORC complex at the origin of replication | 23 | 3.03e-01 | -0.124000 | 4.30e-01 |
| FOXO-mediated transcription | 58 | 1.02e-01 | -0.124000 | 1.97e-01 |
| SLC-mediated transmembrane transport | 174 | 4.83e-03 | -0.124000 | 1.76e-02 |
| Heme signaling | 45 | 1.52e-01 | -0.123000 | 2.62e-01 |
| Inactivation, recovery and regulation of the phototransduction cascade | 26 | 2.76e-01 | 0.123000 | 4.03e-01 |
| Lysine catabolism | 11 | 4.79e-01 | -0.123000 | 6.05e-01 |
| Mitochondrial unfolded protein response (UPRmt) | 17 | 3.80e-01 | -0.123000 | 5.15e-01 |
| Phase 0 - rapid depolarisation | 24 | 2.98e-01 | 0.123000 | 4.25e-01 |
| O-linked glycosylation | 85 | 5.04e-02 | -0.123000 | 1.15e-01 |
| Cytochrome P450 - arranged by substrate type | 39 | 1.87e-01 | 0.122000 | 3.03e-01 |
| Vitamin C (ascorbate) metabolism | 8 | 5.50e-01 | -0.122000 | 6.71e-01 |
| FGFR1 ligand binding and activation | 10 | 5.04e-01 | 0.122000 | 6.30e-01 |
| Regulation of RUNX1 Expression and Activity | 18 | 3.71e-01 | -0.122000 | 5.06e-01 |
| DAP12 signaling | 28 | 2.65e-01 | -0.122000 | 3.94e-01 |
| Activation of GABAB receptors | 30 | 2.49e-01 | -0.122000 | 3.76e-01 |
| GABA B receptor activation | 30 | 2.49e-01 | -0.122000 | 3.76e-01 |
| Gap junction assembly | 17 | 3.87e-01 | -0.121000 | 5.22e-01 |
| NOTCH4 Activation and Transmission of Signal to the Nucleus | 10 | 5.08e-01 | -0.121000 | 6.34e-01 |
| Signaling by EGFR in Cancer | 22 | 3.27e-01 | -0.121000 | 4.56e-01 |
| RHOH GTPase cycle | 33 | 2.30e-01 | -0.121000 | 3.56e-01 |
| Aflatoxin activation and detoxification | 14 | 4.37e-01 | -0.120000 | 5.69e-01 |
| Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP) | 9 | 5.34e-01 | 0.120000 | 6.56e-01 |
| SMAD2/3 Phosphorylation Motif Mutants in Cancer | 6 | 6.12e-01 | 0.120000 | 7.16e-01 |
| TGFBR1 KD Mutants in Cancer | 6 | 6.12e-01 | 0.120000 | 7.16e-01 |
| ROBO receptors bind AKAP5 | 7 | 5.84e-01 | -0.120000 | 6.98e-01 |
| Signaling by FGFR1 in disease | 32 | 2.42e-01 | 0.119000 | 3.70e-01 |
| Fatty acid metabolism | 157 | 1.01e-02 | -0.119000 | 3.23e-02 |
| Insulin processing | 19 | 3.71e-01 | 0.119000 | 5.05e-01 |
| Uptake of dietary cobalamins into enterocytes | 6 | 6.15e-01 | -0.119000 | 7.20e-01 |
| ALK mutants bind TKIs | 11 | 4.96e-01 | 0.118000 | 6.23e-01 |
| Purine catabolism | 16 | 4.14e-01 | -0.118000 | 5.46e-01 |
| ERBB2 Regulates Cell Motility | 10 | 5.20e-01 | -0.118000 | 6.45e-01 |
| O-linked glycosylation of mucins | 47 | 1.63e-01 | -0.118000 | 2.75e-01 |
| RND1 GTPase cycle | 36 | 2.22e-01 | -0.118000 | 3.48e-01 |
| G alpha (q) signalling events | 139 | 1.67e-02 | -0.118000 | 4.85e-02 |
| TNF signaling | 56 | 1.28e-01 | -0.117000 | 2.32e-01 |
| Sensory processing of sound | 58 | 1.23e-01 | -0.117000 | 2.26e-01 |
| Synthesis of bile acids and bile salts via 24-hydroxycholesterol | 9 | 5.44e-01 | -0.117000 | 6.64e-01 |
| Adherens junctions interactions | 38 | 2.13e-01 | -0.117000 | 3.36e-01 |
| HDL remodeling | 6 | 6.21e-01 | -0.117000 | 7.25e-01 |
| Assembly of active LPL and LIPC lipase complexes | 10 | 5.24e-01 | -0.116000 | 6.48e-01 |
| CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde | 7 | 5.94e-01 | -0.116000 | 7.06e-01 |
| RAF activation | 33 | 2.48e-01 | -0.116000 | 3.76e-01 |
| Small interfering RNA (siRNA) biogenesis | 9 | 5.46e-01 | 0.116000 | 6.67e-01 |
| MITF-M-regulated melanocyte development | 113 | 3.32e-02 | -0.116000 | 8.36e-02 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | 41 | 1.99e-01 | -0.116000 | 3.19e-01 |
| Interleukin-17 signaling | 68 | 9.99e-02 | -0.115000 | 1.94e-01 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | 32 | 2.60e-01 | -0.115000 | 3.88e-01 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | 32 | 2.60e-01 | -0.115000 | 3.88e-01 |
| Endosomal/Vacuolar pathway | 12 | 4.90e-01 | 0.115000 | 6.17e-01 |
| Constitutive Signaling by Overexpressed ERBB2 | 11 | 5.11e-01 | -0.115000 | 6.36e-01 |
| PKR-mediated signaling | 67 | 1.05e-01 | -0.115000 | 2.01e-01 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | 56 | 1.39e-01 | -0.114000 | 2.47e-01 |
| Signaling by Activin | 13 | 4.76e-01 | -0.114000 | 6.02e-01 |
| Uptake and function of diphtheria toxin | 6 | 6.30e-01 | -0.114000 | 7.34e-01 |
| Sensory processing of sound by outer hair cells of the cochlea | 41 | 2.08e-01 | -0.114000 | 3.31e-01 |
| Transcriptional regulation of pluripotent stem cells | 19 | 3.94e-01 | 0.113000 | 5.29e-01 |
| Regulated Necrosis | 56 | 1.44e-01 | -0.113000 | 2.52e-01 |
| IkBA variant leads to EDA-ID | 7 | 6.05e-01 | -0.113000 | 7.13e-01 |
| TAK1-dependent IKK and NF-kappa-B activation | 43 | 2.01e-01 | -0.113000 | 3.21e-01 |
| cGMP effects | 12 | 5.00e-01 | 0.112000 | 6.26e-01 |
| Urea cycle | 7 | 6.07e-01 | -0.112000 | 7.13e-01 |
| CD28 dependent Vav1 pathway | 12 | 5.00e-01 | -0.112000 | 6.26e-01 |
| CD209 (DC-SIGN) signaling | 20 | 3.84e-01 | -0.112000 | 5.20e-01 |
| Integration of provirus | 9 | 5.60e-01 | -0.112000 | 6.79e-01 |
| RAC1 GTPase cycle | 172 | 1.15e-02 | -0.112000 | 3.58e-02 |
| Growth hormone receptor signaling | 20 | 3.90e-01 | -0.111000 | 5.24e-01 |
| Sensory processing of sound by inner hair cells of the cochlea | 54 | 1.58e-01 | -0.111000 | 2.69e-01 |
| Glycerophospholipid biosynthesis | 105 | 4.94e-02 | -0.111000 | 1.14e-01 |
| Branched-chain amino acid catabolism | 21 | 3.80e-01 | -0.111000 | 5.15e-01 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | 33 | 2.75e-01 | -0.110000 | 4.02e-01 |
| Signaling by BRAF and RAF1 fusions | 60 | 1.42e-01 | -0.110000 | 2.50e-01 |
| ROS and RNS production in phagocytes | 30 | 3.00e-01 | -0.109000 | 4.27e-01 |
| Integration of energy metabolism | 88 | 7.64e-02 | -0.109000 | 1.58e-01 |
| NOTCH4 Intracellular Domain Regulates Transcription | 17 | 4.36e-01 | -0.109000 | 5.68e-01 |
| SLC transporter disorders | 76 | 1.00e-01 | -0.109000 | 1.94e-01 |
| FBXW7 Mutants and NOTCH1 in Cancer | 5 | 6.73e-01 | -0.109000 | 7.71e-01 |
| Loss of Function of FBXW7 in Cancer and NOTCH1 Signaling | 5 | 6.73e-01 | -0.109000 | 7.71e-01 |
| Signaling by MAPK mutants | 6 | 6.44e-01 | -0.109000 | 7.47e-01 |
| Biosynthesis of EPA-derived SPMs | 6 | 6.45e-01 | -0.109000 | 7.47e-01 |
| ZBP1(DAI) mediated induction of type I IFNs | 20 | 4.01e-01 | -0.108000 | 5.36e-01 |
| Anchoring of the basal body to the plasma membrane | 97 | 6.53e-02 | -0.108000 | 1.39e-01 |
| RAB geranylgeranylation | 63 | 1.39e-01 | -0.108000 | 2.47e-01 |
| MET activates RAS signaling | 10 | 5.57e-01 | -0.107000 | 6.77e-01 |
| Interaction between L1 and Ankyrins | 27 | 3.35e-01 | 0.107000 | 4.66e-01 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | 62 | 1.46e-01 | -0.107000 | 2.55e-01 |
| Activation of AMPK downstream of NMDARs | 20 | 4.11e-01 | -0.106000 | 5.46e-01 |
| Activation of PPARGC1A (PGC-1alpha) by phosphorylation | 8 | 6.04e-01 | -0.106000 | 7.12e-01 |
| Digestion | 5 | 6.82e-01 | -0.106000 | 7.77e-01 |
| Sensing of DNA Double Strand Breaks | 6 | 6.54e-01 | 0.106000 | 7.55e-01 |
| GPCR downstream signalling | 399 | 2.95e-04 | -0.106000 | 1.66e-03 |
| HDR through Single Strand Annealing (SSA) | 37 | 2.68e-01 | -0.105000 | 3.96e-01 |
| Sensory Perception | 194 | 1.16e-02 | 0.105000 | 3.59e-02 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | 66 | 1.40e-01 | -0.105000 | 2.48e-01 |
| Phospholipid metabolism | 183 | 1.46e-02 | -0.105000 | 4.32e-02 |
| Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) | 18 | 4.42e-01 | -0.105000 | 5.75e-01 |
| Specification of primordial germ cells | 6 | 6.57e-01 | 0.105000 | 7.58e-01 |
| SHC1 events in ERBB4 signaling | 10 | 5.67e-01 | 0.105000 | 6.84e-01 |
| Dermatan sulfate biosynthesis | 6 | 6.59e-01 | -0.104000 | 7.59e-01 |
| Metabolism of nitric oxide: NOS3 activation and regulation | 14 | 5.00e-01 | -0.104000 | 6.26e-01 |
| Synthesis of UDP-N-acetyl-glucosamine | 8 | 6.11e-01 | -0.104000 | 7.16e-01 |
| Na+/Cl- dependent neurotransmitter transporters | 8 | 6.12e-01 | 0.104000 | 7.16e-01 |
| SLBP independent Processing of Histone Pre-mRNAs | 10 | 5.72e-01 | -0.103000 | 6.89e-01 |
| Ras activation upon Ca2+ influx through NMDA receptor | 18 | 4.49e-01 | 0.103000 | 5.82e-01 |
| Maturation of nucleoprotein 9683610 | 11 | 5.56e-01 | -0.103000 | 6.76e-01 |
| O-glycosylation of TSR domain-containing proteins | 28 | 3.48e-01 | -0.102000 | 4.79e-01 |
| Signaling by LTK in cancer | 7 | 6.39e-01 | -0.102000 | 7.43e-01 |
| Netrin-1 signaling | 35 | 2.96e-01 | -0.102000 | 4.24e-01 |
| Defective GALNT12 causes CRCS1 | 9 | 5.98e-01 | 0.102000 | 7.08e-01 |
| Miro GTPase Cycle | 8 | 6.19e-01 | -0.102000 | 7.23e-01 |
| Amino acid transport across the plasma membrane | 25 | 3.82e-01 | -0.101000 | 5.17e-01 |
| Antiviral mechanism by IFN-stimulated genes | 140 | 3.89e-02 | -0.101000 | 9.41e-02 |
| POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation | 7 | 6.44e-01 | -0.101000 | 7.47e-01 |
| RUNX3 regulates CDKN1A transcription | 7 | 6.44e-01 | -0.101000 | 7.47e-01 |
| VEGFR2 mediated cell proliferation | 18 | 4.61e-01 | -0.100000 | 5.91e-01 |
| PI3K events in ERBB2 signaling | 11 | 5.65e-01 | 0.100000 | 6.82e-01 |
| Sensory perception of sweet, bitter, and umami (glutamate) taste | 19 | 4.50e-01 | 0.100000 | 5.82e-01 |
| Voltage gated Potassium channels | 27 | 3.71e-01 | 0.099500 | 5.05e-01 |
| Diseases associated with O-glycosylation of proteins | 50 | 2.24e-01 | -0.099300 | 3.50e-01 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | 18 | 4.66e-01 | -0.099200 | 5.93e-01 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | 18 | 4.66e-01 | -0.099200 | 5.93e-01 |
| Toll Like Receptor 3 (TLR3) Cascade | 104 | 8.07e-02 | -0.099100 | 1.65e-01 |
| NS1 Mediated Effects on Host Pathways | 40 | 2.81e-01 | -0.098500 | 4.08e-01 |
| Activated NTRK2 signals through FRS2 and FRS3 | 8 | 6.30e-01 | 0.098200 | 7.34e-01 |
| Processing and activation of SUMO | 10 | 5.92e-01 | -0.098000 | 7.04e-01 |
| Regulation of CDH19 Expression and Function | 6 | 6.78e-01 | -0.097900 | 7.74e-01 |
| Negative regulators of DDX58/IFIH1 signaling | 34 | 3.23e-01 | -0.097900 | 4.53e-01 |
| Ca2+ activated K+ channels | 6 | 6.79e-01 | 0.097700 | 7.75e-01 |
| Activation of Ca-permeable Kainate Receptor | 9 | 6.12e-01 | -0.097700 | 7.16e-01 |
| Ionotropic activity of kainate receptors | 9 | 6.12e-01 | -0.097700 | 7.16e-01 |
| Regulation of Expression and Function of Type II Classical Cadherins | 24 | 4.09e-01 | -0.097400 | 5.44e-01 |
| Regulation of Homotypic Cell-Cell Adhesion | 24 | 4.09e-01 | -0.097400 | 5.44e-01 |
| Signaling by GPCR | 446 | 4.24e-04 | -0.097400 | 2.26e-03 |
| Diseases of DNA repair | 51 | 2.30e-01 | -0.097200 | 3.56e-01 |
| RAC3 GTPase cycle | 87 | 1.19e-01 | -0.096700 | 2.21e-01 |
| MAP kinase activation | 63 | 1.85e-01 | -0.096600 | 3.02e-01 |
| Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol | 18 | 4.79e-01 | -0.096500 | 6.04e-01 |
| Nuclear Events (kinase and transcription factor activation) | 54 | 2.21e-01 | -0.096400 | 3.45e-01 |
| Regulation of FOXO transcriptional activity by acetylation | 10 | 5.99e-01 | -0.096100 | 7.08e-01 |
| Negative regulation of FGFR3 signaling | 21 | 4.46e-01 | -0.096000 | 5.79e-01 |
| Cross-presentation of particulate exogenous antigens (phagosomes) | 8 | 6.38e-01 | 0.095900 | 7.43e-01 |
| L1CAM interactions | 101 | 9.60e-02 | -0.095900 | 1.89e-01 |
| Toll Like Receptor 4 (TLR4) Cascade | 138 | 5.19e-02 | -0.095800 | 1.17e-01 |
| Deadenylation-dependent mRNA decay | 50 | 2.41e-01 | -0.095800 | 3.70e-01 |
| Formation of axial mesoderm | 6 | 6.85e-01 | 0.095500 | 7.80e-01 |
| Oncogenic MAPK signaling | 76 | 1.51e-01 | -0.095400 | 2.60e-01 |
| TICAM1,TRAF6-dependent induction of TAK1 complex | 11 | 5.85e-01 | -0.095000 | 6.99e-01 |
| RET signaling | 32 | 3.52e-01 | -0.095000 | 4.84e-01 |
| PI3K/AKT Signaling in Cancer | 84 | 1.33e-01 | -0.094900 | 2.39e-01 |
| Nuclear signaling by ERBB4 | 24 | 4.24e-01 | -0.094400 | 5.56e-01 |
| Tie2 Signaling | 16 | 5.15e-01 | -0.093900 | 6.40e-01 |
| SHC1 events in EGFR signaling | 11 | 5.91e-01 | -0.093700 | 7.03e-01 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | 100 | 1.05e-01 | -0.093700 | 2.02e-01 |
| Transferrin endocytosis and recycling | 26 | 4.13e-01 | -0.092800 | 5.46e-01 |
| Maturation of nucleoprotein 9694631 | 15 | 5.35e-01 | -0.092600 | 6.56e-01 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | 21 | 4.63e-01 | -0.092500 | 5.92e-01 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | 21 | 4.63e-01 | -0.092500 | 5.92e-01 |
| Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) | 12 | 5.79e-01 | -0.092500 | 6.94e-01 |
| Stimuli-sensing channels | 80 | 1.53e-01 | -0.092400 | 2.64e-01 |
| MyD88 dependent cascade initiated on endosome | 101 | 1.09e-01 | -0.092300 | 2.06e-01 |
| PI Metabolism | 79 | 1.57e-01 | -0.092000 | 2.68e-01 |
| MyD88-independent TLR4 cascade | 108 | 9.91e-02 | -0.091800 | 1.93e-01 |
| TRIF (TICAM1)-mediated TLR4 signaling | 108 | 9.91e-02 | -0.091800 | 1.93e-01 |
| Negative regulation of FGFR4 signaling | 22 | 4.56e-01 | -0.091800 | 5.87e-01 |
| Phase 4 - resting membrane potential | 9 | 6.34e-01 | -0.091700 | 7.38e-01 |
| Loss of Function of SMAD2/3 in Cancer | 7 | 6.77e-01 | 0.091100 | 7.74e-01 |
| Synthesis of PE | 12 | 5.86e-01 | 0.090900 | 6.99e-01 |
| Adrenaline,noradrenaline inhibits insulin secretion | 24 | 4.44e-01 | -0.090300 | 5.76e-01 |
| SOS-mediated signalling | 7 | 6.79e-01 | 0.090300 | 7.75e-01 |
| Regulation of IFNG signaling | 14 | 5.59e-01 | 0.090300 | 6.79e-01 |
| Golgi Associated Vesicle Biogenesis | 55 | 2.47e-01 | -0.090300 | 3.75e-01 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | 27 | 4.21e-01 | -0.089500 | 5.54e-01 |
| Apoptotic execution phase | 46 | 2.95e-01 | -0.089300 | 4.23e-01 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | 16 | 5.39e-01 | -0.088700 | 6.60e-01 |
| MyD88 cascade initiated on plasma membrane | 95 | 1.39e-01 | -0.087800 | 2.47e-01 |
| Toll Like Receptor 10 (TLR10) Cascade | 95 | 1.39e-01 | -0.087800 | 2.47e-01 |
| Toll Like Receptor 5 (TLR5) Cascade | 95 | 1.39e-01 | -0.087800 | 2.47e-01 |
| Signaling by FLT3 ITD and TKD mutants | 15 | 5.57e-01 | -0.087500 | 6.78e-01 |
| Kidney development | 17 | 5.32e-01 | 0.087500 | 6.56e-01 |
| Dectin-2 family | 19 | 5.10e-01 | 0.087300 | 6.36e-01 |
| Cargo trafficking to the periciliary membrane | 48 | 2.96e-01 | -0.087200 | 4.24e-01 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | 105 | 1.23e-01 | -0.087100 | 2.26e-01 |
| Glycosphingolipid biosynthesis | 15 | 5.60e-01 | -0.087000 | 6.79e-01 |
| Integrin cell surface interactions | 65 | 2.26e-01 | -0.086900 | 3.51e-01 |
| MET promotes cell motility | 34 | 3.82e-01 | 0.086600 | 5.17e-01 |
| Insulin receptor recycling | 24 | 4.64e-01 | -0.086300 | 5.93e-01 |
| Synthesis of glycosylphosphatidylinositol (GPI) | 18 | 5.26e-01 | -0.086300 | 6.50e-01 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | 15 | 5.63e-01 | -0.086300 | 6.81e-01 |
| RHO GTPases Activate ROCKs | 18 | 5.29e-01 | -0.085800 | 6.52e-01 |
| Metabolism of Angiotensinogen to Angiotensins | 12 | 6.08e-01 | -0.085600 | 7.14e-01 |
| Keratan sulfate degradation | 9 | 6.57e-01 | -0.085500 | 7.58e-01 |
| Synthesis of PIPs at the plasma membrane | 52 | 2.92e-01 | -0.084500 | 4.21e-01 |
| Toll Like Receptor 2 (TLR2) Cascade | 109 | 1.28e-01 | -0.084500 | 2.32e-01 |
| Toll Like Receptor TLR1:TLR2 Cascade | 109 | 1.28e-01 | -0.084500 | 2.32e-01 |
| Toll-like Receptor Cascades | 162 | 6.36e-02 | -0.084500 | 1.37e-01 |
| Fatty acyl-CoA biosynthesis | 35 | 3.88e-01 | -0.084300 | 5.23e-01 |
| Cilium Assembly | 187 | 4.68e-02 | -0.084300 | 1.09e-01 |
| RIPK1-mediated regulated necrosis | 31 | 4.18e-01 | -0.084000 | 5.51e-01 |
| Regulation of necroptotic cell death | 31 | 4.18e-01 | -0.084000 | 5.51e-01 |
| Collagen degradation | 42 | 3.47e-01 | -0.083800 | 4.79e-01 |
| Regulation of pyruvate dehydrogenase (PDH) complex | 14 | 5.87e-01 | -0.083800 | 7.00e-01 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | 108 | 1.33e-01 | -0.083700 | 2.39e-01 |
| Toll Like Receptor TLR6:TLR2 Cascade | 108 | 1.33e-01 | -0.083700 | 2.39e-01 |
| Negative regulation of FGFR1 signaling | 25 | 4.70e-01 | -0.083500 | 5.96e-01 |
| ERBB2 Activates PTK6 Signaling | 8 | 6.83e-01 | -0.083400 | 7.78e-01 |
| Uptake and actions of bacterial toxins | 27 | 4.56e-01 | -0.082900 | 5.87e-01 |
| Negative regulation of the PI3K/AKT network | 91 | 1.74e-01 | -0.082500 | 2.88e-01 |
| Amine ligand-binding receptors | 10 | 6.52e-01 | 0.082400 | 7.54e-01 |
| mRNA decay by 5’ to 3’ exoribonuclease | 15 | 5.82e-01 | -0.082100 | 6.96e-01 |
| Interferon Signaling | 240 | 2.91e-02 | -0.081800 | 7.46e-02 |
| Triglyceride biosynthesis | 9 | 6.72e-01 | 0.081600 | 7.70e-01 |
| BMAL1:CLOCK,NPAS2 activates circadian gene expression | 25 | 4.81e-01 | -0.081400 | 6.06e-01 |
| Degradation of the extracellular matrix | 96 | 1.70e-01 | -0.081100 | 2.83e-01 |
| Defective B3GALTL causes PpS | 27 | 4.69e-01 | -0.080500 | 5.96e-01 |
| Toll Like Receptor 9 (TLR9) Cascade | 108 | 1.49e-01 | -0.080300 | 2.58e-01 |
| Lipophagy | 7 | 7.15e-01 | -0.079700 | 8.03e-01 |
| Phase II - Conjugation of compounds | 70 | 2.52e-01 | -0.079100 | 3.81e-01 |
| Activation of Matrix Metalloproteinases | 22 | 5.22e-01 | -0.078900 | 6.46e-01 |
| Signaling by MET | 68 | 2.62e-01 | -0.078600 | 3.91e-01 |
| Protein lipoylation | 10 | 6.69e-01 | -0.078000 | 7.68e-01 |
| Triglyceride catabolism | 15 | 6.02e-01 | -0.077900 | 7.10e-01 |
| ISG15 antiviral mechanism | 72 | 2.55e-01 | -0.077700 | 3.84e-01 |
| Metabolism of ingested SeMet, Sec, MeSec into H2Se | 7 | 7.22e-01 | -0.077500 | 8.09e-01 |
| Defective GALNT3 causes HFTC | 9 | 6.90e-01 | 0.076900 | 7.83e-01 |
| Nicotinate metabolism | 27 | 4.89e-01 | 0.076800 | 6.16e-01 |
| RNA Polymerase I Transcription Termination | 30 | 4.70e-01 | -0.076100 | 5.97e-01 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | 84 | 2.35e-01 | -0.075000 | 3.61e-01 |
| Nucleotide catabolism | 28 | 4.96e-01 | -0.074300 | 6.23e-01 |
| Neurexins and neuroligins | 38 | 4.29e-01 | -0.074100 | 5.63e-01 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | 17 | 5.99e-01 | -0.073700 | 7.08e-01 |
| Visual phototransduction | 61 | 3.31e-01 | -0.072000 | 4.61e-01 |
| Apoptosis induced DNA fragmentation | 10 | 6.96e-01 | -0.071300 | 7.88e-01 |
| Unblocking of NMDA receptors, glutamate binding and activation | 16 | 6.23e-01 | 0.071100 | 7.26e-01 |
| Translation of Replicase and Assembly of the Replication Transcription Complex 9694676 | 13 | 6.58e-01 | -0.070800 | 7.59e-01 |
| Downregulation of TGF-beta receptor signaling | 26 | 5.33e-01 | -0.070600 | 6.56e-01 |
| Glutamate Neurotransmitter Release Cycle | 19 | 5.97e-01 | 0.070100 | 7.07e-01 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | 28 | 5.22e-01 | -0.069900 | 6.46e-01 |
| Post NMDA receptor activation events | 64 | 3.38e-01 | -0.069300 | 4.69e-01 |
| Inwardly rectifying K+ channels | 23 | 5.67e-01 | 0.069000 | 6.84e-01 |
| Homologous DNA Pairing and Strand Exchange | 43 | 4.34e-01 | -0.068900 | 5.67e-01 |
| Phase 2 - plateau phase | 11 | 6.92e-01 | 0.068900 | 7.85e-01 |
| MAPK targets/ Nuclear events mediated by MAP kinases | 31 | 5.08e-01 | -0.068700 | 6.34e-01 |
| TNFR1-induced proapoptotic signaling | 24 | 5.63e-01 | -0.068200 | 6.81e-01 |
| Signaling by KIT in disease | 20 | 5.99e-01 | -0.067900 | 7.08e-01 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | 20 | 5.99e-01 | -0.067900 | 7.08e-01 |
| Diseases of Mismatch Repair (MMR) | 5 | 7.94e-01 | 0.067300 | 8.65e-01 |
| Transcriptional Regulation by MECP2 | 49 | 4.16e-01 | -0.067100 | 5.49e-01 |
| Diseases associated with surfactant metabolism | 5 | 7.96e-01 | -0.066600 | 8.66e-01 |
| Signaling by PDGF | 48 | 4.26e-01 | -0.066300 | 5.60e-01 |
| Sialic acid metabolism | 28 | 5.44e-01 | -0.066300 | 6.64e-01 |
| Interleukin-4 and Interleukin-13 signaling | 92 | 2.76e-01 | -0.065700 | 4.03e-01 |
| TRIF-mediated programmed cell death | 9 | 7.33e-01 | -0.065600 | 8.20e-01 |
| Laminin interactions | 26 | 5.64e-01 | 0.065400 | 6.81e-01 |
| TNFR1-induced NF-kappa-B signaling pathway | 32 | 5.24e-01 | -0.065000 | 6.48e-01 |
| Activation of RAC1 | 11 | 7.09e-01 | -0.064900 | 7.99e-01 |
| Interleukin-10 signaling | 39 | 4.85e-01 | 0.064700 | 6.11e-01 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | 15 | 6.65e-01 | -0.064500 | 7.65e-01 |
| Diseases of branched-chain amino acid catabolism | 13 | 6.91e-01 | -0.063600 | 7.84e-01 |
| Deadenylation of mRNA | 22 | 6.07e-01 | -0.063400 | 7.13e-01 |
| Cellular hexose transport | 15 | 6.75e-01 | -0.062600 | 7.72e-01 |
| Platelet Aggregation (Plug Formation) | 29 | 5.60e-01 | -0.062500 | 6.79e-01 |
| eNOS activation | 11 | 7.20e-01 | -0.062400 | 8.07e-01 |
| Non-integrin membrane-ECM interactions | 49 | 4.57e-01 | 0.061400 | 5.88e-01 |
| FGFR1b ligand binding and activation | 5 | 8.12e-01 | -0.061400 | 8.76e-01 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | 17 | 6.61e-01 | 0.061300 | 7.61e-01 |
| Sodium/Calcium exchangers | 9 | 7.51e-01 | 0.061200 | 8.34e-01 |
| SLC15A4:TASL-dependent IRF5 activation | 6 | 7.96e-01 | -0.060900 | 8.66e-01 |
| DAP12 interactions | 39 | 5.11e-01 | -0.060800 | 6.36e-01 |
| Nitric oxide stimulates guanylate cyclase | 15 | 6.84e-01 | 0.060800 | 7.78e-01 |
| Activated NTRK2 signals through RAS | 6 | 7.97e-01 | 0.060700 | 8.66e-01 |
| Activated NTRK3 signals through RAS | 6 | 7.97e-01 | 0.060700 | 8.66e-01 |
| CaMK IV-mediated phosphorylation of CREB | 9 | 7.53e-01 | 0.060600 | 8.35e-01 |
| RHOBTB2 GTPase cycle | 23 | 6.16e-01 | -0.060500 | 7.20e-01 |
| Transport of nucleotide sugars | 9 | 7.54e-01 | -0.060400 | 8.35e-01 |
| Signaling by NTRK3 (TRKC) | 15 | 6.86e-01 | -0.060300 | 7.80e-01 |
| Post-transcriptional silencing by small RNAs | 7 | 7.83e-01 | 0.060200 | 8.56e-01 |
| NOD1/2 Signaling Pathway | 36 | 5.33e-01 | -0.060000 | 6.56e-01 |
| RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) | 9 | 7.56e-01 | -0.059800 | 8.36e-01 |
| P2Y receptors | 10 | 7.43e-01 | 0.059800 | 8.27e-01 |
| FGFR1 mutant receptor activation | 25 | 6.05e-01 | 0.059700 | 7.13e-01 |
| p130Cas linkage to MAPK signaling for integrins | 11 | 7.34e-01 | -0.059100 | 8.21e-01 |
| Pyrimidine catabolism | 9 | 7.60e-01 | -0.058700 | 8.40e-01 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | 20 | 6.50e-01 | -0.058700 | 7.52e-01 |
| WNT ligand biogenesis and trafficking | 20 | 6.50e-01 | 0.058600 | 7.52e-01 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | 14 | 7.07e-01 | -0.058100 | 7.97e-01 |
| Caspase activation via Death Receptors in the presence of ligand | 16 | 6.88e-01 | 0.057900 | 7.82e-01 |
| POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation | 5 | 8.24e-01 | 0.057300 | 8.85e-01 |
| Cell-cell junction organization | 57 | 4.55e-01 | -0.057200 | 5.86e-01 |
| MET activates RAP1 and RAC1 | 10 | 7.56e-01 | 0.056800 | 8.36e-01 |
| Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7 | 14 | 7.14e-01 | -0.056600 | 8.02e-01 |
| Extra-nuclear estrogen signaling | 65 | 4.31e-01 | -0.056500 | 5.63e-01 |
| Defective binding of VWF variant to GPIb:IX:V | 6 | 8.11e-01 | 0.056300 | 8.76e-01 |
| Enhanced binding of GP1BA variant to VWF multimer:collagen | 6 | 8.11e-01 | 0.056300 | 8.76e-01 |
| Nephrin family interactions | 20 | 6.63e-01 | -0.056300 | 7.63e-01 |
| Synthesis of PC | 23 | 6.41e-01 | -0.056100 | 7.45e-01 |
| Protein-protein interactions at synapses | 58 | 4.62e-01 | -0.055900 | 5.91e-01 |
| RHOBTB GTPase Cycle | 35 | 5.68e-01 | -0.055800 | 6.84e-01 |
| Regulation of MITF-M-dependent genes involved in lysosome biogenesis and autophagy | 16 | 7.00e-01 | -0.055600 | 7.91e-01 |
| Signaling by Insulin receptor | 63 | 4.50e-01 | -0.055100 | 5.82e-01 |
| Biological oxidations | 143 | 2.57e-01 | -0.054900 | 3.85e-01 |
| GABA synthesis, release, reuptake and degradation | 11 | 7.53e-01 | -0.054800 | 8.35e-01 |
| RHOT1 GTPase cycle | 5 | 8.32e-01 | -0.054700 | 8.90e-01 |
| FGFR1c ligand binding and activation | 8 | 7.89e-01 | 0.054700 | 8.61e-01 |
| Potassium Channels | 64 | 4.51e-01 | 0.054500 | 5.83e-01 |
| Impaired BRCA2 binding to RAD51 | 35 | 5.80e-01 | -0.054100 | 6.94e-01 |
| TRP channels | 22 | 6.61e-01 | -0.054000 | 7.61e-01 |
| Signaling by PDGFRA extracellular domain mutants | 12 | 7.48e-01 | 0.053600 | 8.31e-01 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | 12 | 7.48e-01 | 0.053600 | 8.31e-01 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | 11 | 7.61e-01 | -0.053000 | 8.40e-01 |
| Prolactin receptor signaling | 11 | 7.61e-01 | -0.052900 | 8.40e-01 |
| Assembly of collagen fibrils and other multimeric structures | 42 | 5.53e-01 | -0.052900 | 6.74e-01 |
| Signaling by FGFR in disease | 52 | 5.10e-01 | -0.052800 | 6.36e-01 |
| Translation of Replicase and Assembly of the Replication Transcription Complex 9679504 | 12 | 7.52e-01 | -0.052600 | 8.35e-01 |
| FOXO-mediated transcription of cell cycle genes | 14 | 7.35e-01 | -0.052200 | 8.22e-01 |
| Acyl chain remodelling of PE | 20 | 6.87e-01 | 0.052100 | 7.80e-01 |
| TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway | 17 | 7.10e-01 | -0.052000 | 7.99e-01 |
| Acyl chain remodelling of PC | 19 | 6.96e-01 | 0.051800 | 7.88e-01 |
| Rap1 signalling | 14 | 7.38e-01 | -0.051700 | 8.23e-01 |
| Neurotransmitter receptors and postsynaptic signal transmission | 139 | 2.93e-01 | -0.051700 | 4.22e-01 |
| SUMO is proteolytically processed | 6 | 8.27e-01 | 0.051400 | 8.87e-01 |
| Formation of the nephric duct | 8 | 8.02e-01 | 0.051300 | 8.68e-01 |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | 41 | 5.75e-01 | -0.050600 | 6.90e-01 |
| Diseases of DNA Double-Strand Break Repair | 41 | 5.75e-01 | -0.050600 | 6.90e-01 |
| Signaling by FGFR2 in disease | 33 | 6.17e-01 | -0.050300 | 7.21e-01 |
| Defects of platelet adhesion to exposed collagen | 7 | 8.18e-01 | -0.050300 | 8.80e-01 |
| Signaling by FGFR1 | 42 | 5.73e-01 | -0.050200 | 6.90e-01 |
| G alpha (i) signalling events | 196 | 2.36e-01 | -0.049100 | 3.62e-01 |
| Signaling by ERBB2 KD Mutants | 20 | 7.06e-01 | 0.048700 | 7.97e-01 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | 21 | 7.00e-01 | -0.048600 | 7.91e-01 |
| IFNG signaling activates MAPKs | 8 | 8.13e-01 | 0.048400 | 8.76e-01 |
| Striated Muscle Contraction | 27 | 6.67e-01 | 0.047900 | 7.66e-01 |
| Phosphate bond hydrolysis by NTPDase proteins | 5 | 8.54e-01 | -0.047500 | 9.04e-01 |
| Free fatty acids regulate insulin secretion | 10 | 7.96e-01 | -0.047200 | 8.66e-01 |
| Blood group systems biosynthesis | 17 | 7.38e-01 | 0.046900 | 8.23e-01 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | 22 | 7.04e-01 | -0.046800 | 7.95e-01 |
| TRAF6 mediated IRF7 activation | 15 | 7.54e-01 | -0.046700 | 8.35e-01 |
| Myogenesis | 20 | 7.18e-01 | -0.046600 | 8.06e-01 |
| Regulation of commissural axon pathfinding by SLIT and ROBO | 7 | 8.31e-01 | 0.046600 | 8.90e-01 |
| Ca2+ pathway | 58 | 5.42e-01 | -0.046200 | 6.64e-01 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | 22 | 7.10e-01 | -0.045900 | 7.99e-01 |
| ABC transporters in lipid homeostasis | 14 | 7.68e-01 | 0.045600 | 8.46e-01 |
| Surfactant metabolism | 20 | 7.29e-01 | 0.044800 | 8.16e-01 |
| Muscle contraction | 145 | 3.53e-01 | -0.044700 | 4.84e-01 |
| Relaxin receptors | 5 | 8.63e-01 | -0.044600 | 9.11e-01 |
| Glucuronidation | 8 | 8.28e-01 | 0.044500 | 8.87e-01 |
| Glycerophospholipid catabolism | 7 | 8.39e-01 | -0.044300 | 8.94e-01 |
| Negative regulation of FGFR2 signaling | 24 | 7.07e-01 | -0.044300 | 7.97e-01 |
| Activation of caspases through apoptosome-mediated cleavage | 6 | 8.51e-01 | 0.044200 | 9.02e-01 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | 30 | 6.76e-01 | -0.044100 | 7.74e-01 |
| Intrinsic Pathway of Fibrin Clot Formation | 15 | 7.72e-01 | 0.043100 | 8.48e-01 |
| PERK regulates gene expression | 31 | 6.81e-01 | 0.042600 | 7.77e-01 |
| Vitamin D (calciferol) metabolism | 11 | 8.08e-01 | -0.042200 | 8.74e-01 |
| RUNX1 regulates estrogen receptor mediated transcription | 6 | 8.59e-01 | 0.041900 | 9.08e-01 |
| Metabolism of steroid hormones | 21 | 7.41e-01 | 0.041700 | 8.26e-01 |
| Syndecan interactions | 25 | 7.25e-01 | 0.040700 | 8.11e-01 |
| Tight junction interactions | 17 | 7.73e-01 | 0.040500 | 8.48e-01 |
| Synthesis of very long-chain fatty acyl-CoAs | 22 | 7.43e-01 | 0.040400 | 8.27e-01 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | 20 | 7.65e-01 | -0.038700 | 8.43e-01 |
| Trafficking of AMPA receptors | 20 | 7.65e-01 | -0.038700 | 8.43e-01 |
| Interferon gamma signaling | 90 | 5.27e-01 | -0.038600 | 6.50e-01 |
| Calcitonin-like ligand receptors | 5 | 8.82e-01 | -0.038400 | 9.22e-01 |
| Signaling by PDGFR in disease | 19 | 7.75e-01 | 0.037900 | 8.49e-01 |
| IRAK1 recruits IKK complex | 14 | 8.06e-01 | -0.037800 | 8.72e-01 |
| IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | 14 | 8.06e-01 | -0.037800 | 8.72e-01 |
| Activation of NMDA receptors and postsynaptic events | 74 | 5.76e-01 | -0.037600 | 6.91e-01 |
| Sensory perception of taste | 22 | 7.61e-01 | 0.037500 | 8.40e-01 |
| Collagen chain trimerization | 27 | 7.37e-01 | 0.037400 | 8.23e-01 |
| Interleukin-6 family signaling | 20 | 7.74e-01 | 0.037200 | 8.48e-01 |
| Defects in cobalamin (B12) metabolism | 13 | 8.18e-01 | -0.036900 | 8.80e-01 |
| NCAM signaling for neurite out-growth | 47 | 6.64e-01 | -0.036600 | 7.64e-01 |
| Cytochrome c-mediated apoptotic response | 13 | 8.24e-01 | -0.035600 | 8.85e-01 |
| Branched-chain ketoacid dehydrogenase kinase deficiency | 5 | 8.90e-01 | -0.035600 | 9.26e-01 |
| Recycling of bile acids and salts | 10 | 8.46e-01 | -0.035500 | 8.98e-01 |
| Physiological factors | 9 | 8.55e-01 | 0.035100 | 9.05e-01 |
| Metabolic disorders of biological oxidation enzymes | 23 | 7.73e-01 | 0.034800 | 8.48e-01 |
| Scavenging by Class A Receptors | 12 | 8.36e-01 | -0.034500 | 8.93e-01 |
| BBSome-mediated cargo-targeting to cilium | 23 | 7.75e-01 | 0.034500 | 8.49e-01 |
| IRAK4 deficiency (TLR2/4) | 15 | 8.18e-01 | 0.034400 | 8.80e-01 |
| Creatine metabolism | 6 | 8.85e-01 | 0.034200 | 9.22e-01 |
| Presynaptic phase of homologous DNA pairing and strand exchange | 40 | 7.10e-01 | -0.033900 | 7.99e-01 |
| Formation of apoptosome | 11 | 8.46e-01 | -0.033900 | 8.98e-01 |
| Regulation of the apoptosome activity | 11 | 8.46e-01 | -0.033900 | 8.98e-01 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | 38 | 7.18e-01 | -0.033900 | 8.06e-01 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | 25 | 7.70e-01 | -0.033800 | 8.46e-01 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | 25 | 7.70e-01 | -0.033800 | 8.46e-01 |
| Defective homologous recombination repair (HRR) due to BRCA1 loss of function | 25 | 7.70e-01 | -0.033800 | 8.46e-01 |
| Defective homologous recombination repair (HRR) due to PALB2 loss of function | 25 | 7.70e-01 | -0.033800 | 8.46e-01 |
| Regulation of MITF-M-dependent genes involved in apoptosis | 16 | 8.15e-01 | 0.033800 | 8.78e-01 |
| Signaling by ERBB2 in Cancer | 21 | 7.91e-01 | 0.033400 | 8.63e-01 |
| Peptide ligand-binding receptors | 102 | 5.62e-01 | 0.033200 | 6.81e-01 |
| Signaling by FGFR3 | 32 | 7.45e-01 | -0.033200 | 8.29e-01 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | 12 | 8.43e-01 | -0.033100 | 8.97e-01 |
| SMAC (DIABLO) binds to IAPs | 7 | 8.82e-01 | -0.032400 | 9.22e-01 |
| SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes | 7 | 8.82e-01 | -0.032400 | 9.22e-01 |
| SMAC, XIAP-regulated apoptotic response | 7 | 8.82e-01 | -0.032400 | 9.22e-01 |
| NCAM1 interactions | 26 | 7.75e-01 | 0.032400 | 8.49e-01 |
| Transmission across Chemical Synapses | 183 | 4.50e-01 | -0.032400 | 5.82e-01 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | 25 | 7.81e-01 | 0.032100 | 8.54e-01 |
| Signaling by NODAL | 15 | 8.32e-01 | -0.031600 | 8.90e-01 |
| Neurotoxicity of clostridium toxins | 8 | 8.79e-01 | -0.031200 | 9.22e-01 |
| ATF4 activates genes in response to endoplasmic reticulum stress | 26 | 7.87e-01 | 0.030700 | 8.59e-01 |
| Caspase activation via extrinsic apoptotic signalling pathway | 25 | 7.91e-01 | -0.030700 | 8.63e-01 |
| Signaling by NTRK2 (TRKB) | 20 | 8.14e-01 | -0.030400 | 8.77e-01 |
| GPCR ligand binding | 245 | 4.13e-01 | -0.030300 | 5.46e-01 |
| GRB2 events in ERBB2 signaling | 11 | 8.62e-01 | 0.030200 | 9.10e-01 |
| Serine biosynthesis | 8 | 8.82e-01 | -0.030200 | 9.22e-01 |
| Interferon alpha/beta signaling | 64 | 6.77e-01 | 0.030100 | 7.74e-01 |
| Constitutive Signaling by Aberrant PI3K in Cancer | 57 | 6.96e-01 | -0.029900 | 7.88e-01 |
| SHC1 events in ERBB2 signaling | 17 | 8.31e-01 | -0.029900 | 8.90e-01 |
| Regulation of beta-cell development | 22 | 8.09e-01 | 0.029800 | 8.74e-01 |
| RAS signaling downstream of NF1 loss-of-function variants | 7 | 8.92e-01 | 0.029700 | 9.26e-01 |
| Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | 14 | 8.47e-01 | -0.029700 | 8.99e-01 |
| CREB phosphorylation | 7 | 8.92e-01 | 0.029600 | 9.26e-01 |
| Synthesis of PA | 31 | 7.77e-01 | 0.029400 | 8.50e-01 |
| Signaling by ERBB2 ECD mutants | 15 | 8.44e-01 | -0.029300 | 8.98e-01 |
| TRAIL signaling | 8 | 8.88e-01 | -0.028900 | 9.24e-01 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | 26 | 8.01e-01 | 0.028600 | 8.68e-01 |
| Estrogen-stimulated signaling through PRKCZ | 6 | 9.04e-01 | -0.028500 | 9.36e-01 |
| Sphingolipid catabolism | 11 | 8.71e-01 | 0.028300 | 9.18e-01 |
| Cardiac conduction | 89 | 6.45e-01 | -0.028300 | 7.47e-01 |
| Histidine catabolism | 7 | 8.97e-01 | -0.028200 | 9.31e-01 |
| Synthesis of Leukotrienes (LT) and Eoxins (EX) | 16 | 8.46e-01 | -0.028000 | 8.98e-01 |
| TICAM1, RIP1-mediated IKK complex recruitment | 19 | 8.35e-01 | -0.027600 | 8.92e-01 |
| Cohesin Loading onto Chromatin | 10 | 8.82e-01 | -0.027000 | 9.22e-01 |
| Vitamin B1 (thiamin) metabolism | 5 | 9.17e-01 | -0.027000 | 9.45e-01 |
| Diseases associated with the TLR signaling cascade | 29 | 8.02e-01 | -0.026900 | 8.68e-01 |
| Diseases of Immune System | 29 | 8.02e-01 | -0.026900 | 8.68e-01 |
| Activation of G protein gated Potassium channels | 19 | 8.39e-01 | -0.026900 | 8.94e-01 |
| G protein gated Potassium channels | 19 | 8.39e-01 | -0.026900 | 8.94e-01 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | 19 | 8.39e-01 | -0.026900 | 8.94e-01 |
| Post-translational modification: synthesis of GPI-anchored proteins | 60 | 7.19e-01 | -0.026900 | 8.07e-01 |
| Loss of Function of TGFBR1 in Cancer | 7 | 9.02e-01 | 0.026800 | 9.35e-01 |
| Gamma-carboxylation of protein precursors | 6 | 9.09e-01 | -0.026800 | 9.40e-01 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | 18 | 8.49e-01 | -0.025900 | 9.00e-01 |
| CASP8 activity is inhibited | 11 | 8.82e-01 | 0.025800 | 9.22e-01 |
| Dimerization of procaspase-8 | 11 | 8.82e-01 | 0.025800 | 9.22e-01 |
| Regulation by c-FLIP | 11 | 8.82e-01 | 0.025800 | 9.22e-01 |
| Signaling by FGFR4 | 32 | 8.01e-01 | -0.025700 | 8.68e-01 |
| GABA receptor activation | 36 | 7.93e-01 | -0.025300 | 8.64e-01 |
| Alpha-protein kinase 1 signaling pathway | 11 | 8.85e-01 | 0.025300 | 9.22e-01 |
| Response of EIF2AK1 (HRI) to heme deficiency | 14 | 8.71e-01 | 0.025200 | 9.18e-01 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | 20 | 8.46e-01 | -0.025100 | 8.98e-01 |
| Formation of Fibrin Clot (Clotting Cascade) | 26 | 8.27e-01 | -0.024700 | 8.87e-01 |
| Sperm Motility And Taxes | 6 | 9.19e-01 | 0.024100 | 9.47e-01 |
| Platelet Adhesion to exposed collagen | 15 | 8.73e-01 | -0.023800 | 9.19e-01 |
| GRB2 events in EGFR signaling | 10 | 8.99e-01 | -0.023200 | 9.32e-01 |
| Cation-coupled Chloride cotransporters | 6 | 9.22e-01 | 0.023000 | 9.48e-01 |
| IRS-mediated signalling | 35 | 8.24e-01 | 0.021700 | 8.85e-01 |
| Neurotransmitter clearance | 5 | 9.35e-01 | 0.021200 | 9.59e-01 |
| Regulation of NPAS4 gene expression | 11 | 9.03e-01 | -0.021200 | 9.36e-01 |
| Cobalamin (Cbl, vitamin B12) transport and metabolism | 18 | 8.82e-01 | -0.020100 | 9.22e-01 |
| Signaling by cytosolic FGFR1 fusion mutants | 18 | 8.89e-01 | -0.019000 | 9.25e-01 |
| Insulin receptor signalling cascade | 40 | 8.36e-01 | -0.018900 | 8.93e-01 |
| SHC-related events triggered by IGF1R | 7 | 9.31e-01 | -0.018900 | 9.56e-01 |
| Neuronal System | 270 | 5.95e-01 | -0.018800 | 7.07e-01 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | 20 | 8.85e-01 | -0.018700 | 9.22e-01 |
| Triglyceride metabolism | 24 | 8.78e-01 | -0.018100 | 9.22e-01 |
| Regulation of signaling by NODAL | 6 | 9.41e-01 | 0.017500 | 9.64e-01 |
| Lewis blood group biosynthesis | 13 | 9.14e-01 | -0.017200 | 9.44e-01 |
| Synthesis of IP2, IP, and Ins in the cytosol | 13 | 9.16e-01 | -0.017000 | 9.45e-01 |
| Xenobiotics | 12 | 9.20e-01 | -0.016800 | 9.47e-01 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | 37 | 8.61e-01 | -0.016700 | 9.09e-01 |
| Fertilization | 13 | 9.20e-01 | 0.016100 | 9.47e-01 |
| Cobalamin (Cbl) metabolism | 7 | 9.42e-01 | 0.016000 | 9.65e-01 |
| PP2A-mediated dephosphorylation of key metabolic factors | 7 | 9.44e-01 | -0.015400 | 9.66e-01 |
| Signaling by ERBB2 TMD/JMD mutants | 17 | 9.13e-01 | -0.015400 | 9.43e-01 |
| IGF1R signaling cascade | 37 | 8.79e-01 | -0.014500 | 9.22e-01 |
| Transport of RCbl within the body | 8 | 9.44e-01 | -0.014400 | 9.66e-01 |
| PI3K Cascade | 31 | 8.91e-01 | -0.014200 | 9.26e-01 |
| Signaling by FLT3 fusion proteins | 18 | 9.17e-01 | 0.014200 | 9.45e-01 |
| tRNA modification in the nucleus and cytosol | 43 | 8.73e-01 | -0.014100 | 9.19e-01 |
| Impaired BRCA2 binding to PALB2 | 24 | 9.05e-01 | -0.014000 | 9.36e-01 |
| FGFR2b ligand binding and activation | 6 | 9.54e-01 | 0.013600 | 9.73e-01 |
| Signaling by TGF-beta Receptor Complex in Cancer | 8 | 9.48e-01 | 0.013400 | 9.68e-01 |
| Toxicity of botulinum toxin type D (botD) | 5 | 9.59e-01 | -0.013200 | 9.74e-01 |
| Toxicity of botulinum toxin type F (botF) | 5 | 9.59e-01 | -0.013200 | 9.74e-01 |
| Intraflagellar transport | 47 | 8.83e-01 | -0.012400 | 9.22e-01 |
| Assembly and cell surface presentation of NMDA receptors | 34 | 9.05e-01 | -0.011900 | 9.36e-01 |
| Establishment of Sister Chromatid Cohesion | 11 | 9.46e-01 | -0.011800 | 9.67e-01 |
| Regulation of TLR by endogenous ligand | 15 | 9.37e-01 | -0.011800 | 9.61e-01 |
| Transport of bile salts and organic acids, metal ions and amine compounds | 53 | 8.85e-01 | -0.011500 | 9.22e-01 |
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | 7 | 9.60e-01 | -0.011000 | 9.74e-01 |
| Regulation of insulin secretion | 63 | 8.86e-01 | -0.010500 | 9.23e-01 |
| Phase I - Functionalization of compounds | 68 | 8.83e-01 | 0.010300 | 9.22e-01 |
| tRNA modification in the mitochondrion | 9 | 9.58e-01 | -0.010100 | 9.74e-01 |
| NGF-stimulated transcription | 32 | 9.22e-01 | -0.010000 | 9.48e-01 |
| AMPK inhibits chREBP transcriptional activation activity | 6 | 9.67e-01 | -0.009640 | 9.79e-01 |
| Competing endogenous RNAs (ceRNAs) regulate PTEN translation | 11 | 9.57e-01 | -0.009420 | 9.74e-01 |
| Aspirin ADME | 15 | 9.51e-01 | -0.009200 | 9.70e-01 |
| Regulation of PTEN localization | 9 | 9.62e-01 | -0.009090 | 9.75e-01 |
| NOTCH2 intracellular domain regulates transcription | 11 | 9.60e-01 | -0.008810 | 9.74e-01 |
| Regulation of CDH11 mRNA translation by microRNAs | 8 | 9.66e-01 | -0.008740 | 9.78e-01 |
| Regulation of NPAS4 mRNA translation | 8 | 9.66e-01 | -0.008740 | 9.78e-01 |
| MECP2 regulates neuronal receptors and channels | 14 | 9.55e-01 | -0.008640 | 9.74e-01 |
| Incretin synthesis, secretion, and inactivation | 14 | 9.60e-01 | -0.007800 | 9.74e-01 |
| Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | 14 | 9.60e-01 | -0.007800 | 9.74e-01 |
| Class A/1 (Rhodopsin-like receptors) | 177 | 8.60e-01 | -0.007690 | 9.09e-01 |
| Arachidonate metabolism | 47 | 9.30e-01 | 0.007370 | 9.56e-01 |
| MyD88 deficiency (TLR2/4) | 14 | 9.62e-01 | -0.007310 | 9.75e-01 |
| IRS-related events triggered by IGF1R | 36 | 9.40e-01 | 0.007290 | 9.64e-01 |
| Gastrin-CREB signalling pathway via PKC and MAPK | 14 | 9.64e-01 | -0.006990 | 9.77e-01 |
| Anchoring fibril formation | 8 | 9.74e-01 | -0.006680 | 9.81e-01 |
| Transcriptional Regulation by NPAS4 | 27 | 9.53e-01 | -0.006570 | 9.72e-01 |
| Neurotransmitter release cycle | 35 | 9.48e-01 | 0.006430 | 9.68e-01 |
| E2F-enabled inhibition of pre-replication complex formation | 9 | 9.74e-01 | -0.006200 | 9.81e-01 |
| Constitutive Signaling by EGFRvIII | 14 | 9.71e-01 | 0.005580 | 9.80e-01 |
| Signaling by EGFRvIII in Cancer | 14 | 9.71e-01 | 0.005580 | 9.80e-01 |
| Regulation of PTEN mRNA translation | 13 | 9.73e-01 | -0.005490 | 9.81e-01 |
| Transcriptional regulation of testis differentiation | 5 | 9.83e-01 | -0.005420 | 9.87e-01 |
| Long-term potentiation | 18 | 9.69e-01 | 0.005300 | 9.80e-01 |
| Peptide hormone metabolism | 53 | 9.48e-01 | 0.005220 | 9.68e-01 |
| Miscellaneous transport and binding events | 20 | 9.70e-01 | 0.004900 | 9.80e-01 |
| Endogenous sterols | 17 | 9.73e-01 | 0.004720 | 9.81e-01 |
| Beta oxidation of butanoyl-CoA to acetyl-CoA | 5 | 9.87e-01 | 0.004200 | 9.90e-01 |
| NPAS4 regulates expression of target genes | 16 | 9.81e-01 | 0.003500 | 9.87e-01 |
| Nucleotide-like (purinergic) receptors | 14 | 9.83e-01 | 0.003270 | 9.87e-01 |
| RHOBTB1 GTPase cycle | 23 | 9.79e-01 | 0.003100 | 9.86e-01 |
| IKK complex recruitment mediated by RIP1 | 23 | 9.83e-01 | -0.002620 | 9.87e-01 |
| Tryptophan catabolism | 12 | 9.88e-01 | 0.002410 | 9.91e-01 |
| Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus | 5 | 9.93e-01 | 0.002410 | 9.94e-01 |
| Signaling by BMP | 23 | 9.87e-01 | 0.001970 | 9.90e-01 |
| Methylation | 13 | 9.90e-01 | -0.001910 | 9.93e-01 |
| ECM proteoglycans | 47 | 9.82e-01 | 0.001860 | 9.87e-01 |
| Defective factor IX causes hemophilia B | 6 | 9.96e-01 | -0.001220 | 9.96e-01 |
| Signaling by ERBB4 | 45 | 9.93e-01 | 0.000710 | 9.94e-01 |
| RUNX3 regulates BCL2L11 (BIM) transcription | 5 | 9.98e-01 | -0.000503 | 9.98e-01 |
Detailed Gene set reports
Phosphorylation of Emi1
| set | Phosphorylation of Emi1 |
| setSize | 6 |
| pANOVA | 0.00103 |
| s.dist | -0.774 |
| p.adjustANOVA | 0.0048 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PLK1 | -10586 |
| FZR1 | -10513 |
| CDK1 | -10503 |
| CDC20 | -8129 |
| CCNB1 | -6919 |
| FBXO5 | -4906 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PLK1 | -10586 |
| FZR1 | -10513 |
| CDK1 | -10503 |
| CDC20 | -8129 |
| CCNB1 | -6919 |
| FBXO5 | -4906 |
Classical antibody-mediated complement activation
| set | Classical antibody-mediated complement activation |
| setSize | 70 |
| pANOVA | 2.66e-28 |
| s.dist | -0.762 |
| p.adjustANOVA | 3.95e-26 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| IGKV1-12 | -11067 |
| IGLV1-51 | -11065 |
| IGLV1-36 | -11059 |
| C1QA | -11052 |
| IGLV3-1 | -11051 |
| IGLV7-43 | -11046 |
| IGLC2 | -11042 |
| IGKV4-1 | -11040 |
| IGHV4-59 | -11039 |
| C1QB | -11037 |
| IGLV3-25 | -11035 |
| C1QC | -11033 |
| IGLV2-11 | -11030 |
| IGKV3-20 | -11027 |
| IGHV4-39 | -11021 |
| IGLC1 | -10973 |
| IGLV1-44 | -10965 |
| IGLV3-21 | -10946 |
| IGHV1-2 | -10941 |
| IGLV2-8 | -10937 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| IGKV1-12 | -11067 |
| IGLV1-51 | -11065 |
| IGLV1-36 | -11059 |
| C1QA | -11052 |
| IGLV3-1 | -11051 |
| IGLV7-43 | -11046 |
| IGLC2 | -11042 |
| IGKV4-1 | -11040 |
| IGHV4-59 | -11039 |
| C1QB | -11037 |
| IGLV3-25 | -11035 |
| C1QC | -11033 |
| IGLV2-11 | -11030 |
| IGKV3-20 | -11027 |
| IGHV4-39 | -11021 |
| IGLC1 | -10973 |
| IGLV1-44 | -10965 |
| IGLV3-21 | -10946 |
| IGHV1-2 | -10941 |
| IGLV2-8 | -10937 |
| IGLV1-40 | -10897 |
| IGHV4-34 | -10895 |
| IGKV3-15 | -10883 |
| IGLV6-57 | -10873 |
| IGLV7-46 | -10868 |
| IGKV1-17 | -10865 |
| IGKV2-28 | -10819 |
| IGHV1-46 | -10813 |
| IGKV3D-20 | -10773 |
| IGLV1-47 | -10750 |
| IGLV8-61 | -10736 |
| IGKV1D-39 | -10727 |
| IGHV3-23 | -10643 |
| IGKV1-16 | -10613 |
| IGKV1-5 | -10565 |
| IGLV2-14 | -10564 |
| IGHG4 | -10382 |
| IGHG1 | -10370 |
| IGLV4-69 | -10237 |
| IGKC | -10177 |
| IGLC3 | -10154 |
| IGHV3-11 | -10150 |
| IGHV2-5 | -9962 |
| IGLV2-23 | -9779 |
| C1R | -9623 |
| IGLV5-45 | -9612 |
| IGHV2-70 | -9577 |
| IGLV3-19 | -9480 |
| IGHG2 | -9403 |
| IGHV3-13 | -9362 |
| IGLV3-27 | -9009 |
| IGHV3-33 | -8976 |
| IGHV3-7 | -8694 |
| IGHV3-30 | -8469 |
| IGLV4-60 | -7967 |
| IGKV1-33 | -7579 |
| IGKV5-2 | -7369 |
| IGHV1-69 | -7091 |
| IGKV2-30 | -6664 |
| IGLV2-18 | -5134 |
| IGHG3 | -4843 |
| IGLV3-12 | -1877 |
| IGLC7 | -1096 |
| IGKV2D-28 | -955 |
| IGKV2-29 | 69 |
| IGHV3-48 | 2427 |
| IGHV3-53 | 4061 |
| IGLV10-54 | 4075 |
| IGKV3-11 | 6935 |
| C1S | 8798 |
NR1H2 & NR1H3 regulate gene expression linked to triglyceride lipolysis in adipose
| set | NR1H2 & NR1H3 regulate gene expression linked to triglyceride lipolysis in adipose |
| setSize | 5 |
| pANOVA | 0.00382 |
| s.dist | -0.747 |
| p.adjustANOVA | 0.0147 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RXRB | -10208 |
| NR1H3 | -8829 |
| RXRA | -7747 |
| NR1H2 | -7717 |
| PLIN1 | -6993 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| RXRB | -10208 |
| NR1H3 | -8829 |
| RXRA | -7747 |
| NR1H2 | -7717 |
| PLIN1 | -6993 |
Scavenging of heme from plasma
| set | Scavenging of heme from plasma |
| setSize | 71 |
| pANOVA | 4.21e-27 |
| s.dist | -0.739 |
| p.adjustANOVA | 5.07e-25 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| IGKV1-12 | -11067 |
| IGLV1-51 | -11065 |
| IGLV1-36 | -11059 |
| IGLV3-1 | -11051 |
| IGLV7-43 | -11046 |
| IGLC2 | -11042 |
| IGKV4-1 | -11040 |
| IGHV4-59 | -11039 |
| IGLV3-25 | -11035 |
| IGLV2-11 | -11030 |
| IGKV3-20 | -11027 |
| IGHV4-39 | -11021 |
| IGHA1 | -10976 |
| IGLC1 | -10973 |
| IGLV1-44 | -10965 |
| IGLV3-21 | -10946 |
| IGHV1-2 | -10941 |
| IGLV2-8 | -10937 |
| IGLV1-40 | -10897 |
| IGHV4-34 | -10895 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| IGKV1-12 | -11067 |
| IGLV1-51 | -11065 |
| IGLV1-36 | -11059 |
| IGLV3-1 | -11051 |
| IGLV7-43 | -11046 |
| IGLC2 | -11042 |
| IGKV4-1 | -11040 |
| IGHV4-59 | -11039 |
| IGLV3-25 | -11035 |
| IGLV2-11 | -11030 |
| IGKV3-20 | -11027 |
| IGHV4-39 | -11021 |
| IGHA1 | -10976 |
| IGLC1 | -10973 |
| IGLV1-44 | -10965 |
| IGLV3-21 | -10946 |
| IGHV1-2 | -10941 |
| IGLV2-8 | -10937 |
| IGLV1-40 | -10897 |
| IGHV4-34 | -10895 |
| IGKV3-15 | -10883 |
| IGLV6-57 | -10873 |
| IGLV7-46 | -10868 |
| IGKV1-17 | -10865 |
| JCHAIN | -10864 |
| IGKV2-28 | -10819 |
| IGHV1-46 | -10813 |
| IGKV3D-20 | -10773 |
| IGLV1-47 | -10750 |
| IGLV8-61 | -10736 |
| IGKV1D-39 | -10727 |
| IGHA2 | -10670 |
| IGHV3-23 | -10643 |
| IGKV1-16 | -10613 |
| IGKV1-5 | -10565 |
| IGLV2-14 | -10564 |
| IGLV4-69 | -10237 |
| HBA1 | -10200 |
| IGKC | -10177 |
| IGLC3 | -10154 |
| IGHV3-11 | -10150 |
| IGHV2-5 | -9962 |
| IGLV2-23 | -9779 |
| HBB | -9778 |
| IGLV5-45 | -9612 |
| IGHV2-70 | -9577 |
| IGLV3-19 | -9480 |
| HP | -9469 |
| IGHV3-13 | -9362 |
| IGLV3-27 | -9009 |
| IGHV3-33 | -8976 |
| IGHV3-7 | -8694 |
| IGHV3-30 | -8469 |
| IGLV4-60 | -7967 |
| IGKV1-33 | -7579 |
| IGKV5-2 | -7369 |
| IGHV1-69 | -7091 |
| IGKV2-30 | -6664 |
| IGLV2-18 | -5134 |
| LRP1 | -4893 |
| IGLV3-12 | -1877 |
| IGLC7 | -1096 |
| IGKV2D-28 | -955 |
| APOL1 | -702 |
| IGKV2-29 | 69 |
| HPX | 868 |
| IGHV3-48 | 2427 |
| IGHV3-53 | 4061 |
| IGLV10-54 | 4075 |
| CD163 | 6766 |
| IGKV3-11 | 6935 |
Creation of C4 and C2 activators
| set | Creation of C4 and C2 activators |
| setSize | 72 |
| pANOVA | 3.28e-27 |
| s.dist | -0.735 |
| p.adjustANOVA | 4.21e-25 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| IGKV1-12 | -11067 |
| IGLV1-51 | -11065 |
| IGLV1-36 | -11059 |
| C1QA | -11052 |
| IGLV3-1 | -11051 |
| IGLV7-43 | -11046 |
| IGLC2 | -11042 |
| IGKV4-1 | -11040 |
| IGHV4-59 | -11039 |
| C1QB | -11037 |
| IGLV3-25 | -11035 |
| C1QC | -11033 |
| IGLV2-11 | -11030 |
| IGKV3-20 | -11027 |
| IGHV4-39 | -11021 |
| IGLC1 | -10973 |
| IGLV1-44 | -10965 |
| IGLV3-21 | -10946 |
| IGHV1-2 | -10941 |
| IGLV2-8 | -10937 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| IGKV1-12 | -11067 |
| IGLV1-51 | -11065 |
| IGLV1-36 | -11059 |
| C1QA | -11052 |
| IGLV3-1 | -11051 |
| IGLV7-43 | -11046 |
| IGLC2 | -11042 |
| IGKV4-1 | -11040 |
| IGHV4-59 | -11039 |
| C1QB | -11037 |
| IGLV3-25 | -11035 |
| C1QC | -11033 |
| IGLV2-11 | -11030 |
| IGKV3-20 | -11027 |
| IGHV4-39 | -11021 |
| IGLC1 | -10973 |
| IGLV1-44 | -10965 |
| IGLV3-21 | -10946 |
| IGHV1-2 | -10941 |
| IGLV2-8 | -10937 |
| IGLV1-40 | -10897 |
| IGHV4-34 | -10895 |
| IGKV3-15 | -10883 |
| IGLV6-57 | -10873 |
| IGLV7-46 | -10868 |
| IGKV1-17 | -10865 |
| IGKV2-28 | -10819 |
| IGHV1-46 | -10813 |
| IGKV3D-20 | -10773 |
| IGLV1-47 | -10750 |
| IGLV8-61 | -10736 |
| IGKV1D-39 | -10727 |
| IGHV3-23 | -10643 |
| IGKV1-16 | -10613 |
| IGKV1-5 | -10565 |
| IGLV2-14 | -10564 |
| IGHG4 | -10382 |
| IGHG1 | -10370 |
| IGLV4-69 | -10237 |
| IGKC | -10177 |
| IGLC3 | -10154 |
| IGHV3-11 | -10150 |
| IGHV2-5 | -9962 |
| IGLV2-23 | -9779 |
| C1R | -9623 |
| IGLV5-45 | -9612 |
| IGHV2-70 | -9577 |
| IGLV3-19 | -9480 |
| IGHG2 | -9403 |
| IGHV3-13 | -9362 |
| IGLV3-27 | -9009 |
| IGHV3-33 | -8976 |
| IGHV3-7 | -8694 |
| IGHV3-30 | -8469 |
| IGLV4-60 | -7967 |
| IGKV1-33 | -7579 |
| IGKV5-2 | -7369 |
| IGHV1-69 | -7091 |
| IGKV2-30 | -6664 |
| IGLV2-18 | -5134 |
| IGHG3 | -4843 |
| IGLV3-12 | -1877 |
| FCN1 | -1235 |
| IGLC7 | -1096 |
| IGKV2D-28 | -955 |
| IGKV2-29 | 69 |
| IGHV3-48 | 2427 |
| IGHV3-53 | 4061 |
| IGLV10-54 | 4075 |
| MASP2 | 4904 |
| IGKV3-11 | 6935 |
| C1S | 8798 |
NR1H2 & NR1H3 regulate gene expression linked to lipogenesis
| set | NR1H2 & NR1H3 regulate gene expression linked to lipogenesis |
| setSize | 8 |
| pANOVA | 0.00046 |
| s.dist | -0.715 |
| p.adjustANOVA | 0.00243 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| FASN | -10931 |
| RXRB | -10208 |
| SREBF1 | -9673 |
| NR1H3 | -8829 |
| SCD | -8750 |
| RXRA | -7747 |
| NR1H2 | -7717 |
| NRIP1 | 258 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| FASN | -10931 |
| RXRB | -10208 |
| SREBF1 | -9673 |
| NR1H3 | -8829 |
| SCD | -8750 |
| RXRA | -7747 |
| NR1H2 | -7717 |
| NRIP1 | 258 |
Maturation of spike protein_9683686
| set | Maturation of spike protein_9683686 |
| setSize | 5 |
| pANOVA | 0.00577 |
| s.dist | -0.713 |
| p.adjustANOVA | 0.0204 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| GANAB | -11031 |
| PRKCSH | -9271 |
| MGAT1 | -8100 |
| MOGS | -7262 |
| CANX | -3965 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| GANAB | -11031 |
| PRKCSH | -9271 |
| MGAT1 | -8100 |
| MOGS | -7262 |
| CANX | -3965 |
Initial triggering of complement
| set | Initial triggering of complement |
| setSize | 80 |
| pANOVA | 8.73e-27 |
| s.dist | -0.692 |
| p.adjustANOVA | 9.48e-25 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| IGKV1-12 | -11067 |
| IGLV1-51 | -11065 |
| IGLV1-36 | -11059 |
| C1QA | -11052 |
| IGLV3-1 | -11051 |
| IGLV7-43 | -11046 |
| IGLC2 | -11042 |
| IGKV4-1 | -11040 |
| IGHV4-59 | -11039 |
| C1QB | -11037 |
| IGLV3-25 | -11035 |
| C1QC | -11033 |
| IGLV2-11 | -11030 |
| IGKV3-20 | -11027 |
| IGHV4-39 | -11021 |
| IGLC1 | -10973 |
| IGLV1-44 | -10965 |
| IGLV3-21 | -10946 |
| IGHV1-2 | -10941 |
| IGLV2-8 | -10937 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| IGKV1-12 | -11067 |
| IGLV1-51 | -11065 |
| IGLV1-36 | -11059 |
| C1QA | -11052 |
| IGLV3-1 | -11051 |
| IGLV7-43 | -11046 |
| IGLC2 | -11042 |
| IGKV4-1 | -11040 |
| IGHV4-59 | -11039 |
| C1QB | -11037 |
| IGLV3-25 | -11035 |
| C1QC | -11033 |
| IGLV2-11 | -11030 |
| IGKV3-20 | -11027 |
| IGHV4-39 | -11021 |
| IGLC1 | -10973 |
| IGLV1-44 | -10965 |
| IGLV3-21 | -10946 |
| IGHV1-2 | -10941 |
| IGLV2-8 | -10937 |
| IGLV1-40 | -10897 |
| IGHV4-34 | -10895 |
| IGKV3-15 | -10883 |
| IGLV6-57 | -10873 |
| IGLV7-46 | -10868 |
| IGKV1-17 | -10865 |
| IGKV2-28 | -10819 |
| IGHV1-46 | -10813 |
| IGKV3D-20 | -10773 |
| IGLV1-47 | -10750 |
| IGLV8-61 | -10736 |
| IGKV1D-39 | -10727 |
| IGHV3-23 | -10643 |
| IGKV1-16 | -10613 |
| IGKV1-5 | -10565 |
| IGLV2-14 | -10564 |
| IGHG4 | -10382 |
| IGHG1 | -10370 |
| IGLV4-69 | -10237 |
| IGKC | -10177 |
| IGLC3 | -10154 |
| IGHV3-11 | -10150 |
| IGHV2-5 | -9962 |
| IGLV2-23 | -9779 |
| C1R | -9623 |
| IGLV5-45 | -9612 |
| IGHV2-70 | -9577 |
| IGLV3-19 | -9480 |
| IGHG2 | -9403 |
| IGHV3-13 | -9362 |
| IGLV3-27 | -9009 |
| IGHV3-33 | -8976 |
| IGHV3-7 | -8694 |
| IGHV3-30 | -8469 |
| IGLV4-60 | -7967 |
| GZMM | -7727 |
| C4A | -7627 |
| IGKV1-33 | -7579 |
| CFD | -7542 |
| CFP | -7502 |
| IGKV5-2 | -7369 |
| IGHV1-69 | -7091 |
| IGKV2-30 | -6664 |
| IGLV2-18 | -5134 |
| IGHG3 | -4843 |
| IGLV3-12 | -1877 |
| C2 | -1840 |
| FCN1 | -1235 |
| IGLC7 | -1096 |
| IGKV2D-28 | -955 |
| CFB | -711 |
| C3 | -512 |
| IGKV2-29 | 69 |
| IGHV3-48 | 2427 |
| IGHV3-53 | 4061 |
| IGLV10-54 | 4075 |
| MASP2 | 4904 |
| C4B | 6359 |
| IGKV3-11 | 6935 |
| C1S | 8798 |
FCGR activation
| set | FCGR activation |
| setSize | 77 |
| pANOVA | 1.59e-25 |
| s.dist | -0.687 |
| p.adjustANOVA | 1.62e-23 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| IGKV1-12 | -11067 |
| IGLV1-51 | -11065 |
| IGLV1-36 | -11059 |
| IGLV3-1 | -11051 |
| IGLV7-43 | -11046 |
| IGLC2 | -11042 |
| IGKV4-1 | -11040 |
| IGHV4-59 | -11039 |
| IGLV3-25 | -11035 |
| IGLV2-11 | -11030 |
| IGKV3-20 | -11027 |
| IGHV4-39 | -11021 |
| IGLC1 | -10973 |
| CD247 | -10968 |
| IGLV1-44 | -10965 |
| IGLV3-21 | -10946 |
| IGHV1-2 | -10941 |
| IGLV2-8 | -10937 |
| IGLV1-40 | -10897 |
| IGHV4-34 | -10895 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| IGKV1-12 | -11067 |
| IGLV1-51 | -11065 |
| IGLV1-36 | -11059 |
| IGLV3-1 | -11051 |
| IGLV7-43 | -11046 |
| IGLC2 | -11042 |
| IGKV4-1 | -11040 |
| IGHV4-59 | -11039 |
| IGLV3-25 | -11035 |
| IGLV2-11 | -11030 |
| IGKV3-20 | -11027 |
| IGHV4-39 | -11021 |
| IGLC1 | -10973 |
| CD247 | -10968 |
| IGLV1-44 | -10965 |
| IGLV3-21 | -10946 |
| IGHV1-2 | -10941 |
| IGLV2-8 | -10937 |
| IGLV1-40 | -10897 |
| IGHV4-34 | -10895 |
| IGKV3-15 | -10883 |
| IGLV6-57 | -10873 |
| IGLV7-46 | -10868 |
| IGKV1-17 | -10865 |
| IGKV2-28 | -10819 |
| IGHV1-46 | -10813 |
| IGKV3D-20 | -10773 |
| IGLV1-47 | -10750 |
| IGLV8-61 | -10736 |
| IGKV1D-39 | -10727 |
| IGHV3-23 | -10643 |
| IGKV1-16 | -10613 |
| IGKV1-5 | -10565 |
| IGLV2-14 | -10564 |
| IGHG4 | -10382 |
| IGHG1 | -10370 |
| IGLV4-69 | -10237 |
| IGKC | -10177 |
| IGLC3 | -10154 |
| IGHV3-11 | -10150 |
| IGHV2-5 | -9962 |
| IGLV2-23 | -9779 |
| IGLV5-45 | -9612 |
| IGHV2-70 | -9577 |
| IGLV3-19 | -9480 |
| IGHG2 | -9403 |
| IGHV3-13 | -9362 |
| IGLV3-27 | -9009 |
| IGHV3-33 | -8976 |
| IGHV3-7 | -8694 |
| IGHV3-30 | -8469 |
| IGLV4-60 | -7967 |
| HCK | -7694 |
| IGKV1-33 | -7579 |
| IGKV5-2 | -7369 |
| IGHV1-69 | -7091 |
| IGKV2-30 | -6664 |
| SRC | -5661 |
| FGR | -5526 |
| IGLV2-18 | -5134 |
| FCGR3A | -4999 |
| IGHG3 | -4843 |
| FYN | -3739 |
| YES1 | -2374 |
| SYK | -2296 |
| IGLV3-12 | -1877 |
| IGLC7 | -1096 |
| IGKV2D-28 | -955 |
| IGKV2-29 | 69 |
| LYN | 593 |
| FCGR1A | 1121 |
| IGHV3-48 | 2427 |
| FCGR2A | 3908 |
| IGHV3-53 | 4061 |
| IGLV10-54 | 4075 |
| IGKV3-11 | 6935 |
| CD3G | 7030 |
Synthesis of GDP-mannose
| set | Synthesis of GDP-mannose |
| setSize | 6 |
| pANOVA | 0.00381 |
| s.dist | -0.682 |
| p.adjustANOVA | 0.0147 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| GMPPB | -10334 |
| MPI | -9581 |
| HK1 | -9485 |
| GMPPA | -6013 |
| PMM1 | -5488 |
| PMM2 | -4636 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| GMPPB | -10334 |
| MPI | -9581 |
| HK1 | -9485 |
| GMPPA | -6013 |
| PMM1 | -5488 |
| PMM2 | -4636 |
CD22 mediated BCR regulation
| set | CD22 mediated BCR regulation |
| setSize | 59 |
| pANOVA | 1.89e-19 |
| s.dist | -0.678 |
| p.adjustANOVA | 8.68e-18 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| IGKV1-12 | -11067 |
| IGLV1-51 | -11065 |
| IGLV3-1 | -11051 |
| IGLV7-43 | -11046 |
| IGLC2 | -11042 |
| IGKV4-1 | -11040 |
| IGHV4-59 | -11039 |
| IGLV3-25 | -11035 |
| IGLV2-11 | -11030 |
| IGKV3-20 | -11027 |
| IGHV4-39 | -11021 |
| IGLC1 | -10973 |
| IGLV1-44 | -10965 |
| IGLV3-21 | -10946 |
| IGHV1-2 | -10941 |
| IGLV2-8 | -10937 |
| IGLV1-40 | -10897 |
| IGHV4-34 | -10895 |
| IGKV3-15 | -10883 |
| IGLV6-57 | -10873 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| IGKV1-12 | -11067 |
| IGLV1-51 | -11065 |
| IGLV3-1 | -11051 |
| IGLV7-43 | -11046 |
| IGLC2 | -11042 |
| IGKV4-1 | -11040 |
| IGHV4-59 | -11039 |
| IGLV3-25 | -11035 |
| IGLV2-11 | -11030 |
| IGKV3-20 | -11027 |
| IGHV4-39 | -11021 |
| IGLC1 | -10973 |
| IGLV1-44 | -10965 |
| IGLV3-21 | -10946 |
| IGHV1-2 | -10941 |
| IGLV2-8 | -10937 |
| IGLV1-40 | -10897 |
| IGHV4-34 | -10895 |
| IGKV3-15 | -10883 |
| IGLV6-57 | -10873 |
| IGKV1-17 | -10865 |
| IGKV2-28 | -10819 |
| IGHV1-46 | -10813 |
| IGKV3D-20 | -10773 |
| IGLV1-47 | -10750 |
| IGKV1D-39 | -10727 |
| IGHV3-23 | -10643 |
| IGKV1-16 | -10613 |
| IGKV1-5 | -10565 |
| IGLV2-14 | -10564 |
| IGKC | -10177 |
| IGLC3 | -10154 |
| IGHV3-11 | -10150 |
| IGHV2-5 | -9962 |
| IGLV2-23 | -9779 |
| IGHV2-70 | -9577 |
| PTPN6 | -9556 |
| IGLV3-19 | -9480 |
| IGHV3-13 | -9362 |
| IGLV3-27 | -9009 |
| IGHV3-33 | -8976 |
| IGHV3-7 | -8694 |
| IGHV3-30 | -8469 |
| IGKV1-33 | -7579 |
| IGKV5-2 | -7369 |
| IGHV1-69 | -7091 |
| IGKV2-30 | -6664 |
| IGLC7 | -1096 |
| IGKV2D-28 | -955 |
| IGKV2-29 | 69 |
| LYN | 593 |
| CD79B | 1946 |
| IGHV3-48 | 2427 |
| CD79A | 3765 |
| IGHV3-53 | 4061 |
| IGHM | 4722 |
| CD22 | 5655 |
| IGHD | 6602 |
| IGKV3-11 | 6935 |
Glycosphingolipid transport
| set | Glycosphingolipid transport |
| setSize | 7 |
| pANOVA | 0.00209 |
| s.dist | -0.672 |
| p.adjustANOVA | 0.00891 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| ESYT1 | -11012 |
| CPTP | -10028 |
| CLN3 | -8617 |
| ARF1 | -8133 |
| ESYT2 | -5883 |
| GLTP | -5622 |
| PLEKHA8 | -3031 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| ESYT1 | -11012 |
| CPTP | -10028 |
| CLN3 | -8617 |
| ARF1 | -8133 |
| ESYT2 | -5883 |
| GLTP | -5622 |
| PLEKHA8 | -3031 |
Formation of annular gap junctions
| set | Formation of annular gap junctions |
| setSize | 10 |
| pANOVA | 0.000251 |
| s.dist | -0.669 |
| p.adjustANOVA | 0.00144 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| DNM2 | -10812 |
| ACTG1 | -10480 |
| AP2M1 | -9215 |
| ACTB | -8785 |
| DAB2 | -8755 |
| CLTA | -8259 |
| CLTB | -7737 |
| CLTCL1 | -6760 |
| CLTC | -3676 |
| DNM1 | 80 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| DNM2 | -10812 |
| ACTG1 | -10480 |
| AP2M1 | -9215 |
| ACTB | -8785 |
| DAB2 | -8755 |
| CLTA | -8259 |
| CLTB | -7737 |
| CLTCL1 | -6760 |
| CLTC | -3676 |
| DNM1 | 80 |
Negative regulation of TCF-dependent signaling by DVL-interacting proteins
| set | Negative regulation of TCF-dependent signaling by DVL-interacting proteins |
| setSize | 5 |
| pANOVA | 0.00993 |
| s.dist | -0.666 |
| p.adjustANOVA | 0.032 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CCDC88C | -10002 |
| DVL3 | -9210 |
| DVL1 | -8455 |
| DVL2 | -8405 |
| CXXC4 | -981 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CCDC88C | -10002 |
| DVL3 | -9210 |
| DVL1 | -8455 |
| DVL2 | -8405 |
| CXXC4 | -981 |
Role of LAT2/NTAL/LAB on calcium mobilization
| set | Role of LAT2/NTAL/LAB on calcium mobilization |
| setSize | 78 |
| pANOVA | 5.8e-23 |
| s.dist | -0.645 |
| p.adjustANOVA | 3.73e-21 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| IGKV1-12 | -11067 |
| IGLV1-51 | -11065 |
| IGLV1-36 | -11059 |
| IGLV3-1 | -11051 |
| IGLV7-43 | -11046 |
| IGLC2 | -11042 |
| IGKV4-1 | -11040 |
| IGHV4-59 | -11039 |
| IGLV3-25 | -11035 |
| IGLV2-11 | -11030 |
| IGKV3-20 | -11027 |
| IGHV4-39 | -11021 |
| IGLC1 | -10973 |
| IGLV1-44 | -10965 |
| IGLV3-21 | -10946 |
| IGHV1-2 | -10941 |
| IGLV2-8 | -10937 |
| IGLV1-40 | -10897 |
| IGHV4-34 | -10895 |
| IGKV3-15 | -10883 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| IGKV1-12 | -11067 |
| IGLV1-51 | -11065 |
| IGLV1-36 | -11059 |
| IGLV3-1 | -11051 |
| IGLV7-43 | -11046 |
| IGLC2 | -11042 |
| IGKV4-1 | -11040 |
| IGHV4-59 | -11039 |
| IGLV3-25 | -11035 |
| IGLV2-11 | -11030 |
| IGKV3-20 | -11027 |
| IGHV4-39 | -11021 |
| IGLC1 | -10973 |
| IGLV1-44 | -10965 |
| IGLV3-21 | -10946 |
| IGHV1-2 | -10941 |
| IGLV2-8 | -10937 |
| IGLV1-40 | -10897 |
| IGHV4-34 | -10895 |
| IGKV3-15 | -10883 |
| IGLV6-57 | -10873 |
| IGLV7-46 | -10868 |
| IGKV1-17 | -10865 |
| IGKV2-28 | -10819 |
| IGHV1-46 | -10813 |
| IGKV3D-20 | -10773 |
| IGLV1-47 | -10750 |
| IGLV8-61 | -10736 |
| IGKV1D-39 | -10727 |
| IGHV3-23 | -10643 |
| IGKV1-16 | -10613 |
| IGKV1-5 | -10565 |
| IGLV2-14 | -10564 |
| IGLV4-69 | -10237 |
| IGKC | -10177 |
| IGLC3 | -10154 |
| IGHV3-11 | -10150 |
| PIK3R2 | -10036 |
| IGHV2-5 | -9962 |
| IGLV2-23 | -9779 |
| IGLV5-45 | -9612 |
| IGHV2-70 | -9577 |
| IGLV3-19 | -9480 |
| IGHV3-13 | -9362 |
| IGLV3-27 | -9009 |
| IGHV3-33 | -8976 |
| SHC1 | -8865 |
| LAT2 | -8828 |
| IGHV3-7 | -8694 |
| IGHV3-30 | -8469 |
| IGLV4-60 | -7967 |
| IGKV1-33 | -7579 |
| IGKV5-2 | -7369 |
| IGHV1-69 | -7091 |
| IGKV2-30 | -6664 |
| IGHE | -6434 |
| IGLV2-18 | -5134 |
| FCER1G | -4866 |
| PDPK1 | -4079 |
| FCER1A | -3940 |
| FYN | -3739 |
| SYK | -2296 |
| IGLV3-12 | -1877 |
| IGLC7 | -1096 |
| IGKV2D-28 | -955 |
| PIK3R1 | -843 |
| GRB2 | -530 |
| MS4A2 | 49 |
| IGKV2-29 | 69 |
| LYN | 593 |
| GAB2 | 947 |
| IGHV3-48 | 2427 |
| IGHV3-53 | 4061 |
| IGLV10-54 | 4075 |
| PIK3CB | 4248 |
| PIK3CA | 4581 |
| SOS1 | 6490 |
| IGKV3-11 | 6935 |
Sulfide oxidation to sulfate
| set | Sulfide oxidation to sulfate |
| setSize | 5 |
| pANOVA | 0.0126 |
| s.dist | -0.645 |
| p.adjustANOVA | 0.0386 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| ETHE1 | -10152 |
| TST | -8994 |
| SLC25A10 | -7663 |
| SUOX | -6023 |
| TSTD1 | -3063 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| ETHE1 | -10152 |
| TST | -8994 |
| SLC25A10 | -7663 |
| SUOX | -6023 |
| TSTD1 | -3063 |
Type I hemidesmosome assembly
| set | Type I hemidesmosome assembly |
| setSize | 8 |
| pANOVA | 0.0016 |
| s.dist | -0.644 |
| p.adjustANOVA | 0.00714 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| KRT5 | -10291 |
| CD151 | -10021 |
| PLEC | -8711 |
| LAMB3 | -8137 |
| ITGB4 | -7960 |
| ITGA6 | -5611 |
| DST | -3798 |
| COL17A1 | -2858 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| KRT5 | -10291 |
| CD151 | -10021 |
| PLEC | -8711 |
| LAMB3 | -8137 |
| ITGB4 | -7960 |
| ITGA6 | -5611 |
| DST | -3798 |
| COL17A1 | -2858 |
Diseases of Base Excision Repair
| set | Diseases of Base Excision Repair |
| setSize | 5 |
| pANOVA | 0.0128 |
| s.dist | -0.642 |
| p.adjustANOVA | 0.0393 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| NEIL1 | -9189 |
| MUTYH | -8713 |
| NTHL1 | -7211 |
| NEIL3 | -5470 |
| OGG1 | -5197 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| NEIL1 | -9189 |
| MUTYH | -8713 |
| NTHL1 | -7211 |
| NEIL3 | -5470 |
| OGG1 | -5197 |
NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis
| set | NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis |
| setSize | 7 |
| pANOVA | 0.00344 |
| s.dist | -0.638 |
| p.adjustANOVA | 0.0135 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RXRB | -10208 |
| NCOR2 | -10144 |
| NR1H3 | -8829 |
| RXRA | -7747 |
| NR1H2 | -7717 |
| NCOA1 | -4107 |
| NCOR1 | -1031 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| RXRB | -10208 |
| NCOR2 | -10144 |
| NR1H3 | -8829 |
| RXRA | -7747 |
| NR1H2 | -7717 |
| NCOA1 | -4107 |
| NCOR1 | -1031 |
NR1H2 & NR1H3 regulate gene expression to limit cholesterol uptake
| set | NR1H2 & NR1H3 regulate gene expression to limit cholesterol uptake |
| setSize | 5 |
| pANOVA | 0.0137 |
| s.dist | -0.636 |
| p.adjustANOVA | 0.041 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RXRB | -10208 |
| NR1H3 | -8829 |
| RXRA | -7747 |
| NR1H2 | -7717 |
| MYLIP | -942 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| RXRB | -10208 |
| NR1H3 | -8829 |
| RXRA | -7747 |
| NR1H2 | -7717 |
| MYLIP | -942 |
Unwinding of DNA
| set | Unwinding of DNA |
| setSize | 12 |
| pANOVA | 0.000196 |
| s.dist | -0.621 |
| p.adjustANOVA | 0.00117 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MCM4 | -10735 |
| MCM2 | -10651 |
| CDC45 | -10175 |
| MCM5 | -10127 |
| GINS4 | -9821 |
| MCM6 | -9757 |
| MCM3 | -9690 |
| MCM7 | -9230 |
| GINS2 | -5188 |
| GINS1 | -3053 |
| MCM8 | 1614 |
| GINS3 | 3810 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| MCM4 | -10735 |
| MCM2 | -10651 |
| CDC45 | -10175 |
| MCM5 | -10127 |
| GINS4 | -9821 |
| MCM6 | -9757 |
| MCM3 | -9690 |
| MCM7 | -9230 |
| GINS2 | -5188 |
| GINS1 | -3053 |
| MCM8 | 1614 |
| GINS3 | 3810 |
Glyoxylate metabolism and glycine degradation
| set | Glyoxylate metabolism and glycine degradation |
| setSize | 13 |
| pANOVA | 0.000108 |
| s.dist | -0.62 |
| p.adjustANOVA | 0.000715 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| ALDH4A1 | -10790 |
| PXMP2 | -10629 |
| DLST | -10504 |
| GRHPR | -10426 |
| GLDC | -10322 |
| GOT2 | -9564 |
| OGDH | -8005 |
| GNMT | -6555 |
| GCSH | -6017 |
| AMT | -4739 |
| MRPS36 | -3986 |
| DDO | 43 |
| DLD | 1652 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| ALDH4A1 | -10790 |
| PXMP2 | -10629 |
| DLST | -10504 |
| GRHPR | -10426 |
| GLDC | -10322 |
| GOT2 | -9564 |
| OGDH | -8005 |
| GNMT | -6555 |
| GCSH | -6017 |
| AMT | -4739 |
| MRPS36 | -3986 |
| DDO | 43 |
| DLD | 1652 |
Activation of NIMA Kinases NEK9, NEK6, NEK7
| set | Activation of NIMA Kinases NEK9, NEK6, NEK7 |
| setSize | 7 |
| pANOVA | 0.0045 |
| s.dist | -0.62 |
| p.adjustANOVA | 0.0168 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PLK1 | -10586 |
| CDK1 | -10503 |
| CCNB2 | -9749 |
| NEK9 | -8130 |
| NEK6 | -7587 |
| CCNB1 | -6919 |
| NEK7 | 5108 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PLK1 | -10586 |
| CDK1 | -10503 |
| CCNB2 | -9749 |
| NEK9 | -8130 |
| NEK6 | -7587 |
| CCNB1 | -6919 |
| NEK7 | 5108 |
G2/M DNA replication checkpoint
| set | G2/M DNA replication checkpoint |
| setSize | 5 |
| pANOVA | 0.017 |
| s.dist | -0.616 |
| p.adjustANOVA | 0.049 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PKMYT1 | -10786 |
| CDK1 | -10503 |
| CCNB2 | -9749 |
| CCNB1 | -6919 |
| WEE1 | 3598 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PKMYT1 | -10786 |
| CDK1 | -10503 |
| CCNB2 | -9749 |
| CCNB1 | -6919 |
| WEE1 | 3598 |
Role of phospholipids in phagocytosis
| set | Role of phospholipids in phagocytosis |
| setSize | 89 |
| pANOVA | 2.16e-23 |
| s.dist | -0.61 |
| p.adjustANOVA | 1.48e-21 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| IGKV1-12 | -11067 |
| IGLV1-51 | -11065 |
| IGLV1-36 | -11059 |
| IGLV3-1 | -11051 |
| IGLV7-43 | -11046 |
| IGLC2 | -11042 |
| IGKV4-1 | -11040 |
| IGHV4-59 | -11039 |
| IGLV3-25 | -11035 |
| IGLV2-11 | -11030 |
| IGKV3-20 | -11027 |
| IGHV4-39 | -11021 |
| IGLC1 | -10973 |
| CD247 | -10968 |
| IGLV1-44 | -10965 |
| IGLV3-21 | -10946 |
| IGHV1-2 | -10941 |
| IGLV2-8 | -10937 |
| IGLV1-40 | -10897 |
| IGHV4-34 | -10895 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| IGKV1-12 | -11067 |
| IGLV1-51 | -11065 |
| IGLV1-36 | -11059 |
| IGLV3-1 | -11051 |
| IGLV7-43 | -11046 |
| IGLC2 | -11042 |
| IGKV4-1 | -11040 |
| IGHV4-59 | -11039 |
| IGLV3-25 | -11035 |
| IGLV2-11 | -11030 |
| IGKV3-20 | -11027 |
| IGHV4-39 | -11021 |
| IGLC1 | -10973 |
| CD247 | -10968 |
| IGLV1-44 | -10965 |
| IGLV3-21 | -10946 |
| IGHV1-2 | -10941 |
| IGLV2-8 | -10937 |
| IGLV1-40 | -10897 |
| IGHV4-34 | -10895 |
| IGKV3-15 | -10883 |
| IGLV6-57 | -10873 |
| IGLV7-46 | -10868 |
| IGKV1-17 | -10865 |
| IGKV2-28 | -10819 |
| IGHV1-46 | -10813 |
| IGKV3D-20 | -10773 |
| IGLV1-47 | -10750 |
| IGLV8-61 | -10736 |
| IGKV1D-39 | -10727 |
| IGHV3-23 | -10643 |
| IGKV1-16 | -10613 |
| IGKV1-5 | -10565 |
| IGLV2-14 | -10564 |
| IGHG4 | -10382 |
| IGHG1 | -10370 |
| IGLV4-69 | -10237 |
| IGKC | -10177 |
| IGLC3 | -10154 |
| IGHV3-11 | -10150 |
| PIK3R2 | -10036 |
| IGHV2-5 | -9962 |
| PLD4 | -9881 |
| IGLV2-23 | -9779 |
| IGLV5-45 | -9612 |
| IGHV2-70 | -9577 |
| PLA2G6 | -9525 |
| IGLV3-19 | -9480 |
| PLD3 | -9434 |
| IGHG2 | -9403 |
| IGHV3-13 | -9362 |
| IGLV3-27 | -9009 |
| IGHV3-33 | -8976 |
| IGHV3-7 | -8694 |
| IGHV3-30 | -8469 |
| IGLV4-60 | -7967 |
| IGKV1-33 | -7579 |
| IGKV5-2 | -7369 |
| ITPR3 | -7199 |
| IGHV1-69 | -7091 |
| IGKV2-30 | -6664 |
| PLCG2 | -5933 |
| IGLV2-18 | -5134 |
| FCGR3A | -4999 |
| PRKCD | -4982 |
| IGHG3 | -4843 |
| PLD1 | -3902 |
| AHCYL1 | -2656 |
| SYK | -2296 |
| PLD2 | -2272 |
| PLCG1 | -1939 |
| IGLV3-12 | -1877 |
| IGLC7 | -1096 |
| IGKV2D-28 | -955 |
| PIK3R1 | -843 |
| IGKV2-29 | 69 |
| PRKCE | 773 |
| FCGR1A | 1121 |
| IGHV3-48 | 2427 |
| FCGR2A | 3908 |
| IGHV3-53 | 4061 |
| IGLV10-54 | 4075 |
| PIK3CB | 4248 |
| PIK3CA | 4581 |
| ITPR1 | 4813 |
| ITPR2 | 5386 |
| IGKV3-11 | 6935 |
| CD3G | 7030 |
| PLPP5 | 7883 |
Binding and Uptake of Ligands by Scavenger Receptors
| set | Binding and Uptake of Ligands by Scavenger Receptors |
| setSize | 93 |
| pANOVA | 1.56e-23 |
| s.dist | -0.599 |
| p.adjustANOVA | 1.11e-21 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| IGKV1-12 | -11067 |
| IGLV1-51 | -11065 |
| IGLV1-36 | -11059 |
| IGLV3-1 | -11051 |
| IGLV7-43 | -11046 |
| IGLC2 | -11042 |
| IGKV4-1 | -11040 |
| IGHV4-59 | -11039 |
| IGLV3-25 | -11035 |
| IGLV2-11 | -11030 |
| IGKV3-20 | -11027 |
| IGHV4-39 | -11021 |
| IGHA1 | -10976 |
| IGLC1 | -10973 |
| IGLV1-44 | -10965 |
| IGLV3-21 | -10946 |
| IGHV1-2 | -10941 |
| IGLV2-8 | -10937 |
| IGLV1-40 | -10897 |
| IGHV4-34 | -10895 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| IGKV1-12 | -11067 |
| IGLV1-51 | -11065 |
| IGLV1-36 | -11059 |
| IGLV3-1 | -11051 |
| IGLV7-43 | -11046 |
| IGLC2 | -11042 |
| IGKV4-1 | -11040 |
| IGHV4-59 | -11039 |
| IGLV3-25 | -11035 |
| IGLV2-11 | -11030 |
| IGKV3-20 | -11027 |
| IGHV4-39 | -11021 |
| IGHA1 | -10976 |
| IGLC1 | -10973 |
| IGLV1-44 | -10965 |
| IGLV3-21 | -10946 |
| IGHV1-2 | -10941 |
| IGLV2-8 | -10937 |
| IGLV1-40 | -10897 |
| IGHV4-34 | -10895 |
| IGKV3-15 | -10883 |
| IGLV6-57 | -10873 |
| IGLV7-46 | -10868 |
| IGKV1-17 | -10865 |
| JCHAIN | -10864 |
| IGKV2-28 | -10819 |
| IGHV1-46 | -10813 |
| IGKV3D-20 | -10773 |
| IGLV1-47 | -10750 |
| IGLV8-61 | -10736 |
| IGKV1D-39 | -10727 |
| HYOU1 | -10689 |
| IGHA2 | -10670 |
| IGHV3-23 | -10643 |
| IGKV1-16 | -10613 |
| IGKV1-5 | -10565 |
| IGLV2-14 | -10564 |
| IGLV4-69 | -10237 |
| HBA1 | -10200 |
| IGKC | -10177 |
| IGLC3 | -10154 |
| IGHV3-11 | -10150 |
| IGHV2-5 | -9962 |
| IGLV2-23 | -9779 |
| HBB | -9778 |
| IGLV5-45 | -9612 |
| IGHV2-70 | -9577 |
| IGLV3-19 | -9480 |
| HP | -9469 |
| IGHV3-13 | -9362 |
| CALR | -9361 |
| IGLV3-27 | -9009 |
| IGHV3-33 | -8976 |
| SCARB1 | -8804 |
| IGHV3-7 | -8694 |
| IGHV3-30 | -8469 |
| IGLV4-60 | -7967 |
| IGKV1-33 | -7579 |
| IGKV5-2 | -7369 |
| SCARA5 | -7160 |
| IGHV1-69 | -7091 |
| HSP90B1 | -6959 |
| IGKV2-30 | -6664 |
| IGLV2-18 | -5134 |
| FTL | -5015 |
| LRP1 | -4893 |
| STAB1 | -4860 |
| STAB2 | -4816 |
| SCARF1 | -3917 |
| APOE | -3549 |
| HSPH1 | -3073 |
| SPARC | -2805 |
| IGLV3-12 | -1877 |
| SSC5D | -1200 |
| IGLC7 | -1096 |
| IGKV2D-28 | -955 |
| APOL1 | -702 |
| COL1A1 | -239 |
| IGKV2-29 | 69 |
| SCGB3A2 | 137 |
| FTH1 | 370 |
| HPX | 868 |
| MSR1 | 1534 |
| HSP90AA1 | 1741 |
| IGHV3-48 | 2427 |
| MARCO | 3565 |
| IGHV3-53 | 4061 |
| IGLV10-54 | 4075 |
| CD36 | 6757 |
| CD163 | 6766 |
| IGKV3-11 | 6935 |
| COLEC12 | 9970 |
| COL4A2 | 10587 |
Regulation of NFE2L2 gene expression
| set | Regulation of NFE2L2 gene expression |
| setSize | 8 |
| pANOVA | 0.00368 |
| s.dist | -0.593 |
| p.adjustANOVA | 0.0143 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| NOTCH1 | -10914 |
| RELA | -10888 |
| CREBBP | -9268 |
| MYC | -8975 |
| MAFK | -8470 |
| NFKB1 | -3418 |
| EP300 | -3086 |
| NFE2L2 | 2103 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| NOTCH1 | -10914 |
| RELA | -10888 |
| CREBBP | -9268 |
| MYC | -8975 |
| MAFK | -8470 |
| NFKB1 | -3418 |
| EP300 | -3086 |
| NFE2L2 | 2103 |
Nef Mediated CD4 Down-regulation
| set | Nef Mediated CD4 Down-regulation |
| setSize | 9 |
| pANOVA | 0.00216 |
| s.dist | -0.59 |
| p.adjustANOVA | 0.00919 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| AP2A1 | -9898 |
| AP2A2 | -9716 |
| AP2M1 | -9215 |
| ARF1 | -8133 |
| LCK | -5802 |
| AP2S1 | -5665 |
| CD4 | -4765 |
| AP2B1 | -3814 |
| ATP6V1H | -2266 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| AP2A1 | -9898 |
| AP2A2 | -9716 |
| AP2M1 | -9215 |
| ARF1 | -8133 |
| LCK | -5802 |
| AP2S1 | -5665 |
| CD4 | -4765 |
| AP2B1 | -3814 |
| ATP6V1H | -2266 |
Expression and translocation of olfactory receptors
| set | Expression and translocation of olfactory receptors |
| setSize | 52 |
| pANOVA | 2.4e-13 |
| s.dist | 0.587 |
| p.adjustANOVA | 7.59e-12 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| OR1D2 | 10801 |
| OR2M3 | 10790 |
| OR4K17 | 10757 |
| OR2AT4 | 10739 |
| OR5K2 | 10626 |
| OR14J1 | 10583 |
| OR2M4 | 10578 |
| OR6C75 | 10399 |
| OR2G6 | 10375 |
| OR7C1 | 10206 |
| OR5AS1 | 10160 |
| OR10H5 | 10079 |
| OR10G3 | 10049 |
| OR1I1 | 10021 |
| OR2A5 | 9792 |
| OR2C3 | 9766 |
| OR6Y1 | 9695 |
| OR5A1 | 9689 |
| OR5AU1 | 9678 |
| OR7D2 | 9599 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| OR1D2 | 10801 |
| OR2M3 | 10790 |
| OR4K17 | 10757 |
| OR2AT4 | 10739 |
| OR5K2 | 10626 |
| OR14J1 | 10583 |
| OR2M4 | 10578 |
| OR6C75 | 10399 |
| OR2G6 | 10375 |
| OR7C1 | 10206 |
| OR5AS1 | 10160 |
| OR10H5 | 10079 |
| OR10G3 | 10049 |
| OR1I1 | 10021 |
| OR2A5 | 9792 |
| OR2C3 | 9766 |
| OR6Y1 | 9695 |
| OR5A1 | 9689 |
| OR5AU1 | 9678 |
| OR7D2 | 9599 |
| OR8A1 | 9581 |
| OR4E1 | 9465 |
| OR2H2 | 9183 |
| OR4D9 | 9156 |
| OR2V2 | 9084 |
| OR13A1 | 8902 |
| OR51L1 | 8720 |
| OR10A6 | 8506 |
| OR5A2 | 8428 |
| OR1M1 | 7446 |
| OR2L2 | 7380 |
| OR5B2 | 7039 |
| OR52N4 | 7001 |
| OR4D1 | 6771 |
| OR7A17 | 6430 |
| OR2A1 | 5725 |
| OR2B11 | 5675 |
| OR52K1 | 5381 |
| EBF1 | 5372 |
| OR1A1 | 4840 |
| OR10H1 | 4578 |
| OR2T33 | 2110 |
| OR56A1 | 1299 |
| OR5AN1 | 122 |
| OR10AC1 | 35 |
| OR2I1P | -1071 |
| OR10G2 | -2668 |
| OR6K3 | -3838 |
| OR2A7 | -3874 |
| OR2W3 | -5752 |
| OR6N1 | -8825 |
| LDB1 | -10611 |
FCGR3A-mediated IL10 synthesis
| set | FCGR3A-mediated IL10 synthesis |
| setSize | 100 |
| pANOVA | 5.75e-24 |
| s.dist | -0.584 |
| p.adjustANOVA | 4.26e-22 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| IGKV1-12 | -11067 |
| IGLV1-51 | -11065 |
| IGLV1-36 | -11059 |
| IGLV3-1 | -11051 |
| IGLV7-43 | -11046 |
| IGLC2 | -11042 |
| IGKV4-1 | -11040 |
| IGHV4-59 | -11039 |
| IGLV3-25 | -11035 |
| IGLV2-11 | -11030 |
| IGKV3-20 | -11027 |
| IGHV4-39 | -11021 |
| IGLC1 | -10973 |
| CD247 | -10968 |
| IGLV1-44 | -10965 |
| IGLV3-21 | -10946 |
| IGHV1-2 | -10941 |
| IGLV2-8 | -10937 |
| IGLV1-40 | -10897 |
| IGHV4-34 | -10895 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| IGKV1-12 | -11067 |
| IGLV1-51 | -11065 |
| IGLV1-36 | -11059 |
| IGLV3-1 | -11051 |
| IGLV7-43 | -11046 |
| IGLC2 | -11042 |
| IGKV4-1 | -11040 |
| IGHV4-59 | -11039 |
| IGLV3-25 | -11035 |
| IGLV2-11 | -11030 |
| IGKV3-20 | -11027 |
| IGHV4-39 | -11021 |
| IGLC1 | -10973 |
| CD247 | -10968 |
| IGLV1-44 | -10965 |
| IGLV3-21 | -10946 |
| IGHV1-2 | -10941 |
| IGLV2-8 | -10937 |
| IGLV1-40 | -10897 |
| IGHV4-34 | -10895 |
| IGKV3-15 | -10883 |
| IGLV6-57 | -10873 |
| IGLV7-46 | -10868 |
| IGKV1-17 | -10865 |
| IGKV2-28 | -10819 |
| IGHV1-46 | -10813 |
| IGKV3D-20 | -10773 |
| IGLV1-47 | -10750 |
| IGLV8-61 | -10736 |
| IGKV1D-39 | -10727 |
| IGHV3-23 | -10643 |
| IGKV1-16 | -10613 |
| IGKV1-5 | -10565 |
| IGLV2-14 | -10564 |
| IGHG4 | -10382 |
| IGHG1 | -10370 |
| IGLV4-69 | -10237 |
| IGKC | -10177 |
| IGLC3 | -10154 |
| IGHV3-11 | -10150 |
| IGHV2-5 | -9962 |
| ADCY3 | -9807 |
| ADCY7 | -9800 |
| IGLV2-23 | -9779 |
| IGLV5-45 | -9612 |
| IGHV2-70 | -9577 |
| IGLV3-19 | -9480 |
| IGHG2 | -9403 |
| IGHV3-13 | -9362 |
| ADCY6 | -9168 |
| IGLV3-27 | -9009 |
| IGHV3-33 | -8976 |
| ADCY9 | -8948 |
| IGHV3-7 | -8694 |
| IGHV3-30 | -8469 |
| IGLV4-60 | -7967 |
| HCK | -7694 |
| IGKV1-33 | -7579 |
| IGKV5-2 | -7369 |
| ADCY4 | -7345 |
| ITPR3 | -7199 |
| IGHV1-69 | -7091 |
| PRKACA | -6940 |
| IGKV2-30 | -6664 |
| CALM1 | -6561 |
| PLCG2 | -5933 |
| SRC | -5661 |
| FGR | -5526 |
| IGLV2-18 | -5134 |
| FCGR3A | -4999 |
| IGHG3 | -4843 |
| FYN | -3739 |
| PRKAR2A | -3529 |
| IL10 | -3422 |
| PRKAR1A | -2707 |
| AHCYL1 | -2656 |
| YES1 | -2374 |
| SYK | -2296 |
| PLCG1 | -1939 |
| PRKAR2B | -1912 |
| IGLV3-12 | -1877 |
| PRKX | -1486 |
| IGLC7 | -1096 |
| IGKV2D-28 | -955 |
| PRKACB | -404 |
| IGKV2-29 | 69 |
| LYN | 593 |
| PRKAR1B | 624 |
| FCGR1A | 1121 |
| IGHV3-48 | 2427 |
| FCGR2A | 3908 |
| IGHV3-53 | 4061 |
| IGLV10-54 | 4075 |
| ADCY5 | 4739 |
| ITPR1 | 4813 |
| ITPR2 | 5386 |
| ADCY2 | 5909 |
| CREB1 | 6772 |
| IGKV3-11 | 6935 |
| CD3G | 7030 |
Retrograde neurotrophin signalling
| set | Retrograde neurotrophin signalling |
| setSize | 12 |
| pANOVA | 0.000479 |
| s.dist | -0.582 |
| p.adjustANOVA | 0.00252 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| DNM2 | -10812 |
| AP2A1 | -9898 |
| AP2A2 | -9716 |
| AP2M1 | -9215 |
| CLTA | -8259 |
| DNAL4 | -8222 |
| NTRK1 | -6213 |
| AP2S1 | -5665 |
| AP2B1 | -3814 |
| CLTC | -3676 |
| DNM3 | -2531 |
| DNM1 | 80 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| DNM2 | -10812 |
| AP2A1 | -9898 |
| AP2A2 | -9716 |
| AP2M1 | -9215 |
| CLTA | -8259 |
| DNAL4 | -8222 |
| NTRK1 | -6213 |
| AP2S1 | -5665 |
| AP2B1 | -3814 |
| CLTC | -3676 |
| DNM3 | -2531 |
| DNM1 | 80 |
Formation of ATP by chemiosmotic coupling
| set | Formation of ATP by chemiosmotic coupling |
| setSize | 20 |
| pANOVA | 7.81e-06 |
| s.dist | -0.577 |
| p.adjustANOVA | 7.75e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| ATP5MF | -9620 |
| ATP5ME | -9585 |
| ATP5F1B | -9536 |
| ATP5F1E | -9394 |
| ATP5MC2 | -9375 |
| ATP5PF | -9116 |
| MT-ATP6 | -8542 |
| ATP5MC3 | -8341 |
| ATP5F1A | -8332 |
| ATP5MJ | -8136 |
| ATP5PO | -7511 |
| ATP5MG | -7269 |
| MT-ATP8 | -6801 |
| ATP5MK | -6488 |
| ATP5F1D | -5120 |
| ATP5MC1 | -3419 |
| ATP5PB | -3376 |
| ATP5PD | -3131 |
| ATP5F1C | -2285 |
| DMAC2L | 6593 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| ATP5MF | -9620 |
| ATP5ME | -9585 |
| ATP5F1B | -9536 |
| ATP5F1E | -9394 |
| ATP5MC2 | -9375 |
| ATP5PF | -9116 |
| MT-ATP6 | -8542 |
| ATP5MC3 | -8341 |
| ATP5F1A | -8332 |
| ATP5MJ | -8136 |
| ATP5PO | -7511 |
| ATP5MG | -7269 |
| MT-ATP8 | -6801 |
| ATP5MK | -6488 |
| ATP5F1D | -5120 |
| ATP5MC1 | -3419 |
| ATP5PB | -3376 |
| ATP5PD | -3131 |
| ATP5F1C | -2285 |
| DMAC2L | 6593 |
FCERI mediated Ca+2 mobilization
| set | FCERI mediated Ca+2 mobilization |
| setSize | 93 |
| pANOVA | 1.22e-21 |
| s.dist | -0.573 |
| p.adjustANOVA | 6.01e-20 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| IGKV1-12 | -11067 |
| IGLV1-51 | -11065 |
| IGLV1-36 | -11059 |
| IGLV3-1 | -11051 |
| IGLV7-43 | -11046 |
| IGLC2 | -11042 |
| IGKV4-1 | -11040 |
| IGHV4-59 | -11039 |
| IGLV3-25 | -11035 |
| IGLV2-11 | -11030 |
| IGKV3-20 | -11027 |
| IGHV4-39 | -11021 |
| IGLC1 | -10973 |
| IGLV1-44 | -10965 |
| VAV1 | -10950 |
| IGLV3-21 | -10946 |
| IGHV1-2 | -10941 |
| IGLV2-8 | -10937 |
| IGLV1-40 | -10897 |
| IGHV4-34 | -10895 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| IGKV1-12 | -11067 |
| IGLV1-51 | -11065 |
| IGLV1-36 | -11059 |
| IGLV3-1 | -11051 |
| IGLV7-43 | -11046 |
| IGLC2 | -11042 |
| IGKV4-1 | -11040 |
| IGHV4-59 | -11039 |
| IGLV3-25 | -11035 |
| IGLV2-11 | -11030 |
| IGKV3-20 | -11027 |
| IGHV4-39 | -11021 |
| IGLC1 | -10973 |
| IGLV1-44 | -10965 |
| VAV1 | -10950 |
| IGLV3-21 | -10946 |
| IGHV1-2 | -10941 |
| IGLV2-8 | -10937 |
| IGLV1-40 | -10897 |
| IGHV4-34 | -10895 |
| IGKV3-15 | -10883 |
| IGLV6-57 | -10873 |
| IGLV7-46 | -10868 |
| IGKV1-17 | -10865 |
| IGKV2-28 | -10819 |
| IGHV1-46 | -10813 |
| IGKV3D-20 | -10773 |
| IGLV1-47 | -10750 |
| IGLV8-61 | -10736 |
| IGKV1D-39 | -10727 |
| IGHV3-23 | -10643 |
| IGKV1-16 | -10613 |
| IGKV1-5 | -10565 |
| IGLV2-14 | -10564 |
| IGLV4-69 | -10237 |
| IGKC | -10177 |
| IGLC3 | -10154 |
| IGHV3-11 | -10150 |
| IGHV2-5 | -9962 |
| IGLV2-23 | -9779 |
| IGLV5-45 | -9612 |
| IGHV2-70 | -9577 |
| IGLV3-19 | -9480 |
| IGHV3-13 | -9362 |
| IGLV3-27 | -9009 |
| IGHV3-33 | -8976 |
| SHC1 | -8865 |
| IGHV3-7 | -8694 |
| IGHV3-30 | -8469 |
| NFATC3 | -8221 |
| IGLV4-60 | -7967 |
| VAV2 | -7600 |
| IGKV1-33 | -7579 |
| IGKV5-2 | -7369 |
| ITPR3 | -7199 |
| IGHV1-69 | -7091 |
| NFATC2 | -6930 |
| NFATC1 | -6924 |
| IGKV2-30 | -6664 |
| CALM1 | -6561 |
| IGHE | -6434 |
| LAT | -6070 |
| PLCG2 | -5933 |
| IGLV2-18 | -5134 |
| FCER1G | -4866 |
| FCER1A | -3940 |
| LCP2 | -3170 |
| AHCYL1 | -2656 |
| GRAP2 | -2303 |
| SYK | -2296 |
| PLCG1 | -1939 |
| IGLV3-12 | -1877 |
| TXK | -1609 |
| IGLC7 | -1096 |
| IGKV2D-28 | -955 |
| GRB2 | -530 |
| MS4A2 | 49 |
| IGKV2-29 | 69 |
| LYN | 593 |
| ITK | 1044 |
| TEC | 1194 |
| PPP3CB | 1624 |
| IGHV3-48 | 2427 |
| VAV3 | 2504 |
| PPP3R1 | 2563 |
| PPP3CA | 3780 |
| BTK | 3975 |
| IGHV3-53 | 4061 |
| IGLV10-54 | 4075 |
| ITPR1 | 4813 |
| ITPR2 | 5386 |
| SOS1 | 6490 |
| IGKV3-11 | 6935 |
Synthesis of PG
| set | Synthesis of PG |
| setSize | 8 |
| pANOVA | 0.00518 |
| s.dist | -0.571 |
| p.adjustANOVA | 0.0186 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PGS1 | -10204 |
| PLD4 | -9881 |
| PLD3 | -9434 |
| DUSP23 | -7753 |
| PLD6 | -5952 |
| PLD1 | -3902 |
| PLD2 | -2272 |
| CDS2 | -1569 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PGS1 | -10204 |
| PLD4 | -9881 |
| PLD3 | -9434 |
| DUSP23 | -7753 |
| PLD6 | -5952 |
| PLD1 | -3902 |
| PLD2 | -2272 |
| CDS2 | -1569 |
Regulation of Complement cascade
| set | Regulation of Complement cascade |
| setSize | 97 |
| pANOVA | 4.37e-22 |
| s.dist | -0.567 |
| p.adjustANOVA | 2.63e-20 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| IGKV1-12 | -11067 |
| IGLV1-51 | -11065 |
| IGLV1-36 | -11059 |
| C1QA | -11052 |
| IGLV3-1 | -11051 |
| IGLV7-43 | -11046 |
| IGLC2 | -11042 |
| IGKV4-1 | -11040 |
| IGHV4-59 | -11039 |
| C1QB | -11037 |
| IGLV3-25 | -11035 |
| C1QC | -11033 |
| IGLV2-11 | -11030 |
| IGKV3-20 | -11027 |
| IGHV4-39 | -11021 |
| IGLC1 | -10973 |
| IGLV1-44 | -10965 |
| IGLV3-21 | -10946 |
| IGHV1-2 | -10941 |
| IGLV2-8 | -10937 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| IGKV1-12 | -11067 |
| IGLV1-51 | -11065 |
| IGLV1-36 | -11059 |
| C1QA | -11052 |
| IGLV3-1 | -11051 |
| IGLV7-43 | -11046 |
| IGLC2 | -11042 |
| IGKV4-1 | -11040 |
| IGHV4-59 | -11039 |
| C1QB | -11037 |
| IGLV3-25 | -11035 |
| C1QC | -11033 |
| IGLV2-11 | -11030 |
| IGKV3-20 | -11027 |
| IGHV4-39 | -11021 |
| IGLC1 | -10973 |
| IGLV1-44 | -10965 |
| IGLV3-21 | -10946 |
| IGHV1-2 | -10941 |
| IGLV2-8 | -10937 |
| IGLV1-40 | -10897 |
| IGHV4-34 | -10895 |
| IGKV3-15 | -10883 |
| IGLV6-57 | -10873 |
| IGLV7-46 | -10868 |
| IGKV1-17 | -10865 |
| IGKV2-28 | -10819 |
| IGHV1-46 | -10813 |
| IGKV3D-20 | -10773 |
| IGLV1-47 | -10750 |
| IGLV8-61 | -10736 |
| IGKV1D-39 | -10727 |
| IGHV3-23 | -10643 |
| IGKV1-16 | -10613 |
| IGKV1-5 | -10565 |
| IGLV2-14 | -10564 |
| IGHG4 | -10382 |
| IGHG1 | -10370 |
| IGLV4-69 | -10237 |
| IGKC | -10177 |
| IGLC3 | -10154 |
| IGHV3-11 | -10150 |
| CD59 | -10051 |
| IGHV2-5 | -9962 |
| IGLV2-23 | -9779 |
| C1R | -9623 |
| IGLV5-45 | -9612 |
| IGHV2-70 | -9577 |
| IGLV3-19 | -9480 |
| IGHG2 | -9403 |
| IGHV3-13 | -9362 |
| ELANE | -9151 |
| IGLV3-27 | -9009 |
| IGHV3-33 | -8976 |
| IGHV3-7 | -8694 |
| IGHV3-30 | -8469 |
| IGLV4-60 | -7967 |
| CD81 | -7945 |
| VTN | -7933 |
| C4A | -7627 |
| IGKV1-33 | -7579 |
| CFP | -7502 |
| IGKV5-2 | -7369 |
| IGHV1-69 | -7091 |
| IGKV2-30 | -6664 |
| C8G | -5579 |
| IGLV2-18 | -5134 |
| IGHG3 | -4843 |
| CD55 | -4050 |
| C4BPB | -2912 |
| CPN2 | -2533 |
| C5AR2 | -2289 |
| IGLV3-12 | -1877 |
| C2 | -1840 |
| CLU | -1395 |
| C5 | -1099 |
| IGLC7 | -1096 |
| IGKV2D-28 | -955 |
| CFB | -711 |
| C3 | -512 |
| CR2 | 46 |
| IGKV2-29 | 69 |
| CR1 | 1190 |
| IGHV3-48 | 2427 |
| C3AR1 | 2858 |
| PROS1 | 3412 |
| C5AR1 | 3587 |
| IGHV3-53 | 4061 |
| IGLV10-54 | 4075 |
| C4BPA | 4554 |
| SERPING1 | 5663 |
| C4B | 6359 |
| CD46 | 6809 |
| IGKV3-11 | 6935 |
| CD19 | 7511 |
| C1S | 8798 |
| CFH | 9758 |
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
| set | TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest |
| setSize | 18 |
| pANOVA | 3.15e-05 |
| s.dist | -0.567 |
| p.adjustANOVA | 0.000265 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| TFDP1 | -11050 |
| CDK1 | -10503 |
| E2F4 | -10273 |
| TFDP2 | -10153 |
| CARM1 | -9839 |
| GADD45A | -8550 |
| PRMT1 | -8195 |
| CDC25C | -7979 |
| PCNA | -7812 |
| TP53 | -7337 |
| CCNB1 | -6919 |
| AURKA | -5720 |
| BAX | -5009 |
| RBL2 | -4392 |
| EP300 | -3086 |
| SFN | -1586 |
| ZNF385A | -960 |
| RBL1 | 5549 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| TFDP1 | -11050 |
| CDK1 | -10503 |
| E2F4 | -10273 |
| TFDP2 | -10153 |
| CARM1 | -9839 |
| GADD45A | -8550 |
| PRMT1 | -8195 |
| CDC25C | -7979 |
| PCNA | -7812 |
| TP53 | -7337 |
| CCNB1 | -6919 |
| AURKA | -5720 |
| BAX | -5009 |
| RBL2 | -4392 |
| EP300 | -3086 |
| SFN | -1586 |
| ZNF385A | -960 |
| RBL1 | 5549 |
Nef Mediated CD8 Down-regulation
| set | Nef Mediated CD8 Down-regulation |
| setSize | 7 |
| pANOVA | 0.00953 |
| s.dist | -0.566 |
| p.adjustANOVA | 0.0309 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| AP2A1 | -9898 |
| AP2A2 | -9716 |
| AP2M1 | -9215 |
| AP2S1 | -5665 |
| AP2B1 | -3814 |
| CD8B | -3651 |
| ATP6V1H | -2266 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| AP2A1 | -9898 |
| AP2A2 | -9716 |
| AP2M1 | -9215 |
| AP2S1 | -5665 |
| AP2B1 | -3814 |
| CD8B | -3651 |
| ATP6V1H | -2266 |
PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1
| set | PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 |
| setSize | 9 |
| pANOVA | 0.0034 |
| s.dist | -0.564 |
| p.adjustANOVA | 0.0134 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| AKT1 | -10780 |
| ARAP1 | -9867 |
| UBB | -9728 |
| UBA52 | -7173 |
| DOK1 | -6775 |
| PTK6 | -6365 |
| UBC | -2555 |
| CBL | -1971 |
| RPS27A | -1438 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| AKT1 | -10780 |
| ARAP1 | -9867 |
| UBB | -9728 |
| UBA52 | -7173 |
| DOK1 | -6775 |
| PTK6 | -6365 |
| UBC | -2555 |
| CBL | -1971 |
| RPS27A | -1438 |
Beta oxidation of hexanoyl-CoA to butanoyl-CoA
| set | Beta oxidation of hexanoyl-CoA to butanoyl-CoA |
| setSize | 5 |
| pANOVA | 0.0294 |
| s.dist | -0.562 |
| p.adjustANOVA | 0.0752 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| HADHA | -8310 |
| HADH | -6724 |
| HADHB | -6385 |
| ACADS | -6119 |
| ECHS1 | -3869 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| HADHA | -8310 |
| HADH | -6724 |
| HADHB | -6385 |
| ACADS | -6119 |
| ECHS1 | -3869 |
VLDLR internalisation and degradation
| set | VLDLR internalisation and degradation |
| setSize | 15 |
| pANOVA | 0.000171 |
| s.dist | -0.56 |
| p.adjustANOVA | 0.00105 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| AP2A1 | -9898 |
| UBB | -9728 |
| AP2A2 | -9716 |
| AP2M1 | -9215 |
| NR1H3 | -8829 |
| CLTA | -8259 |
| NR1H2 | -7717 |
| UBA52 | -7173 |
| AP2S1 | -5665 |
| VLDLR | -5228 |
| AP2B1 | -3814 |
| CLTC | -3676 |
| UBC | -2555 |
| RPS27A | -1438 |
| MYLIP | -942 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| AP2A1 | -9898 |
| UBB | -9728 |
| AP2A2 | -9716 |
| AP2M1 | -9215 |
| NR1H3 | -8829 |
| CLTA | -8259 |
| NR1H2 | -7717 |
| UBA52 | -7173 |
| AP2S1 | -5665 |
| VLDLR | -5228 |
| AP2B1 | -3814 |
| CLTC | -3676 |
| UBC | -2555 |
| RPS27A | -1438 |
| MYLIP | -942 |
Pausing and recovery of Tat-mediated HIV elongation
| set | Pausing and recovery of Tat-mediated HIV elongation |
| setSize | 30 |
| pANOVA | 1.37e-07 |
| s.dist | -0.556 |
| p.adjustANOVA | 1.9e-06 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CTDP1 | -10880 |
| POLR2I | -10549 |
| POLR2G | -10393 |
| SSRP1 | -10263 |
| CDK9 | -10044 |
| NELFCD | -9504 |
| POLR2L | -9475 |
| POLR2E | -9467 |
| POLR2A | -9053 |
| POLR2J | -8987 |
| NELFB | -8543 |
| POLR2C | -8442 |
| NELFE | -8165 |
| ELOB | -8025 |
| SUPT5H | -7604 |
| GTF2F1 | -7237 |
| ELL | -6075 |
| SUPT4H1 | -5804 |
| POLR2F | -5739 |
| POLR2D | -5646 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CTDP1 | -10880 |
| POLR2I | -10549 |
| POLR2G | -10393 |
| SSRP1 | -10263 |
| CDK9 | -10044 |
| NELFCD | -9504 |
| POLR2L | -9475 |
| POLR2E | -9467 |
| POLR2A | -9053 |
| POLR2J | -8987 |
| NELFB | -8543 |
| POLR2C | -8442 |
| NELFE | -8165 |
| ELOB | -8025 |
| SUPT5H | -7604 |
| GTF2F1 | -7237 |
| ELL | -6075 |
| SUPT4H1 | -5804 |
| POLR2F | -5739 |
| POLR2D | -5646 |
| POLR2H | -5291 |
| POLR2B | -4372 |
| NELFA | -4353 |
| GTF2F2 | -2504 |
| SUPT16H | -2440 |
| ELOC | -1358 |
| ELOA | 228 |
| TCEA1 | 519 |
| CCNT1 | 567 |
| POLR2K | 2888 |
Tat-mediated HIV elongation arrest and recovery
| set | Tat-mediated HIV elongation arrest and recovery |
| setSize | 30 |
| pANOVA | 1.37e-07 |
| s.dist | -0.556 |
| p.adjustANOVA | 1.9e-06 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CTDP1 | -10880 |
| POLR2I | -10549 |
| POLR2G | -10393 |
| SSRP1 | -10263 |
| CDK9 | -10044 |
| NELFCD | -9504 |
| POLR2L | -9475 |
| POLR2E | -9467 |
| POLR2A | -9053 |
| POLR2J | -8987 |
| NELFB | -8543 |
| POLR2C | -8442 |
| NELFE | -8165 |
| ELOB | -8025 |
| SUPT5H | -7604 |
| GTF2F1 | -7237 |
| ELL | -6075 |
| SUPT4H1 | -5804 |
| POLR2F | -5739 |
| POLR2D | -5646 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CTDP1 | -10880 |
| POLR2I | -10549 |
| POLR2G | -10393 |
| SSRP1 | -10263 |
| CDK9 | -10044 |
| NELFCD | -9504 |
| POLR2L | -9475 |
| POLR2E | -9467 |
| POLR2A | -9053 |
| POLR2J | -8987 |
| NELFB | -8543 |
| POLR2C | -8442 |
| NELFE | -8165 |
| ELOB | -8025 |
| SUPT5H | -7604 |
| GTF2F1 | -7237 |
| ELL | -6075 |
| SUPT4H1 | -5804 |
| POLR2F | -5739 |
| POLR2D | -5646 |
| POLR2H | -5291 |
| POLR2B | -4372 |
| NELFA | -4353 |
| GTF2F2 | -2504 |
| SUPT16H | -2440 |
| ELOC | -1358 |
| ELOA | 228 |
| TCEA1 | 519 |
| CCNT1 | 567 |
| POLR2K | 2888 |
Complement cascade
| set | Complement cascade |
| setSize | 101 |
| pANOVA | 5.17e-22 |
| s.dist | -0.555 |
| p.adjustANOVA | 3.02e-20 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| IGKV1-12 | -11067 |
| IGLV1-51 | -11065 |
| IGLV1-36 | -11059 |
| C1QA | -11052 |
| IGLV3-1 | -11051 |
| IGLV7-43 | -11046 |
| IGLC2 | -11042 |
| IGKV4-1 | -11040 |
| IGHV4-59 | -11039 |
| C1QB | -11037 |
| IGLV3-25 | -11035 |
| C1QC | -11033 |
| IGLV2-11 | -11030 |
| IGKV3-20 | -11027 |
| IGHV4-39 | -11021 |
| IGLC1 | -10973 |
| IGLV1-44 | -10965 |
| IGLV3-21 | -10946 |
| IGHV1-2 | -10941 |
| IGLV2-8 | -10937 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| IGKV1-12 | -11067 |
| IGLV1-51 | -11065 |
| IGLV1-36 | -11059 |
| C1QA | -11052 |
| IGLV3-1 | -11051 |
| IGLV7-43 | -11046 |
| IGLC2 | -11042 |
| IGKV4-1 | -11040 |
| IGHV4-59 | -11039 |
| C1QB | -11037 |
| IGLV3-25 | -11035 |
| C1QC | -11033 |
| IGLV2-11 | -11030 |
| IGKV3-20 | -11027 |
| IGHV4-39 | -11021 |
| IGLC1 | -10973 |
| IGLV1-44 | -10965 |
| IGLV3-21 | -10946 |
| IGHV1-2 | -10941 |
| IGLV2-8 | -10937 |
| IGLV1-40 | -10897 |
| IGHV4-34 | -10895 |
| IGKV3-15 | -10883 |
| IGLV6-57 | -10873 |
| IGLV7-46 | -10868 |
| IGKV1-17 | -10865 |
| IGKV2-28 | -10819 |
| IGHV1-46 | -10813 |
| IGKV3D-20 | -10773 |
| IGLV1-47 | -10750 |
| IGLV8-61 | -10736 |
| IGKV1D-39 | -10727 |
| IGHV3-23 | -10643 |
| IGKV1-16 | -10613 |
| IGKV1-5 | -10565 |
| IGLV2-14 | -10564 |
| IGHG4 | -10382 |
| IGHG1 | -10370 |
| IGLV4-69 | -10237 |
| IGKC | -10177 |
| IGLC3 | -10154 |
| IGHV3-11 | -10150 |
| CD59 | -10051 |
| IGHV2-5 | -9962 |
| IGLV2-23 | -9779 |
| C1R | -9623 |
| IGLV5-45 | -9612 |
| IGHV2-70 | -9577 |
| IGLV3-19 | -9480 |
| IGHG2 | -9403 |
| IGHV3-13 | -9362 |
| ELANE | -9151 |
| IGLV3-27 | -9009 |
| IGHV3-33 | -8976 |
| IGHV3-7 | -8694 |
| IGHV3-30 | -8469 |
| IGLV4-60 | -7967 |
| CD81 | -7945 |
| VTN | -7933 |
| GZMM | -7727 |
| C4A | -7627 |
| IGKV1-33 | -7579 |
| CFD | -7542 |
| CFP | -7502 |
| IGKV5-2 | -7369 |
| IGHV1-69 | -7091 |
| IGKV2-30 | -6664 |
| C8G | -5579 |
| IGLV2-18 | -5134 |
| IGHG3 | -4843 |
| CD55 | -4050 |
| C4BPB | -2912 |
| CPN2 | -2533 |
| C5AR2 | -2289 |
| IGLV3-12 | -1877 |
| C2 | -1840 |
| CLU | -1395 |
| FCN1 | -1235 |
| C5 | -1099 |
| IGLC7 | -1096 |
| IGKV2D-28 | -955 |
| CFB | -711 |
| C3 | -512 |
| CR2 | 46 |
| IGKV2-29 | 69 |
| CR1 | 1190 |
| IGHV3-48 | 2427 |
| C3AR1 | 2858 |
| PROS1 | 3412 |
| C5AR1 | 3587 |
| IGHV3-53 | 4061 |
| IGLV10-54 | 4075 |
| C4BPA | 4554 |
| MASP2 | 4904 |
| SERPING1 | 5663 |
| C4B | 6359 |
| CD46 | 6809 |
| IGKV3-11 | 6935 |
| CD19 | 7511 |
| C1S | 8798 |
| CFH | 9758 |
FCGR3A-mediated phagocytosis
| set | FCGR3A-mediated phagocytosis |
| setSize | 122 |
| pANOVA | 2.77e-25 |
| s.dist | -0.544 |
| p.adjustANOVA | 2.42e-23 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| IGKV1-12 | -11067 |
| IGLV1-51 | -11065 |
| IGLV1-36 | -11059 |
| ABL1 | -11056 |
| IGLV3-1 | -11051 |
| IGLV7-43 | -11046 |
| IGLC2 | -11042 |
| IGKV4-1 | -11040 |
| IGHV4-59 | -11039 |
| IGLV3-25 | -11035 |
| IGLV2-11 | -11030 |
| IGKV3-20 | -11027 |
| IGHV4-39 | -11021 |
| IGLC1 | -10973 |
| CD247 | -10968 |
| IGLV1-44 | -10965 |
| VAV1 | -10950 |
| IGLV3-21 | -10946 |
| IGHV1-2 | -10941 |
| IGLV2-8 | -10937 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| IGKV1-12 | -11067 |
| IGLV1-51 | -11065 |
| IGLV1-36 | -11059 |
| ABL1 | -11056 |
| IGLV3-1 | -11051 |
| IGLV7-43 | -11046 |
| IGLC2 | -11042 |
| IGKV4-1 | -11040 |
| IGHV4-59 | -11039 |
| IGLV3-25 | -11035 |
| IGLV2-11 | -11030 |
| IGKV3-20 | -11027 |
| IGHV4-39 | -11021 |
| IGLC1 | -10973 |
| CD247 | -10968 |
| IGLV1-44 | -10965 |
| VAV1 | -10950 |
| IGLV3-21 | -10946 |
| IGHV1-2 | -10941 |
| IGLV2-8 | -10937 |
| IGLV1-40 | -10897 |
| IGHV4-34 | -10895 |
| IGKV3-15 | -10883 |
| IGLV6-57 | -10873 |
| IGLV7-46 | -10868 |
| IGKV1-17 | -10865 |
| IGKV2-28 | -10819 |
| IGHV1-46 | -10813 |
| IGKV3D-20 | -10773 |
| IGLV1-47 | -10750 |
| IGLV8-61 | -10736 |
| IGKV1D-39 | -10727 |
| IGHV3-23 | -10643 |
| IGKV1-16 | -10613 |
| MYH9 | -10602 |
| IGKV1-5 | -10565 |
| IGLV2-14 | -10564 |
| ACTG1 | -10480 |
| IGHG4 | -10382 |
| IGHG1 | -10370 |
| IGLV4-69 | -10237 |
| MYO9B | -10221 |
| IGKC | -10177 |
| IGLC3 | -10154 |
| IGHV3-11 | -10150 |
| IGHV2-5 | -9962 |
| IGLV2-23 | -9779 |
| IGLV5-45 | -9612 |
| IGHV2-70 | -9577 |
| IGLV3-19 | -9480 |
| IGHG2 | -9403 |
| IGHV3-13 | -9362 |
| ARPC2 | -9351 |
| IGLV3-27 | -9009 |
| IGHV3-33 | -8976 |
| ACTB | -8785 |
| IGHV3-7 | -8694 |
| IGHV3-30 | -8469 |
| WAS | -8450 |
| ARPC4 | -8290 |
| NCKIPSD | -7994 |
| IGLV4-60 | -7967 |
| HCK | -7694 |
| VAV2 | -7600 |
| IGKV1-33 | -7579 |
| ARPC1B | -7538 |
| MAPK3 | -7523 |
| IGKV5-2 | -7369 |
| IGHV1-69 | -7091 |
| IGKV2-30 | -6664 |
| BRK1 | -6506 |
| MYO1C | -6364 |
| CYFIP2 | -5981 |
| WASF2 | -5827 |
| ELMO1 | -5717 |
| NCKAP1L | -5667 |
| SRC | -5661 |
| ARPC1A | -5558 |
| FGR | -5526 |
| IGLV2-18 | -5134 |
| FCGR3A | -4999 |
| IGHG3 | -4843 |
| FYN | -3739 |
| RAC1 | -3508 |
| DOCK1 | -3341 |
| CYFIP1 | -2792 |
| ELMO2 | -2387 |
| YES1 | -2374 |
| SYK | -2296 |
| MAPK1 | -2210 |
| WIPF1 | -2068 |
| NCK1 | -1944 |
| IGLV3-12 | -1877 |
| PTK2 | -1803 |
| BAIAP2 | -1430 |
| MYO5A | -1116 |
| IGLC7 | -1096 |
| IGKV2D-28 | -955 |
| CDC42 | -587 |
| GRB2 | -530 |
| IGKV2-29 | 69 |
| ACTR3 | 192 |
| WASF3 | 462 |
| LYN | 593 |
| WASF1 | 732 |
| ARPC5 | 1039 |
| ARPC3 | 1114 |
| WIPF2 | 1160 |
| ACTR2 | 2107 |
| ABI1 | 2158 |
| IGHV3-48 | 2427 |
| VAV3 | 2504 |
| CRK | 3327 |
| MYO10 | 3351 |
| BTK | 3975 |
| IGHV3-53 | 4061 |
| IGLV10-54 | 4075 |
| ABI2 | 5060 |
| WASL | 5452 |
| NCKAP1 | 5762 |
| IGKV3-11 | 6935 |
| CD3G | 7030 |
Leishmania phagocytosis
| set | Leishmania phagocytosis |
| setSize | 122 |
| pANOVA | 2.77e-25 |
| s.dist | -0.544 |
| p.adjustANOVA | 2.42e-23 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| IGKV1-12 | -11067 |
| IGLV1-51 | -11065 |
| IGLV1-36 | -11059 |
| ABL1 | -11056 |
| IGLV3-1 | -11051 |
| IGLV7-43 | -11046 |
| IGLC2 | -11042 |
| IGKV4-1 | -11040 |
| IGHV4-59 | -11039 |
| IGLV3-25 | -11035 |
| IGLV2-11 | -11030 |
| IGKV3-20 | -11027 |
| IGHV4-39 | -11021 |
| IGLC1 | -10973 |
| CD247 | -10968 |
| IGLV1-44 | -10965 |
| VAV1 | -10950 |
| IGLV3-21 | -10946 |
| IGHV1-2 | -10941 |
| IGLV2-8 | -10937 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| IGKV1-12 | -11067 |
| IGLV1-51 | -11065 |
| IGLV1-36 | -11059 |
| ABL1 | -11056 |
| IGLV3-1 | -11051 |
| IGLV7-43 | -11046 |
| IGLC2 | -11042 |
| IGKV4-1 | -11040 |
| IGHV4-59 | -11039 |
| IGLV3-25 | -11035 |
| IGLV2-11 | -11030 |
| IGKV3-20 | -11027 |
| IGHV4-39 | -11021 |
| IGLC1 | -10973 |
| CD247 | -10968 |
| IGLV1-44 | -10965 |
| VAV1 | -10950 |
| IGLV3-21 | -10946 |
| IGHV1-2 | -10941 |
| IGLV2-8 | -10937 |
| IGLV1-40 | -10897 |
| IGHV4-34 | -10895 |
| IGKV3-15 | -10883 |
| IGLV6-57 | -10873 |
| IGLV7-46 | -10868 |
| IGKV1-17 | -10865 |
| IGKV2-28 | -10819 |
| IGHV1-46 | -10813 |
| IGKV3D-20 | -10773 |
| IGLV1-47 | -10750 |
| IGLV8-61 | -10736 |
| IGKV1D-39 | -10727 |
| IGHV3-23 | -10643 |
| IGKV1-16 | -10613 |
| MYH9 | -10602 |
| IGKV1-5 | -10565 |
| IGLV2-14 | -10564 |
| ACTG1 | -10480 |
| IGHG4 | -10382 |
| IGHG1 | -10370 |
| IGLV4-69 | -10237 |
| MYO9B | -10221 |
| IGKC | -10177 |
| IGLC3 | -10154 |
| IGHV3-11 | -10150 |
| IGHV2-5 | -9962 |
| IGLV2-23 | -9779 |
| IGLV5-45 | -9612 |
| IGHV2-70 | -9577 |
| IGLV3-19 | -9480 |
| IGHG2 | -9403 |
| IGHV3-13 | -9362 |
| ARPC2 | -9351 |
| IGLV3-27 | -9009 |
| IGHV3-33 | -8976 |
| ACTB | -8785 |
| IGHV3-7 | -8694 |
| IGHV3-30 | -8469 |
| WAS | -8450 |
| ARPC4 | -8290 |
| NCKIPSD | -7994 |
| IGLV4-60 | -7967 |
| HCK | -7694 |
| VAV2 | -7600 |
| IGKV1-33 | -7579 |
| ARPC1B | -7538 |
| MAPK3 | -7523 |
| IGKV5-2 | -7369 |
| IGHV1-69 | -7091 |
| IGKV2-30 | -6664 |
| BRK1 | -6506 |
| MYO1C | -6364 |
| CYFIP2 | -5981 |
| WASF2 | -5827 |
| ELMO1 | -5717 |
| NCKAP1L | -5667 |
| SRC | -5661 |
| ARPC1A | -5558 |
| FGR | -5526 |
| IGLV2-18 | -5134 |
| FCGR3A | -4999 |
| IGHG3 | -4843 |
| FYN | -3739 |
| RAC1 | -3508 |
| DOCK1 | -3341 |
| CYFIP1 | -2792 |
| ELMO2 | -2387 |
| YES1 | -2374 |
| SYK | -2296 |
| MAPK1 | -2210 |
| WIPF1 | -2068 |
| NCK1 | -1944 |
| IGLV3-12 | -1877 |
| PTK2 | -1803 |
| BAIAP2 | -1430 |
| MYO5A | -1116 |
| IGLC7 | -1096 |
| IGKV2D-28 | -955 |
| CDC42 | -587 |
| GRB2 | -530 |
| IGKV2-29 | 69 |
| ACTR3 | 192 |
| WASF3 | 462 |
| LYN | 593 |
| WASF1 | 732 |
| ARPC5 | 1039 |
| ARPC3 | 1114 |
| WIPF2 | 1160 |
| ACTR2 | 2107 |
| ABI1 | 2158 |
| IGHV3-48 | 2427 |
| VAV3 | 2504 |
| CRK | 3327 |
| MYO10 | 3351 |
| BTK | 3975 |
| IGHV3-53 | 4061 |
| IGLV10-54 | 4075 |
| ABI2 | 5060 |
| WASL | 5452 |
| NCKAP1 | 5762 |
| IGKV3-11 | 6935 |
| CD3G | 7030 |
Parasite infection
| set | Parasite infection |
| setSize | 122 |
| pANOVA | 2.77e-25 |
| s.dist | -0.544 |
| p.adjustANOVA | 2.42e-23 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| IGKV1-12 | -11067 |
| IGLV1-51 | -11065 |
| IGLV1-36 | -11059 |
| ABL1 | -11056 |
| IGLV3-1 | -11051 |
| IGLV7-43 | -11046 |
| IGLC2 | -11042 |
| IGKV4-1 | -11040 |
| IGHV4-59 | -11039 |
| IGLV3-25 | -11035 |
| IGLV2-11 | -11030 |
| IGKV3-20 | -11027 |
| IGHV4-39 | -11021 |
| IGLC1 | -10973 |
| CD247 | -10968 |
| IGLV1-44 | -10965 |
| VAV1 | -10950 |
| IGLV3-21 | -10946 |
| IGHV1-2 | -10941 |
| IGLV2-8 | -10937 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| IGKV1-12 | -11067 |
| IGLV1-51 | -11065 |
| IGLV1-36 | -11059 |
| ABL1 | -11056 |
| IGLV3-1 | -11051 |
| IGLV7-43 | -11046 |
| IGLC2 | -11042 |
| IGKV4-1 | -11040 |
| IGHV4-59 | -11039 |
| IGLV3-25 | -11035 |
| IGLV2-11 | -11030 |
| IGKV3-20 | -11027 |
| IGHV4-39 | -11021 |
| IGLC1 | -10973 |
| CD247 | -10968 |
| IGLV1-44 | -10965 |
| VAV1 | -10950 |
| IGLV3-21 | -10946 |
| IGHV1-2 | -10941 |
| IGLV2-8 | -10937 |
| IGLV1-40 | -10897 |
| IGHV4-34 | -10895 |
| IGKV3-15 | -10883 |
| IGLV6-57 | -10873 |
| IGLV7-46 | -10868 |
| IGKV1-17 | -10865 |
| IGKV2-28 | -10819 |
| IGHV1-46 | -10813 |
| IGKV3D-20 | -10773 |
| IGLV1-47 | -10750 |
| IGLV8-61 | -10736 |
| IGKV1D-39 | -10727 |
| IGHV3-23 | -10643 |
| IGKV1-16 | -10613 |
| MYH9 | -10602 |
| IGKV1-5 | -10565 |
| IGLV2-14 | -10564 |
| ACTG1 | -10480 |
| IGHG4 | -10382 |
| IGHG1 | -10370 |
| IGLV4-69 | -10237 |
| MYO9B | -10221 |
| IGKC | -10177 |
| IGLC3 | -10154 |
| IGHV3-11 | -10150 |
| IGHV2-5 | -9962 |
| IGLV2-23 | -9779 |
| IGLV5-45 | -9612 |
| IGHV2-70 | -9577 |
| IGLV3-19 | -9480 |
| IGHG2 | -9403 |
| IGHV3-13 | -9362 |
| ARPC2 | -9351 |
| IGLV3-27 | -9009 |
| IGHV3-33 | -8976 |
| ACTB | -8785 |
| IGHV3-7 | -8694 |
| IGHV3-30 | -8469 |
| WAS | -8450 |
| ARPC4 | -8290 |
| NCKIPSD | -7994 |
| IGLV4-60 | -7967 |
| HCK | -7694 |
| VAV2 | -7600 |
| IGKV1-33 | -7579 |
| ARPC1B | -7538 |
| MAPK3 | -7523 |
| IGKV5-2 | -7369 |
| IGHV1-69 | -7091 |
| IGKV2-30 | -6664 |
| BRK1 | -6506 |
| MYO1C | -6364 |
| CYFIP2 | -5981 |
| WASF2 | -5827 |
| ELMO1 | -5717 |
| NCKAP1L | -5667 |
| SRC | -5661 |
| ARPC1A | -5558 |
| FGR | -5526 |
| IGLV2-18 | -5134 |
| FCGR3A | -4999 |
| IGHG3 | -4843 |
| FYN | -3739 |
| RAC1 | -3508 |
| DOCK1 | -3341 |
| CYFIP1 | -2792 |
| ELMO2 | -2387 |
| YES1 | -2374 |
| SYK | -2296 |
| MAPK1 | -2210 |
| WIPF1 | -2068 |
| NCK1 | -1944 |
| IGLV3-12 | -1877 |
| PTK2 | -1803 |
| BAIAP2 | -1430 |
| MYO5A | -1116 |
| IGLC7 | -1096 |
| IGKV2D-28 | -955 |
| CDC42 | -587 |
| GRB2 | -530 |
| IGKV2-29 | 69 |
| ACTR3 | 192 |
| WASF3 | 462 |
| LYN | 593 |
| WASF1 | 732 |
| ARPC5 | 1039 |
| ARPC3 | 1114 |
| WIPF2 | 1160 |
| ACTR2 | 2107 |
| ABI1 | 2158 |
| IGHV3-48 | 2427 |
| VAV3 | 2504 |
| CRK | 3327 |
| MYO10 | 3351 |
| BTK | 3975 |
| IGHV3-53 | 4061 |
| IGLV10-54 | 4075 |
| ABI2 | 5060 |
| WASL | 5452 |
| NCKAP1 | 5762 |
| IGKV3-11 | 6935 |
| CD3G | 7030 |
Abortive elongation of HIV-1 transcript in the absence of Tat
| set | Abortive elongation of HIV-1 transcript in the absence of Tat |
| setSize | 23 |
| pANOVA | 6.98e-06 |
| s.dist | -0.541 |
| p.adjustANOVA | 7.08e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CTDP1 | -10880 |
| POLR2I | -10549 |
| POLR2G | -10393 |
| NELFCD | -9504 |
| POLR2L | -9475 |
| POLR2E | -9467 |
| POLR2A | -9053 |
| POLR2J | -8987 |
| NELFB | -8543 |
| POLR2C | -8442 |
| NELFE | -8165 |
| SUPT5H | -7604 |
| GTF2F1 | -7237 |
| SUPT4H1 | -5804 |
| POLR2F | -5739 |
| POLR2D | -5646 |
| POLR2H | -5291 |
| POLR2B | -4372 |
| NELFA | -4353 |
| GTF2F2 | -2504 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CTDP1 | -10880 |
| POLR2I | -10549 |
| POLR2G | -10393 |
| NELFCD | -9504 |
| POLR2L | -9475 |
| POLR2E | -9467 |
| POLR2A | -9053 |
| POLR2J | -8987 |
| NELFB | -8543 |
| POLR2C | -8442 |
| NELFE | -8165 |
| SUPT5H | -7604 |
| GTF2F1 | -7237 |
| SUPT4H1 | -5804 |
| POLR2F | -5739 |
| POLR2D | -5646 |
| POLR2H | -5291 |
| POLR2B | -4372 |
| NELFA | -4353 |
| GTF2F2 | -2504 |
| POLR2K | 2888 |
| NCBP2 | 4700 |
| NCBP1 | 5388 |
Gap junction degradation
| set | Gap junction degradation |
| setSize | 11 |
| pANOVA | 0.00198 |
| s.dist | -0.539 |
| p.adjustANOVA | 0.00852 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| DNM2 | -10812 |
| ACTG1 | -10480 |
| AP2M1 | -9215 |
| ACTB | -8785 |
| DAB2 | -8755 |
| CLTA | -8259 |
| CLTB | -7737 |
| CLTCL1 | -6760 |
| CLTC | -3676 |
| DNM1 | 80 |
| MYO6 | 8179 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| DNM2 | -10812 |
| ACTG1 | -10480 |
| AP2M1 | -9215 |
| ACTB | -8785 |
| DAB2 | -8755 |
| CLTA | -8259 |
| CLTB | -7737 |
| CLTCL1 | -6760 |
| CLTC | -3676 |
| DNM1 | 80 |
| MYO6 | 8179 |
Activation of PUMA and translocation to mitochondria
| set | Activation of PUMA and translocation to mitochondria |
| setSize | 9 |
| pANOVA | 0.00524 |
| s.dist | -0.537 |
| p.adjustANOVA | 0.0188 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| TFDP1 | -11050 |
| TFDP2 | -10153 |
| TP73 | -8453 |
| E2F1 | -7653 |
| TP53 | -7337 |
| PPP1R13B | -5038 |
| BBC3 | -4441 |
| TP63 | -1439 |
| TP53BP2 | 1511 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| TFDP1 | -11050 |
| TFDP2 | -10153 |
| TP73 | -8453 |
| E2F1 | -7653 |
| TP53 | -7337 |
| PPP1R13B | -5038 |
| BBC3 | -4441 |
| TP63 | -1439 |
| TP53BP2 | 1511 |
Prevention of phagosomal-lysosomal fusion
| set | Prevention of phagosomal-lysosomal fusion |
| setSize | 9 |
| pANOVA | 0.0053 |
| s.dist | -0.537 |
| p.adjustANOVA | 0.019 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| UBB | -9728 |
| CORO1A | -9656 |
| HGS | -9464 |
| VPS33B | -9142 |
| UBA52 | -7173 |
| RAB7A | -7097 |
| UBC | -2555 |
| RPS27A | -1438 |
| RAB5A | 2267 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| UBB | -9728 |
| CORO1A | -9656 |
| HGS | -9464 |
| VPS33B | -9142 |
| UBA52 | -7173 |
| RAB7A | -7097 |
| UBC | -2555 |
| RPS27A | -1438 |
| RAB5A | 2267 |
Network diagram
Only used for one-dimensional analysis.
Here, the network diagram is used to depict the similarity between
some of the top ranked gene sets. It makes separate charts for up and
downregulated sets. It works best when prioritisation is done by effect
size during the mitch_calc() step. By default, we only show
the top 20 genes, but you can use the networkplot() command
yourself with other options. See ?networkplot for more
detail. There is an element of stochasticity with regard to the network
projection, so if you see a lot of overlapping labels or labels getting
cut off, you could repeat the chart generation until you get a nice
layout. See ?networkplot for more detail.
Below the network diagrams, you will see lists of genes that make up the up and downregulated sets respectively. For upregulated genes the score needs to be >2 and for downregulated genes it needs to be < -2. This is to remove genes that have uninteresting differential expression and do not contribute enrichment.
if (d==1) {
networkplot(eres=res,FDR=0.05,n_sets=20)
network_genes(eres=res,FDR=0.05,n_sets=20)
} else {
message("Network charts only generated in one-dimensional analysis.")
}## Can't plot upregulated sets. Fewer than 5 found.
## [[1]]
## [[1]]$`UP genesets.Expression and translocation of olfactory receptors`
## [1] "OR10G3" "OR10H5" "OR14J1" "OR1D2" "OR1I1" "OR2A5" "OR2AT4" "OR2C3"
## [9] "OR2G6" "OR2M3" "OR2M4" "OR4K17" "OR5A1" "OR5AS1" "OR5AU1" "OR5K2"
## [17] "OR6C75" "OR6Y1" "OR7C1" "OR7D2" "OR8A1"
##
## [[1]]$`UP genesets.Olfactory Signaling Pathway`
## [1] "OR10G3" "OR10H5" "OR14J1" "OR1D2" "OR1I1" "OR2A5" "OR2AT4" "OR2C3"
## [9] "OR2G6" "OR2M3" "OR2M4" "OR4K17" "OR5A1" "OR5AS1" "OR5AU1" "OR5K2"
## [17] "OR6C75" "OR6Y1" "OR7C1" "OR7D2" "OR8A1"
##
## [[1]]$`UP genesets.Sensory Perception`
## [1] "CACNB2" "GNAT1" "LRP2" "OR10G3" "OR10H5" "OR14J1" "OR1D2" "OR1I1"
## [9] "OR2A5" "OR2AT4" "OR2C3" "OR2G6" "OR2M3" "OR2M4" "OR4K17" "OR5A1"
## [17] "OR5AS1" "OR5AU1" "OR5K2" "OR6C75" "OR6Y1" "OR7C1" "OR7D2" "OR8A1"
## [25] "PDE6A" "SAG" "SCN2A" "SCN2B" "SCN3A" "TMC1" "WHRN"
##
## [[1]]$`DOWN genesets.CD22 mediated BCR regulation`
## [1] "CD22" "CD79A" "CD79B" "IGHD" "IGHM" "IGHV1-2"
## [7] "IGHV1-46" "IGHV1-69" "IGHV2-5" "IGHV2-70" "IGHV3-11" "IGHV3-13"
## [13] "IGHV3-23" "IGHV3-30" "IGHV3-33" "IGHV3-48" "IGHV3-53" "IGHV3-7"
## [19] "IGHV4-34" "IGHV4-39" "IGHV4-59" "IGKC" "IGKV1-12" "IGKV1-16"
## [25] "IGKV1-17" "IGKV1-33" "IGKV1-5" "IGKV1D-39" "IGKV2-28" "IGKV2-29"
## [31] "IGKV2-30" "IGKV2D-28" "IGKV3-11" "IGKV3-15" "IGKV3-20" "IGKV3D-20"
## [37] "IGKV4-1" "IGKV5-2" "IGLC1" "IGLC2" "IGLC3" "IGLC7"
## [43] "IGLV1-40" "IGLV1-44" "IGLV1-47" "IGLV1-51" "IGLV2-11" "IGLV2-14"
## [49] "IGLV2-23" "IGLV2-8" "IGLV3-1" "IGLV3-19" "IGLV3-21" "IGLV3-25"
## [55] "IGLV3-27" "IGLV6-57" "IGLV7-43" "LYN" "PTPN6"
##
## [[1]]$`DOWN genesets.Classical antibody-mediated complement activation`
## [1] "C1QA" "C1QB" "C1QC" "C1R" "C1S" "IGHG1"
## [7] "IGHG2" "IGHG3" "IGHG4" "IGHV1-2" "IGHV1-46" "IGHV1-69"
## [13] "IGHV2-5" "IGHV2-70" "IGHV3-11" "IGHV3-13" "IGHV3-23" "IGHV3-30"
## [19] "IGHV3-33" "IGHV3-48" "IGHV3-53" "IGHV3-7" "IGHV4-34" "IGHV4-39"
## [25] "IGHV4-59" "IGKC" "IGKV1-12" "IGKV1-16" "IGKV1-17" "IGKV1-33"
## [31] "IGKV1-5" "IGKV1D-39" "IGKV2-28" "IGKV2-29" "IGKV2-30" "IGKV2D-28"
## [37] "IGKV3-11" "IGKV3-15" "IGKV3-20" "IGKV3D-20" "IGKV4-1" "IGKV5-2"
## [43] "IGLC1" "IGLC2" "IGLC3" "IGLC7" "IGLV1-36" "IGLV1-40"
## [49] "IGLV1-44" "IGLV1-47" "IGLV1-51" "IGLV10-54" "IGLV2-11" "IGLV2-14"
## [55] "IGLV2-18" "IGLV2-23" "IGLV2-8" "IGLV3-1" "IGLV3-12" "IGLV3-19"
## [61] "IGLV3-21" "IGLV3-25" "IGLV3-27" "IGLV4-60" "IGLV4-69" "IGLV5-45"
## [67] "IGLV6-57" "IGLV7-43" "IGLV7-46" "IGLV8-61"
##
## [[1]]$`DOWN genesets.Creation of C4 and C2 activators`
## [1] "C1QA" "C1QB" "C1QC" "C1R" "C1S" "FCN1"
## [7] "IGHG1" "IGHG2" "IGHG3" "IGHG4" "IGHV1-2" "IGHV1-46"
## [13] "IGHV1-69" "IGHV2-5" "IGHV2-70" "IGHV3-11" "IGHV3-13" "IGHV3-23"
## [19] "IGHV3-30" "IGHV3-33" "IGHV3-48" "IGHV3-53" "IGHV3-7" "IGHV4-34"
## [25] "IGHV4-39" "IGHV4-59" "IGKC" "IGKV1-12" "IGKV1-16" "IGKV1-17"
## [31] "IGKV1-33" "IGKV1-5" "IGKV1D-39" "IGKV2-28" "IGKV2-29" "IGKV2-30"
## [37] "IGKV2D-28" "IGKV3-11" "IGKV3-15" "IGKV3-20" "IGKV3D-20" "IGKV4-1"
## [43] "IGKV5-2" "IGLC1" "IGLC2" "IGLC3" "IGLC7" "IGLV1-36"
## [49] "IGLV1-40" "IGLV1-44" "IGLV1-47" "IGLV1-51" "IGLV10-54" "IGLV2-11"
## [55] "IGLV2-14" "IGLV2-18" "IGLV2-23" "IGLV2-8" "IGLV3-1" "IGLV3-12"
## [61] "IGLV3-19" "IGLV3-21" "IGLV3-25" "IGLV3-27" "IGLV4-60" "IGLV4-69"
## [67] "IGLV5-45" "IGLV6-57" "IGLV7-43" "IGLV7-46" "IGLV8-61" "MASP2"
##
## [[1]]$`DOWN genesets.Diseases of Base Excision Repair`
## [1] "MUTYH" "NEIL1" "NEIL3" "NTHL1" "OGG1"
##
## [[1]]$`DOWN genesets.FCGR activation`
## [1] "CD247" "CD3G" "FCGR1A" "FCGR2A" "FCGR3A" "FGR"
## [7] "FYN" "HCK" "IGHG1" "IGHG2" "IGHG3" "IGHG4"
## [13] "IGHV1-2" "IGHV1-46" "IGHV1-69" "IGHV2-5" "IGHV2-70" "IGHV3-11"
## [19] "IGHV3-13" "IGHV3-23" "IGHV3-30" "IGHV3-33" "IGHV3-48" "IGHV3-53"
## [25] "IGHV3-7" "IGHV4-34" "IGHV4-39" "IGHV4-59" "IGKC" "IGKV1-12"
## [31] "IGKV1-16" "IGKV1-17" "IGKV1-33" "IGKV1-5" "IGKV1D-39" "IGKV2-28"
## [37] "IGKV2-29" "IGKV2-30" "IGKV2D-28" "IGKV3-11" "IGKV3-15" "IGKV3-20"
## [43] "IGKV3D-20" "IGKV4-1" "IGKV5-2" "IGLC1" "IGLC2" "IGLC3"
## [49] "IGLC7" "IGLV1-36" "IGLV1-40" "IGLV1-44" "IGLV1-47" "IGLV1-51"
## [55] "IGLV10-54" "IGLV2-11" "IGLV2-14" "IGLV2-18" "IGLV2-23" "IGLV2-8"
## [61] "IGLV3-1" "IGLV3-12" "IGLV3-19" "IGLV3-21" "IGLV3-25" "IGLV3-27"
## [67] "IGLV4-60" "IGLV4-69" "IGLV5-45" "IGLV6-57" "IGLV7-43" "IGLV7-46"
## [73] "IGLV8-61" "LYN" "SRC" "SYK" "YES1"
##
## [[1]]$`DOWN genesets.Formation of annular gap junctions`
## [1] "ACTB" "ACTG1" "AP2M1" "CLTA" "CLTB" "CLTC" "CLTCL1" "DAB2"
## [9] "DNM1" "DNM2"
##
## [[1]]$`DOWN genesets.Glycosphingolipid transport`
## [1] "ARF1" "CLN3" "CPTP" "ESYT1" "ESYT2" "GLTP" "PLEKHA8"
##
## [[1]]$`DOWN genesets.Initial triggering of complement`
## [1] "C1QA" "C1QB" "C1QC" "C1R" "C1S" "C2"
## [7] "C3" "C4A" "C4B" "CFB" "CFD" "CFP"
## [13] "FCN1" "GZMM" "IGHG1" "IGHG2" "IGHG3" "IGHG4"
## [19] "IGHV1-2" "IGHV1-46" "IGHV1-69" "IGHV2-5" "IGHV2-70" "IGHV3-11"
## [25] "IGHV3-13" "IGHV3-23" "IGHV3-30" "IGHV3-33" "IGHV3-48" "IGHV3-53"
## [31] "IGHV3-7" "IGHV4-34" "IGHV4-39" "IGHV4-59" "IGKC" "IGKV1-12"
## [37] "IGKV1-16" "IGKV1-17" "IGKV1-33" "IGKV1-5" "IGKV1D-39" "IGKV2-28"
## [43] "IGKV2-29" "IGKV2-30" "IGKV2D-28" "IGKV3-11" "IGKV3-15" "IGKV3-20"
## [49] "IGKV3D-20" "IGKV4-1" "IGKV5-2" "IGLC1" "IGLC2" "IGLC3"
## [55] "IGLC7" "IGLV1-36" "IGLV1-40" "IGLV1-44" "IGLV1-47" "IGLV1-51"
## [61] "IGLV10-54" "IGLV2-11" "IGLV2-14" "IGLV2-18" "IGLV2-23" "IGLV2-8"
## [67] "IGLV3-1" "IGLV3-12" "IGLV3-19" "IGLV3-21" "IGLV3-25" "IGLV3-27"
## [73] "IGLV4-60" "IGLV4-69" "IGLV5-45" "IGLV6-57" "IGLV7-43" "IGLV7-46"
## [79] "IGLV8-61" "MASP2"
##
## [[1]]$`DOWN genesets.Maturation of spike protein_9683686`
## [1] "CANX" "GANAB" "MGAT1" "MOGS" "PRKCSH"
##
## [[1]]$`DOWN genesets.NR1H2 & NR1H3 regulate gene expression linked to lipogenesis`
## [1] "FASN" "NR1H2" "NR1H3" "NRIP1" "RXRA" "RXRB" "SCD" "SREBF1"
##
## [[1]]$`DOWN genesets.NR1H2 & NR1H3 regulate gene expression linked to triglyceride lipolysis in adipose`
## [1] "NR1H2" "NR1H3" "PLIN1" "RXRA" "RXRB"
##
## [[1]]$`DOWN genesets.NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis`
## [1] "NCOA1" "NCOR1" "NCOR2" "NR1H2" "NR1H3" "RXRA" "RXRB"
##
## [[1]]$`DOWN genesets.NR1H2 & NR1H3 regulate gene expression to limit cholesterol uptake`
## [1] "MYLIP" "NR1H2" "NR1H3" "RXRA" "RXRB"
##
## [[1]]$`DOWN genesets.Negative regulation of TCF-dependent signaling by DVL-interacting proteins`
## [1] "CCDC88C" "CXXC4" "DVL1" "DVL2" "DVL3"
##
## [[1]]$`DOWN genesets.Phosphorylation of Emi1`
## [1] "CCNB1" "CDC20" "CDK1" "FBXO5" "FZR1" "PLK1"
##
## [[1]]$`DOWN genesets.Role of LAT2/NTAL/LAB on calcium mobilization`
## [1] "FCER1A" "FCER1G" "FYN" "GAB2" "GRB2" "IGHE"
## [7] "IGHV1-2" "IGHV1-46" "IGHV1-69" "IGHV2-5" "IGHV2-70" "IGHV3-11"
## [13] "IGHV3-13" "IGHV3-23" "IGHV3-30" "IGHV3-33" "IGHV3-48" "IGHV3-53"
## [19] "IGHV3-7" "IGHV4-34" "IGHV4-39" "IGHV4-59" "IGKC" "IGKV1-12"
## [25] "IGKV1-16" "IGKV1-17" "IGKV1-33" "IGKV1-5" "IGKV1D-39" "IGKV2-28"
## [31] "IGKV2-29" "IGKV2-30" "IGKV2D-28" "IGKV3-11" "IGKV3-15" "IGKV3-20"
## [37] "IGKV3D-20" "IGKV4-1" "IGKV5-2" "IGLC1" "IGLC2" "IGLC3"
## [43] "IGLC7" "IGLV1-36" "IGLV1-40" "IGLV1-44" "IGLV1-47" "IGLV1-51"
## [49] "IGLV10-54" "IGLV2-11" "IGLV2-14" "IGLV2-18" "IGLV2-23" "IGLV2-8"
## [55] "IGLV3-1" "IGLV3-12" "IGLV3-19" "IGLV3-21" "IGLV3-25" "IGLV3-27"
## [61] "IGLV4-60" "IGLV4-69" "IGLV5-45" "IGLV6-57" "IGLV7-43" "IGLV7-46"
## [67] "IGLV8-61" "LAT2" "LYN" "MS4A2" "PDPK1" "PIK3CA"
## [73] "PIK3CB" "PIK3R1" "PIK3R2" "SHC1" "SOS1" "SYK"
##
## [[1]]$`DOWN genesets.Scavenging of heme from plasma`
## [1] "APOL1" "CD163" "HBA1" "HBB" "HP" "HPX"
## [7] "IGHA1" "IGHA2" "IGHV1-2" "IGHV1-46" "IGHV1-69" "IGHV2-5"
## [13] "IGHV2-70" "IGHV3-11" "IGHV3-13" "IGHV3-23" "IGHV3-30" "IGHV3-33"
## [19] "IGHV3-48" "IGHV3-53" "IGHV3-7" "IGHV4-34" "IGHV4-39" "IGHV4-59"
## [25] "IGKC" "IGKV1-12" "IGKV1-16" "IGKV1-17" "IGKV1-33" "IGKV1-5"
## [31] "IGKV1D-39" "IGKV2-28" "IGKV2-29" "IGKV2-30" "IGKV2D-28" "IGKV3-11"
## [37] "IGKV3-15" "IGKV3-20" "IGKV3D-20" "IGKV4-1" "IGKV5-2" "IGLC1"
## [43] "IGLC2" "IGLC3" "IGLC7" "IGLV1-36" "IGLV1-40" "IGLV1-44"
## [49] "IGLV1-47" "IGLV1-51" "IGLV10-54" "IGLV2-11" "IGLV2-14" "IGLV2-18"
## [55] "IGLV2-23" "IGLV2-8" "IGLV3-1" "IGLV3-12" "IGLV3-19" "IGLV3-21"
## [61] "IGLV3-25" "IGLV3-27" "IGLV4-60" "IGLV4-69" "IGLV5-45" "IGLV6-57"
## [67] "IGLV7-43" "IGLV7-46" "IGLV8-61" "JCHAIN" "LRP1"
##
## [[1]]$`DOWN genesets.Sulfide oxidation to sulfate`
## [1] "ETHE1" "SLC25A10" "SUOX" "TST" "TSTD1"
##
## [[1]]$`DOWN genesets.Synthesis of GDP-mannose`
## [1] "GMPPA" "GMPPB" "HK1" "MPI" "PMM1" "PMM2"
##
## [[1]]$`DOWN genesets.Type I hemidesmosome assembly`
## [1] "CD151" "COL17A1" "DST" "ITGA6" "ITGB4" "KRT5" "LAMB3"
## [8] "PLEC"Session information
Here is the session info with all the versions of packages used.
sessionInfo()## R version 4.5.2 (2025-10-31)
## Platform: x86_64-pc-linux-gnu
## Running under: Ubuntu 24.04.4 LTS
##
## Matrix products: default
## BLAS: /usr/lib/x86_64-linux-gnu/openblas-pthread/libblas.so.3
## LAPACK: /usr/lib/x86_64-linux-gnu/openblas-pthread/libopenblasp-r0.3.26.so; LAPACK version 3.12.0
##
## locale:
## [1] LC_CTYPE=en_US.UTF-8 LC_NUMERIC=C
## [3] LC_TIME=en_US.UTF-8 LC_COLLATE=en_US.UTF-8
## [5] LC_MONETARY=en_US.UTF-8 LC_MESSAGES=en_US.UTF-8
## [7] LC_PAPER=en_US.UTF-8 LC_NAME=en_US.UTF-8
## [9] LC_ADDRESS=en_US.UTF-8 LC_TELEPHONE=en_US.UTF-8
## [11] LC_MEASUREMENT=en_US.UTF-8 LC_IDENTIFICATION=en_US.UTF-8
##
## time zone: Etc/UTC
## tzcode source: system (glibc)
##
## attached base packages:
## [1] stats4 stats graphics grDevices utils datasets methods
## [8] base
##
## other attached packages:
## [1] RhpcBLASctl_0.23-42 gtools_3.9.5
## [3] xlsx_0.6.5 DT_0.34.0
## [5] ggplot2_4.0.3 kableExtra_1.4.0
## [7] beeswarm_0.4.0 eulerr_7.1.0
## [9] MASS_7.3-65 mitch_1.22.1
## [11] DESeq2_1.50.2 SummarizedExperiment_1.40.0
## [13] Biobase_2.70.0 MatrixGenerics_1.22.0
## [15] matrixStats_1.5.0 GenomicRanges_1.62.1
## [17] Seqinfo_1.0.0 IRanges_2.44.0
## [19] S4Vectors_0.48.1 BiocGenerics_0.56.0
## [21] generics_0.1.4 dplyr_1.2.1
## [23] WGCNA_1.74 fastcluster_1.3.0
## [25] dynamicTreeCut_1.63-1 reshape2_1.4.5
## [27] gplots_3.3.0
##
## loaded via a namespace (and not attached):
## [1] RColorBrewer_1.1-3 rstudioapi_0.17.1 jsonlite_2.0.0
## [4] magrittr_2.0.4 farver_2.1.2 rmarkdown_2.30
## [7] vctrs_0.7.3 base64enc_0.1-3 htmltools_0.5.8.1
## [10] S4Arrays_1.10.1 progress_1.2.3 SparseArray_1.10.10
## [13] Formula_1.2-5 sass_0.4.10 KernSmooth_2.23-26
## [16] bslib_0.9.0 htmlwidgets_1.6.4 plyr_1.8.9
## [19] echarts4r_0.5.0 impute_1.84.0 cachem_1.1.0
## [22] mime_0.13 lifecycle_1.0.5 iterators_1.0.14
## [25] pkgconfig_2.0.3 Matrix_1.7-4 R6_2.6.1
## [28] fastmap_1.2.0 shiny_1.11.1 digest_0.6.39
## [31] colorspace_2.1-2 GGally_2.4.0 textshaping_1.0.4
## [34] crosstalk_1.2.2 Hmisc_5.2-5 labeling_0.4.3
## [37] polyclip_1.10-7 abind_1.4-8 compiler_4.5.2
## [40] withr_3.0.2 doParallel_1.0.17 htmlTable_2.5.0
## [43] S7_0.2.2 backports_1.5.1 BiocParallel_1.44.0
## [46] ggstats_0.13.0 DelayedArray_0.36.1 caTools_1.18.3
## [49] tools_4.5.2 foreign_0.8-90 otel_0.2.0
## [52] httpuv_1.6.16 nnet_7.3-20 glue_1.8.0
## [55] promises_1.5.0 grid_4.5.2 polylabelr_1.0.0
## [58] checkmate_2.3.4 cluster_2.1.8.1 gtable_0.3.6
## [61] preprocessCore_1.72.0 tidyr_1.3.2 hms_1.1.4
## [64] data.table_1.18.2.1 xml2_1.5.1 XVector_0.50.0
## [67] foreach_1.5.2 pillar_1.11.1 stringr_1.6.0
## [70] later_1.4.4 rJava_1.0-18 splines_4.5.2
## [73] lattice_0.22-7 survival_3.8-3 tidyselect_1.2.1
## [76] locfit_1.5-9.12 knitr_1.50 gridExtra_2.3
## [79] svglite_2.2.2 xfun_0.54 stringi_1.8.7
## [82] statnet.common_4.13.0 yaml_2.3.11 evaluate_1.0.5
## [85] codetools_0.2-20 xlsxjars_0.9.0 tibble_3.3.0
## [88] cli_3.6.5 rpart_4.1.24 xtable_1.8-4
## [91] systemfonts_1.3.1 jquerylib_0.1.4 network_1.20.0
## [94] Rcpp_1.1.1-1.1 coda_0.19-4.1 parallel_4.5.2
## [97] prettyunits_1.2.0 bitops_1.0-9 viridisLite_0.4.3
## [100] scales_1.4.0 purrr_1.2.0 crayon_1.5.3
## [103] rlang_1.2.0END of report